PH12014501504B1 - THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES - Google Patents
THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES Download PDFInfo
- Publication number
- PH12014501504B1 PH12014501504B1 PH12014501504A PH12014501504A PH12014501504B1 PH 12014501504 B1 PH12014501504 B1 PH 12014501504B1 PH 12014501504 A PH12014501504 A PH 12014501504A PH 12014501504 A PH12014501504 A PH 12014501504A PH 12014501504 B1 PH12014501504 B1 PH 12014501504B1
- Authority
- PH
- Philippines
- Prior art keywords
- amino
- pyrimidine
- carboxamide
- thieno
- methylisoquinolin
- Prior art date
Links
- 102000001253 Protein Kinase Human genes 0.000 title claims abstract description 23
- 108060006633 protein kinase Proteins 0.000 title claims abstract description 23
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical class C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 title abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- 230000002159 abnormal effect Effects 0.000 claims abstract description 16
- 230000002265 prevention Effects 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 281
- -1 methylisoquinolin-5-yl Chemical group 0.000 claims description 136
- 238000006243 chemical reaction Methods 0.000 claims description 129
- RJJMKEIWVGHKAV-UHFFFAOYSA-N thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=CN=C2C(C(=O)N)=CSC2=C1 RJJMKEIWVGHKAV-UHFFFAOYSA-N 0.000 claims description 81
- 150000003857 carboxamides Chemical class 0.000 claims description 57
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 52
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 239000003112 inhibitor Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 230000004913 activation Effects 0.000 claims description 13
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 13
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims description 12
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 108010077182 raf Kinases Proteins 0.000 claims description 8
- 102000009929 raf Kinases Human genes 0.000 claims description 8
- 102100036723 Discoidin domain-containing receptor 2 Human genes 0.000 claims description 6
- 101710127786 Discoidin domain-containing receptor 2 Proteins 0.000 claims description 6
- 229910020008 S(O) Inorganic materials 0.000 claims description 6
- 239000003102 growth factor Substances 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- OMFOPOQYSHUVGE-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-[3-(trifluoromethyl)anilino]isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(C(F)(F)F)=C1 OMFOPOQYSHUVGE-UHFFFAOYSA-N 0.000 claims description 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 230000024245 cell differentiation Effects 0.000 claims description 5
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 230000019491 signal transduction Effects 0.000 claims description 5
- WFPRKWFCJTUXKD-UHFFFAOYSA-N 4-amino-n-(6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CN=CC4=CC=C3C)=CSC2=C1N WFPRKWFCJTUXKD-UHFFFAOYSA-N 0.000 claims description 4
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 claims description 4
- SOSMYFFEQTXSOC-UHFFFAOYSA-N 4-amino-n-[1-[4-chloro-3-(piperidin-1-ylmethyl)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC(C=1)=CC=C(Cl)C=1CN1CCCCC1 SOSMYFFEQTXSOC-UHFFFAOYSA-N 0.000 claims description 4
- VSODPKNVXXCESA-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-[3-(2,2,2-trifluoroacetyl)anilino]isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(C(=O)C(F)(F)F)=C1 VSODPKNVXXCESA-UHFFFAOYSA-N 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- FPRGZXHURIVOKZ-UHFFFAOYSA-N tert-butyl 4-[[5-[[5-[(4-aminothieno[3,2-d]pyrimidine-7-carbonyl)amino]-6-methylisoquinolin-1-yl]amino]-2-chlorophenyl]methyl]piperazine-1-carboxylate Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC(C=1)=CC=C(Cl)C=1CN1CCN(C(=O)OC(C)(C)C)CC1 FPRGZXHURIVOKZ-UHFFFAOYSA-N 0.000 claims description 4
- DHGAFAVQGXPANJ-UHFFFAOYSA-N 4-amino-n-[1-(1,3-benzodioxol-5-ylamino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CN=C(NC=5C=C6OCOC6=CC=5)C4=CC=C3C)=CSC2=C1N DHGAFAVQGXPANJ-UHFFFAOYSA-N 0.000 claims description 3
- HAOMZGXWDQZEHL-UHFFFAOYSA-N 4-amino-n-[1-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CN=C(NC=5C=C6OCCOC6=CC=5)C4=CC=C3C)=CSC2=C1N HAOMZGXWDQZEHL-UHFFFAOYSA-N 0.000 claims description 3
- GIWYFYUWMKGREB-UHFFFAOYSA-N 4-amino-n-[1-(2-methoxy-4-morpholin-4-ylanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C=1C=C(NC=2C3=CC=C(C)C(NC(=O)C=4C5=NC=NC(N)=C5SC=4)=C3C=CN=2)C(OC)=CC=1N1CCOCC1 GIWYFYUWMKGREB-UHFFFAOYSA-N 0.000 claims description 3
- IQLYOMSTQATNLD-UHFFFAOYSA-N 4-amino-n-[1-(3,4-dichloroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C(Cl)=C1 IQLYOMSTQATNLD-UHFFFAOYSA-N 0.000 claims description 3
- JWIJWAKKUSXBTN-UHFFFAOYSA-N 4-amino-n-[1-(3,4-dimethoxyanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1NC(C1=CC=C2C)=NC=CC1=C2NC(=O)C1=CSC2=C(N)N=CN=C12 JWIJWAKKUSXBTN-UHFFFAOYSA-N 0.000 claims description 3
- GRXGEAYWBKPRDD-UHFFFAOYSA-N 4-amino-n-[1-(3-bromo-4-chloroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C(Br)=C1 GRXGEAYWBKPRDD-UHFFFAOYSA-N 0.000 claims description 3
- ZWIWSEFWCLHYIT-UHFFFAOYSA-N 4-amino-n-[1-(3-fluoro-4-methoxyanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=C(F)C(OC)=CC=C1NC(C1=CC=C2C)=NC=CC1=C2NC(=O)C1=CSC2=C(N)N=CN=C12 ZWIWSEFWCLHYIT-UHFFFAOYSA-N 0.000 claims description 3
- SWSVJLRGFWGAQE-UHFFFAOYSA-N 4-amino-n-[1-(4-bromo-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(Br)C=C1F SWSVJLRGFWGAQE-UHFFFAOYSA-N 0.000 claims description 3
- NZWFKJTVAZTKAN-UHFFFAOYSA-N 4-amino-n-[1-(4-chloro-3-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C(F)=C1 NZWFKJTVAZTKAN-UHFFFAOYSA-N 0.000 claims description 3
- JHOLRFQCCWLZPC-UHFFFAOYSA-N 4-amino-n-[1-(5-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC(Cl)=CC=C1F JHOLRFQCCWLZPC-UHFFFAOYSA-N 0.000 claims description 3
- LNTMCCPUTLPCNP-UHFFFAOYSA-N 4-amino-n-[1-(benzylamino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NCC1=CC=CC=C1 LNTMCCPUTLPCNP-UHFFFAOYSA-N 0.000 claims description 3
- GHMSTLORNGUFPU-UHFFFAOYSA-N 4-amino-n-[1-[(1,4-diethyl-2,3-dihydroquinoxalin-6-yl)amino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CN=C(C4=CC=C3C)NC=3C=C4N(CC)CCN(C4=CC=3)CC)=CSC2=C1N GHMSTLORNGUFPU-UHFFFAOYSA-N 0.000 claims description 3
- FHNFKGBAHJAYJR-UHFFFAOYSA-N 4-amino-n-[1-[(6-chloropyridin-3-yl)amino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(Cl)N=C1 FHNFKGBAHJAYJR-UHFFFAOYSA-N 0.000 claims description 3
- RULTUEAMPBRHSH-UHFFFAOYSA-N 4-amino-n-[1-[(6-methoxypyridin-3-yl)amino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=NC(OC)=CC=C1NC(C1=CC=C2C)=NC=CC1=C2NC(=O)C1=CSC2=C(N)N=CN=C12 RULTUEAMPBRHSH-UHFFFAOYSA-N 0.000 claims description 3
- KELUHVTXRNPRRB-UHFFFAOYSA-N 4-amino-n-[1-[2-(4-chlorophenyl)hydrazinyl]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NNC1=CC=C(Cl)C=C1 KELUHVTXRNPRRB-UHFFFAOYSA-N 0.000 claims description 3
- GGNYSXJXVKSBGN-UHFFFAOYSA-N 4-amino-n-[1-[3-(dimethylcarbamoyl)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound CN(C)C(=O)C1=CC=CC(NC=2C3=CC=C(C)C(NC(=O)C=4C5=NC=NC(N)=C5SC=4)=C3C=CN=2)=C1 GGNYSXJXVKSBGN-UHFFFAOYSA-N 0.000 claims description 3
- XCFQFVZSDRTNNR-UHFFFAOYSA-N 4-amino-n-[1-[4-(2-methoxyethoxy)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=CC(OCCOC)=CC=C1NC(C1=CC=C2C)=NC=CC1=C2NC(=O)C1=CSC2=C(N)N=CN=C12 XCFQFVZSDRTNNR-UHFFFAOYSA-N 0.000 claims description 3
- QAFUEBLZGAXFFZ-UHFFFAOYSA-N 4-amino-n-[1-[4-(4-ethylpiperazin-1-yl)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC(C1=CC=C2C)=NC=CC1=C2NC(=O)C1=CSC2=C(N)N=CN=C12 QAFUEBLZGAXFFZ-UHFFFAOYSA-N 0.000 claims description 3
- WSVRCSFMNFUWEQ-UHFFFAOYSA-N 4-amino-n-[1-[4-(difluoromethoxy)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(OC(F)F)C=C1 WSVRCSFMNFUWEQ-UHFFFAOYSA-N 0.000 claims description 3
- ZSJHIUWZYQMTDI-UHFFFAOYSA-N 4-amino-n-[1-[4-(dimethylcarbamoyl)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1NC(C1=CC=C2C)=NC=CC1=C2NC(=O)C1=CSC2=C(N)N=CN=C12 ZSJHIUWZYQMTDI-UHFFFAOYSA-N 0.000 claims description 3
- BPFODVNJGQUCCT-UHFFFAOYSA-N 4-amino-n-[1-[4-(fluoromethoxy)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(OCF)C=C1 BPFODVNJGQUCCT-UHFFFAOYSA-N 0.000 claims description 3
- FUPOWHFXRARIRH-UHFFFAOYSA-N 4-amino-n-[1-[4-chloro-3-(diethylaminomethyl)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=C(Cl)C(CN(CC)CC)=CC(NC=2C3=CC=C(C)C(NC(=O)C=4C5=NC=NC(N)=C5SC=4)=C3C=CN=2)=C1 FUPOWHFXRARIRH-UHFFFAOYSA-N 0.000 claims description 3
- XJBZASNGFCHCCZ-UHFFFAOYSA-N 4-amino-n-[1-[4-chloro-3-(methanesulfonamido)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C(NS(C)(=O)=O)=C1 XJBZASNGFCHCCZ-UHFFFAOYSA-N 0.000 claims description 3
- MUIOAQJXVRHMDI-UHFFFAOYSA-N 4-amino-n-[1-[4-chloro-3-(morpholin-4-ylmethyl)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC(C=1)=CC=C(Cl)C=1CN1CCOCC1 MUIOAQJXVRHMDI-UHFFFAOYSA-N 0.000 claims description 3
- SLCWKPNWOMBQAA-UHFFFAOYSA-N 4-amino-n-[1-[4-chloro-3-[(dimethylamino)methyl]anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=C(Cl)C(CN(C)C)=CC(NC=2C3=CC=C(C)C(NC(=O)C=4C5=NC=NC(N)=C5SC=4)=C3C=CN=2)=C1 SLCWKPNWOMBQAA-UHFFFAOYSA-N 0.000 claims description 3
- NNRULVURDYEHSA-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-(3-methylsulfonylanilino)isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(S(C)(=O)=O)=C1 NNRULVURDYEHSA-UHFFFAOYSA-N 0.000 claims description 3
- RQRMPGIDOHGZEC-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-(4-propan-2-yloxyanilino)isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=CC(OC(C)C)=CC=C1NC(C1=CC=C2C)=NC=CC1=C2NC(=O)C1=CSC2=C(N)N=CN=C12 RQRMPGIDOHGZEC-UHFFFAOYSA-N 0.000 claims description 3
- RZMJRUAVSWMTPO-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-(5,6,7,8-tetrahydronaphthalen-2-ylamino)isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CN=C(NC=5C=C6CCCCC6=CC=5)C4=CC=C3C)=CSC2=C1N RZMJRUAVSWMTPO-UHFFFAOYSA-N 0.000 claims description 3
- KGDHAGFBEZMNCH-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-[(2-methylindazol-5-yl)amino]isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CN=C(NC5=CC6=CN(C)N=C6C=C5)C4=CC=C3C)=CSC2=C1N KGDHAGFBEZMNCH-UHFFFAOYSA-N 0.000 claims description 3
- WVPGNXQJZVARDD-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-[(6-methylpyridin-3-yl)amino]isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=NC(C)=CC=C1NC(C1=CC=C2C)=NC=CC1=C2NC(=O)C1=CSC2=C(N)N=CN=C12 WVPGNXQJZVARDD-UHFFFAOYSA-N 0.000 claims description 3
- DIVSWGJFMRQNLO-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-[3-(methylcarbamoyl)anilino]isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound CNC(=O)C1=CC=CC(NC=2C3=CC=C(C)C(NC(=O)C=4C5=NC=NC(N)=C5SC=4)=C3C=CN=2)=C1 DIVSWGJFMRQNLO-UHFFFAOYSA-N 0.000 claims description 3
- 229940088872 Apoptosis inhibitor Drugs 0.000 claims description 3
- 229940049937 Pgp inhibitor Drugs 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 239000002168 alkylating agent Substances 0.000 claims description 3
- 229940100198 alkylating agent Drugs 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000002280 anti-androgenic effect Effects 0.000 claims description 3
- 230000000340 anti-metabolite Effects 0.000 claims description 3
- 239000000051 antiandrogen Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 239000013059 antihormonal agent Substances 0.000 claims description 3
- 239000002256 antimetabolite Substances 0.000 claims description 3
- 229940100197 antimetabolite Drugs 0.000 claims description 3
- 239000000158 apoptosis inhibitor Substances 0.000 claims description 3
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 3
- 239000002748 glycoprotein P inhibitor Substances 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 230000011278 mitosis Effects 0.000 claims description 3
- 239000003607 modifier Substances 0.000 claims description 3
- GVHSTZUQJGSYTF-UHFFFAOYSA-N n-[1-(3-acetamidoanilino)-6-methylisoquinolin-5-yl]-4-aminothieno[3,2-d]pyrimidine-7-carboxamide Chemical compound CC(=O)NC1=CC=CC(NC=2C3=CC=C(C)C(NC(=O)C=4C5=NC=NC(N)=C5SC=4)=C3C=CN=2)=C1 GVHSTZUQJGSYTF-UHFFFAOYSA-N 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 230000004083 survival effect Effects 0.000 claims description 3
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- QVPGHFJNLSYKII-UHFFFAOYSA-N 4-(cyclopropylamino)-n-[1-(4-methoxyanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(C1=CC=C2C)=NC=CC1=C2NC(=O)C(C1=NC=N2)=CSC1=C2NC1CC1 QVPGHFJNLSYKII-UHFFFAOYSA-N 0.000 claims description 2
- GNWNJKLEKJPWDH-UHFFFAOYSA-N 4-(cyclopropylamino)-n-[1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1CN(CC)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(C1=CC=C2C)=NC=CC1=C2NC(=O)C(C1=NC=N2)=CSC1=C2NC1CC1 GNWNJKLEKJPWDH-UHFFFAOYSA-N 0.000 claims description 2
- VEEGSEHEVFMILT-UHFFFAOYSA-N 4-(cyclopropylamino)-n-[6-methyl-1-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)anilino]isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=NC(C)=CN1C1=CC(NC=2C3=CC=C(C)C(NC(=O)C=4C5=NC=NC(NC6CC6)=C5SC=4)=C3C=CN=2)=CC(C(F)(F)F)=C1 VEEGSEHEVFMILT-UHFFFAOYSA-N 0.000 claims description 2
- WYQWNUOCOQEQFE-UHFFFAOYSA-N 4-(cyclopropylamino)-n-[6-methyl-1-[3-(trifluoromethyl)anilino]isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(NC5CC5)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(C(F)(F)F)=C1 WYQWNUOCOQEQFE-UHFFFAOYSA-N 0.000 claims description 2
- XBVJPJUCTBDXSV-UHFFFAOYSA-N 4-amino-n-(6-methyl-1-phenoxyisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1OC1=CC=CC=C1 XBVJPJUCTBDXSV-UHFFFAOYSA-N 0.000 claims description 2
- PDTFISDUASPSLR-UHFFFAOYSA-N 4-amino-n-(6-methyl-1-piperidin-1-ylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1N1CCCCC1 PDTFISDUASPSLR-UHFFFAOYSA-N 0.000 claims description 2
- QNDIZCVZLGBGOV-UHFFFAOYSA-N 4-amino-n-[1-(1,3-benzothiazol-6-ylamino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CN=C(NC=5C=C6SC=NC6=CC=5)C4=CC=C3C)=CSC2=C1N QNDIZCVZLGBGOV-UHFFFAOYSA-N 0.000 claims description 2
- OFUZMWNIHVMVTD-UHFFFAOYSA-N 4-amino-n-[1-(1h-indazol-5-ylamino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CN=C(NC=5C=C6C=NNC6=CC=5)C4=CC=C3C)=CSC2=C1N OFUZMWNIHVMVTD-UHFFFAOYSA-N 0.000 claims description 2
- IUHCHHJFWZQGCL-UHFFFAOYSA-N 4-amino-n-[1-(3,5-dichloroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC(Cl)=CC(Cl)=C1 IUHCHHJFWZQGCL-UHFFFAOYSA-N 0.000 claims description 2
- QIPXITDMCMSALH-UHFFFAOYSA-N 4-amino-n-[1-(3-bromoanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Br)=C1 QIPXITDMCMSALH-UHFFFAOYSA-N 0.000 claims description 2
- GNDBDDNLWIOKDN-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-4-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(F)C(Cl)=C1 GNDBDDNLWIOKDN-UHFFFAOYSA-N 0.000 claims description 2
- UCEIASNEZSNDKZ-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-4-methoxyanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=C(Cl)C(OC)=CC=C1NC(C1=CC=C2C)=NC=CC1=C2NC(=O)C1=CSC2=C(N)N=CN=C12 UCEIASNEZSNDKZ-UHFFFAOYSA-N 0.000 claims description 2
- OXZJUMXOBGMHEE-UHFFFAOYSA-N 4-amino-n-[1-(4-chloro-3-methoxyanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC=C(C)C(NC(=O)C=4C5=NC=NC(N)=C5SC=4)=C3C=CN=2)=C1 OXZJUMXOBGMHEE-UHFFFAOYSA-N 0.000 claims description 2
- ZIJYBRBVEOCWIN-UHFFFAOYSA-N 4-amino-n-[1-(4-hexanoylanilino)-6-methylisoquinolin-3-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=CC(C(=O)CCCCC)=CC=C1NC1=NC(NC(=O)C=2C3=NC=NC(N)=C3SC=2)=CC2=CC(C)=CC=C12 ZIJYBRBVEOCWIN-UHFFFAOYSA-N 0.000 claims description 2
- LBYZLOWPJLYEGX-UHFFFAOYSA-N 4-amino-n-[1-(4-methoxyanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(C1=CC=C2C)=NC=CC1=C2NC(=O)C1=CSC2=C(N)N=CN=C12 LBYZLOWPJLYEGX-UHFFFAOYSA-N 0.000 claims description 2
- SFCDLJQWUUDLLV-UHFFFAOYSA-N 4-amino-n-[1-[2-methoxy-5-(trifluoromethyl)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound COC1=CC=C(C(F)(F)F)C=C1NC(C1=CC=C2C)=NC=CC1=C2NC(=O)C1=CSC2=C(N)N=CN=C12 SFCDLJQWUUDLLV-UHFFFAOYSA-N 0.000 claims description 2
- KRJHLFHEGPBLGW-UHFFFAOYSA-N 4-amino-n-[1-[3-(methanesulfonamido)-4-methoxyanilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=C(NS(C)(=O)=O)C(OC)=CC=C1NC(C1=CC=C2C)=NC=CC1=C2NC(=O)C1=CSC2=C(N)N=CN=C12 KRJHLFHEGPBLGW-UHFFFAOYSA-N 0.000 claims description 2
- JULBSVOGQGLFSB-UHFFFAOYSA-N 4-amino-n-[1-[3-(methanesulfonamidomethyl)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(CNS(C)(=O)=O)=C1 JULBSVOGQGLFSB-UHFFFAOYSA-N 0.000 claims description 2
- OGXZZJNPWWZTSV-UHFFFAOYSA-N 4-amino-n-[1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1CN(CC)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(C1=CC=C2C)=NC=CC1=C2NC(=O)C1=CSC2=C(N)N=CN=C12 OGXZZJNPWWZTSV-UHFFFAOYSA-N 0.000 claims description 2
- PQUXOYXKMLTNPJ-UHFFFAOYSA-N 4-amino-n-[1-[4-chloro-3-(methoxymethyl)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=C(Cl)C(COC)=CC(NC=2C3=CC=C(C)C(NC(=O)C=4C5=NC=NC(N)=C5SC=4)=C3C=CN=2)=C1 PQUXOYXKMLTNPJ-UHFFFAOYSA-N 0.000 claims description 2
- KWVGSYVVOJAKJJ-UHFFFAOYSA-N 4-amino-n-[1-[4-chloro-3-(piperazin-1-ylmethyl)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC(C=1)=CC=C(Cl)C=1CN1CCNCC1 KWVGSYVVOJAKJJ-UHFFFAOYSA-N 0.000 claims description 2
- KIXHLIHNWDFJPZ-UHFFFAOYSA-N 4-amino-n-[1-[4-chloro-3-(trifluoromethyl)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C(C(F)(F)F)=C1 KIXHLIHNWDFJPZ-UHFFFAOYSA-N 0.000 claims description 2
- SAJBJKUYRDGASF-UHFFFAOYSA-N 4-amino-n-[1-[4-chloro-3-[[di(propan-2-yl)amino]methyl]anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=C(Cl)C(CN(C(C)C)C(C)C)=CC(NC=2C3=CC=C(C)C(NC(=O)C=4C5=NC=NC(N)=C5SC=4)=C3C=CN=2)=C1 SAJBJKUYRDGASF-UHFFFAOYSA-N 0.000 claims description 2
- ZVRLDDQTWANOOT-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-(3,4,5-trichloroanilino)isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC(Cl)=C(Cl)C(Cl)=C1 ZVRLDDQTWANOOT-UHFFFAOYSA-N 0.000 claims description 2
- PTTHHNZXEGXXRQ-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-(4-methylsulfinylanilino)isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(S(C)=O)C=C1 PTTHHNZXEGXXRQ-UHFFFAOYSA-N 0.000 claims description 2
- XFNFTBXMAXFRCS-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-(4-propanoylanilino)isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=CC(C(=O)CC)=CC=C1NC(C1=CC=C2C)=NC=CC1=C2NC(=O)C1=CSC2=C(N)N=CN=C12 XFNFTBXMAXFRCS-UHFFFAOYSA-N 0.000 claims description 2
- VUPOMWLNLJLRRE-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-(4-pyrrol-1-ylanilino)isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC(C=C1)=CC=C1N1C=CC=C1 VUPOMWLNLJLRRE-UHFFFAOYSA-N 0.000 claims description 2
- LAYZVUVIDISBSE-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-[(1-methylindazol-6-yl)amino]isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CN=C(NC=5C=C6N(C)N=CC6=CC=5)C4=CC=C3C)=CSC2=C1N LAYZVUVIDISBSE-UHFFFAOYSA-N 0.000 claims description 2
- QYKSXQNKZJVBBC-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-[(2-methyl-1,3-dioxoisoindol-5-yl)amino]isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CN=C(C4=CC=C3C)NC3=CC=C4C(=O)N(C(C4=C3)=O)C)=CSC2=C1N QYKSXQNKZJVBBC-UHFFFAOYSA-N 0.000 claims description 2
- BNOAZSXEBAOAIC-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-[(2-methylindazol-6-yl)amino]isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CN=C(NC5=CC6=NN(C)C=C6C=C5)C4=CC=C3C)=CSC2=C1N BNOAZSXEBAOAIC-UHFFFAOYSA-N 0.000 claims description 2
- AWHXEOZILHBAHI-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-[4-(trifluoromethoxy)anilino]isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(OC(F)(F)F)C=C1 AWHXEOZILHBAHI-UHFFFAOYSA-N 0.000 claims description 2
- YVYVHURMUXANFB-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-[4-(trifluoromethyl)anilino]isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(C(F)(F)F)C=C1 YVYVHURMUXANFB-UHFFFAOYSA-N 0.000 claims description 2
- 208000030090 Acute Disease Diseases 0.000 claims description 2
- 206010001233 Adenoma benign Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 201000000054 Coronary Restenosis Diseases 0.000 claims description 2
- 206010056489 Coronary artery restenosis Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000007659 Fibroadenoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000022873 Ocular disease Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 206010046431 Urethral cancer Diseases 0.000 claims description 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000003149 breast fibroadenoma Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000011066 hemangioma Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 2
- 239000004530 micro-emulsion Substances 0.000 claims description 2
- VDPIYNSZQSYYGQ-UHFFFAOYSA-N n-[1-(4-acetylanilino)-6-methylisoquinolin-5-yl]-4-aminothieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=CC(C(=O)C)=CC=C1NC(C1=CC=C2C)=NC=CC1=C2NC(=O)C1=CSC2=C(N)N=CN=C12 VDPIYNSZQSYYGQ-UHFFFAOYSA-N 0.000 claims description 2
- QNFXUJHQHGYLLV-UHFFFAOYSA-N n-[1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)anilino]-6-methylisoquinolin-5-yl]-4-(methylamino)thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1CN(CC)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(C1=CC=C2C)=NC=CC1=C2NC(=O)C1=CSC2=C(NC)N=CN=C12 QNFXUJHQHGYLLV-UHFFFAOYSA-N 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000008662 sclerosing adenosis of breast Diseases 0.000 claims description 2
- 201000002314 small intestine cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- LVFKCAMMRXCQQH-UHFFFAOYSA-N tert-butyl 6-[[5-[(4-aminothieno[3,2-d]pyrimidine-7-carbonyl)amino]-6-methylisoquinolin-1-yl]amino]indazole-1-carboxylate Chemical compound Cc1ccc2c(Nc3ccc4cnn(C(=O)OC(C)(C)C)c4c3)nccc2c1NC(=O)c1csc2c(N)ncnc12 LVFKCAMMRXCQQH-UHFFFAOYSA-N 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- WWGHMUKTDSVXNY-UHFFFAOYSA-N 4-amino-n-[1-(2,3-dihydro-1h-indol-6-ylamino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CN=C(NC=5C=C6NCCC6=CC=5)C4=CC=C3C)=CSC2=C1N WWGHMUKTDSVXNY-UHFFFAOYSA-N 0.000 claims 1
- IKSUOLMGDGVULN-UHFFFAOYSA-N 4-amino-n-[1-[(2-chloropyridin-4-yl)amino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=NC(Cl)=C1 IKSUOLMGDGVULN-UHFFFAOYSA-N 0.000 claims 1
- CYSUFUFGFDZSES-UHFFFAOYSA-N 4-amino-n-[1-[3-(dimethylamino)propylamino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CN=C(C4=CC=C3C)NCCCN(C)C)=CSC2=C1N CYSUFUFGFDZSES-UHFFFAOYSA-N 0.000 claims 1
- IUBMAABGOHZYBI-UHFFFAOYSA-N 4-amino-n-[1-[4-(methanesulfonamido)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(NS(C)(=O)=O)C=C1 IUBMAABGOHZYBI-UHFFFAOYSA-N 0.000 claims 1
- YOBVJKHKGDHDMD-UHFFFAOYSA-N 4-amino-n-[1-[4-chloro-3-(pyrrolidin-1-ylmethyl)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC(C=1)=CC=C(Cl)C=1CN1CCCC1 YOBVJKHKGDHDMD-UHFFFAOYSA-N 0.000 claims 1
- VRLDQOJWBZSZAH-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-(3,4,5-trimethoxyanilino)isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(NC=2C3=CC=C(C)C(NC(=O)C=4C5=NC=NC(N)=C5SC=4)=C3C=CN=2)=C1 VRLDQOJWBZSZAH-UHFFFAOYSA-N 0.000 claims 1
- PBRRHVYSPMKKAP-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-(4-morpholin-4-ylanilino)isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC(C=C1)=CC=C1N1CCOCC1 PBRRHVYSPMKKAP-UHFFFAOYSA-N 0.000 claims 1
- RTZCUSLGNIXZAL-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-(propan-2-ylamino)isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CN=C(C4=CC=C3C)NC(C)C)=CSC2=C1N RTZCUSLGNIXZAL-UHFFFAOYSA-N 0.000 claims 1
- RGTZRXZFUDHWPN-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-[3-(trifluoromethoxy)anilino]isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(OC(F)(F)F)=C1 RGTZRXZFUDHWPN-UHFFFAOYSA-N 0.000 claims 1
- 101000959121 Xenopus laevis Peptidyl-alpha-hydroxyglycine alpha-amidating lyase A Proteins 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 230000010261 cell growth Effects 0.000 abstract description 13
- 208000037824 growth disorder Diseases 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 description 225
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 204
- 238000005160 1H NMR spectroscopy Methods 0.000 description 163
- 238000001228 spectrum Methods 0.000 description 163
- 239000000243 solution Substances 0.000 description 139
- 238000000034 method Methods 0.000 description 133
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 90
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 73
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
- 239000007787 solid Substances 0.000 description 71
- 239000011541 reaction mixture Substances 0.000 description 70
- 235000019439 ethyl acetate Nutrition 0.000 description 68
- 229940093499 ethyl acetate Drugs 0.000 description 68
- 238000003756 stirring Methods 0.000 description 63
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 60
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 57
- 239000012044 organic layer Substances 0.000 description 55
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 42
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 40
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- 239000007864 aqueous solution Substances 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- 229960004592 isopropanol Drugs 0.000 description 25
- 239000012267 brine Substances 0.000 description 23
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- 239000011259 mixed solution Substances 0.000 description 21
- 235000017557 sodium bicarbonate Nutrition 0.000 description 21
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
- 238000010898 silica gel chromatography Methods 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 16
- 239000012153 distilled water Substances 0.000 description 16
- 238000000605 extraction Methods 0.000 description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 13
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 101000744436 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Trans-acting factor D Proteins 0.000 description 10
- 239000005457 ice water Substances 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 235000011054 acetic acid Nutrition 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 8
- 102100036725 Epithelial discoidin domain-containing receptor 1 Human genes 0.000 description 8
- 101710131668 Epithelial discoidin domain-containing receptor 1 Proteins 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 229910052742 iron Inorganic materials 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 8
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 8
- RWGBXAQMUBGGKQ-UHFFFAOYSA-N 4-(trifluoromethyl)pyridin-2-amine Chemical compound NC1=CC(C(F)(F)F)=CC=N1 RWGBXAQMUBGGKQ-UHFFFAOYSA-N 0.000 description 7
- 102000002706 Discoidin Domain Receptors Human genes 0.000 description 7
- 108010043648 Discoidin Domain Receptors Proteins 0.000 description 7
- 108091054455 MAP kinase family Proteins 0.000 description 7
- 102000043136 MAP kinase family Human genes 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- XHAMZTOKACCSNT-UHFFFAOYSA-N 4-aminothieno[3,2-d]pyrimidine-7-carboxylic acid Chemical compound NC1=NC=NC2=C1SC=C2C(O)=O XHAMZTOKACCSNT-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 239000010936 titanium Substances 0.000 description 6
- IWLPTUUERGDBAR-UHFFFAOYSA-N 1-chloro-6-methyl-5-nitroisoquinoline Chemical compound ClC1=NC=CC2=C([N+]([O-])=O)C(C)=CC=C21 IWLPTUUERGDBAR-UHFFFAOYSA-N 0.000 description 5
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 5
- CMEATEQCIZPULA-UHFFFAOYSA-N 4-chloro-3-[(dimethylamino)methyl]aniline Chemical compound CN(C)CC1=CC(N)=CC=C1Cl CMEATEQCIZPULA-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229910001873 dinitrogen Inorganic materials 0.000 description 5
- RIDGBLOXJGPVPE-UHFFFAOYSA-N n-(4-chlorophenyl)-6-methyl-5-nitroisoquinolin-1-amine Chemical compound N=1C=CC2=C([N+]([O-])=O)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 RIDGBLOXJGPVPE-UHFFFAOYSA-N 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 5
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- VOOSYUIRCUGKKB-UHFFFAOYSA-N 4-(cyclopropylamino)thieno[3,2-d]pyrimidine-7-carboxylic acid Chemical compound N1=CN=C2C(C(=O)O)=CSC2=C1NC1CC1 VOOSYUIRCUGKKB-UHFFFAOYSA-N 0.000 description 4
- NFBVTGIGCZBIBN-UHFFFAOYSA-N 5-n-(4-chlorophenyl)-6-methylisoquinoline-1,5-diamine Chemical compound CC1=CC=C2C(N)=NC=CC2=C1NC1=CC=C(Cl)C=C1 NFBVTGIGCZBIBN-UHFFFAOYSA-N 0.000 description 4
- PPEJLOXOMBAXES-UHFFFAOYSA-N 6-methylisoquinoline Chemical compound C1=NC=CC2=CC(C)=CC=C21 PPEJLOXOMBAXES-UHFFFAOYSA-N 0.000 description 4
- ORZRMRUXSPNQQL-UHFFFAOYSA-N 6-nitro-1h-indazole Chemical compound [O-][N+](=O)C1=CC=C2C=NNC2=C1 ORZRMRUXSPNQQL-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 101100248451 Arabidopsis thaliana RICE2 gene Proteins 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 description 4
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 230000005907 cancer growth Effects 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 229960003862 vemurafenib Drugs 0.000 description 4
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- BZORFPDSXLZWJF-UHFFFAOYSA-N N,N-dimethyl-1,4-phenylenediamine Chemical compound CN(C)C1=CC=C(N)C=C1 BZORFPDSXLZWJF-UHFFFAOYSA-N 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000006317 cyclopropyl amino group Chemical group 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 238000003541 multi-stage reaction Methods 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000004323 potassium nitrate Substances 0.000 description 3
- 235000010333 potassium nitrate Nutrition 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- GYERFGYLRQDHLO-UHFFFAOYSA-N 1-N-[4-chloro-3-[(dimethylamino)methyl]phenyl]-6-methylisoquinoline-1,5-diamine Chemical compound CN(C)Cc1cc(Nc2nccc3c(N)c(C)ccc23)ccc1Cl GYERFGYLRQDHLO-UHFFFAOYSA-N 0.000 description 2
- ABMIIJPKPFSMLK-UHFFFAOYSA-N 1-chloro-5-nitroisoquinoline Chemical compound N1=CC=C2C([N+](=O)[O-])=CC=CC2=C1Cl ABMIIJPKPFSMLK-UHFFFAOYSA-N 0.000 description 2
- JHPMRMBDPINHAV-UHFFFAOYSA-N 1-methyl-5-nitroindazole Chemical compound [O-][N+](=O)C1=CC=C2N(C)N=CC2=C1 JHPMRMBDPINHAV-UHFFFAOYSA-N 0.000 description 2
- PYOFNPHTKBSXOM-UHFFFAOYSA-N 1-methylindazol-5-amine Chemical compound NC1=CC=C2N(C)N=CC2=C1 PYOFNPHTKBSXOM-UHFFFAOYSA-N 0.000 description 2
- MTZOSTDWLSSPHA-UHFFFAOYSA-N 1-methylindol-6-amine Chemical compound C1=C(N)C=C2N(C)C=CC2=C1 MTZOSTDWLSSPHA-UHFFFAOYSA-N 0.000 description 2
- PZMKGWRBZNOIPQ-UHFFFAOYSA-N 1h-thieno[3,2-d]pyrimidin-4-one Chemical compound OC1=NC=NC2=C1SC=C2 PZMKGWRBZNOIPQ-UHFFFAOYSA-N 0.000 description 2
- QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 2
- MJIJVSMBCITEKW-UHFFFAOYSA-N 2-methylindazol-5-amine Chemical compound C1=C(N)C=CC2=NN(C)C=C21 MJIJVSMBCITEKW-UHFFFAOYSA-N 0.000 description 2
- FSWXOANXOQPCFF-UHFFFAOYSA-N 4'-aminopropiophenone Chemical compound CCC(=O)C1=CC=C(N)C=C1 FSWXOANXOQPCFF-UHFFFAOYSA-N 0.000 description 2
- DOMGWJZIKVFCTE-UHFFFAOYSA-N 4-(fluoromethoxy)aniline Chemical compound NC1=CC=C(OCF)C=C1 DOMGWJZIKVFCTE-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- PTABYIBXXLDSFH-UHFFFAOYSA-N 4-amino-n-[1-(2,4-dichloroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1Cl PTABYIBXXLDSFH-UHFFFAOYSA-N 0.000 description 2
- DOCXIFOGVNMDEM-UHFFFAOYSA-N 4-amino-n-[1-(4-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1F DOCXIFOGVNMDEM-UHFFFAOYSA-N 0.000 description 2
- SPXBOPPTLSURSC-UHFFFAOYSA-N 4-amino-n-[1-(4-ethoxyanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=CC(OCC)=CC=C1NC(C1=CC=C2C)=NC=CC1=C2NC(=O)C1=CSC2=C(N)N=CN=C12 SPXBOPPTLSURSC-UHFFFAOYSA-N 0.000 description 2
- QTOZWNDJWXEOLB-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-[(1-methylindazol-5-yl)amino]isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CN=C(NC=5C=C6C=NN(C)C6=CC=5)C4=CC=C3C)=CSC2=C1N QTOZWNDJWXEOLB-UHFFFAOYSA-N 0.000 description 2
- UUWISXIAFAGKEJ-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)anilino]isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1=NC(C)=CN1C1=CC(NC=2C3=CC=C(C)C(NC(=O)C=4C5=NC=NC(N)=C5SC=4)=C3C=CN=2)=CC(C(F)(F)F)=C1 UUWISXIAFAGKEJ-UHFFFAOYSA-N 0.000 description 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- MOVNHKVVWAPCKF-UHFFFAOYSA-N 4-aminothieno[3,2-d]pyrimidine-7-carbaldehyde Chemical compound NC1=NC=NC2=C1SC=C2C=O MOVNHKVVWAPCKF-UHFFFAOYSA-N 0.000 description 2
- PYRMWQDQTPVYRN-UHFFFAOYSA-N 4-chloro-3-(diethylaminomethyl)aniline Chemical compound CCN(CC)CC1=CC(N)=CC=C1Cl PYRMWQDQTPVYRN-UHFFFAOYSA-N 0.000 description 2
- IVRDOOUBVAGNMQ-UHFFFAOYSA-N 4-chloro-3-[[di(propan-2-yl)amino]methyl]aniline Chemical compound CC(C)N(C(C)C)CC1=CC(N)=CC=C1Cl IVRDOOUBVAGNMQ-UHFFFAOYSA-N 0.000 description 2
- YYPKZGWCMPOFRV-UHFFFAOYSA-N 6-methyl-5-nitroisoquinoline Chemical compound C1=NC=CC2=C([N+]([O-])=O)C(C)=CC=C21 YYPKZGWCMPOFRV-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- OGTWWDCYFPWKBA-UHFFFAOYSA-N C(C)N1CCN(CC1)CC1=C(C=C(C=C1)NC=1C=2C=CN=C(C2C=CC1C)N)C(F)(F)F Chemical compound C(C)N1CCN(CC1)CC1=C(C=C(C=C1)NC=1C=2C=CN=C(C2C=CC1C)N)C(F)(F)F OGTWWDCYFPWKBA-UHFFFAOYSA-N 0.000 description 2
- LMMJFBMMJUMSJS-UHFFFAOYSA-N CH5126766 Chemical compound CNS(=O)(=O)NC1=NC=CC(CC=2C(OC3=CC(OC=4N=CC=CN=4)=CC=C3C=2C)=O)=C1F LMMJFBMMJUMSJS-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005441 aurora Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- FUPHFLDQBJIQHC-UHFFFAOYSA-N methyl 4-[[5-[(4-aminothieno[3,2-d]pyrimidine-7-carbonyl)amino]-6-methylisoquinolin-1-yl]amino]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1NC(C1=CC=C2C)=NC=CC1=C2NC(=O)C1=CSC2=C(N)N=CN=C12 FUPHFLDQBJIQHC-UHFFFAOYSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 2
- RDNWNTBGUJDVOA-UHFFFAOYSA-N n-(1h-indazol-6-yl)-6-methyl-5-nitroisoquinolin-1-amine Chemical compound C1=C2C=NNC2=CC(NC=2C3=CC=C(C(=C3C=CN=2)[N+]([O-])=O)C)=C1 RDNWNTBGUJDVOA-UHFFFAOYSA-N 0.000 description 2
- KUDPGZONDFORKU-UHFFFAOYSA-N n-chloroaniline Chemical compound ClNC1=CC=CC=C1 KUDPGZONDFORKU-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 2
- 229960002218 sodium chlorite Drugs 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- PUWCNAHJTYTHKV-UHFFFAOYSA-N thieno[3,2-d]pyrimidine-7-carboxylic acid Chemical compound N1=CN=C2C(C(=O)O)=CSC2=C1 PUWCNAHJTYTHKV-UHFFFAOYSA-N 0.000 description 2
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 2
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 2
- 125000001680 trimethoxyphenyl group Chemical group 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- XGNXYCFREOZBOL-UHFFFAOYSA-N 1,3-benzodioxol-5-amine Chemical compound NC1=CC=C2OCOC2=C1 XGNXYCFREOZBOL-UHFFFAOYSA-N 0.000 description 1
- FAYAYUOZWYJNBD-UHFFFAOYSA-N 1,3-benzothiazol-6-amine Chemical compound NC1=CC=C2N=CSC2=C1 FAYAYUOZWYJNBD-UHFFFAOYSA-N 0.000 description 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- XNDXIAJIVPCCQR-UHFFFAOYSA-N 1,4-diethyl-2,3-dihydroquinoxalin-6-amine Chemical compound NC1=CC=C2N(CC)CCN(CC)C2=C1 XNDXIAJIVPCCQR-UHFFFAOYSA-N 0.000 description 1
- MPAKRADBVATBMQ-UHFFFAOYSA-N 1-(2-chloro-5-nitrophenyl)-n,n-dimethylmethanamine Chemical compound CN(C)CC1=CC([N+]([O-])=O)=CC=C1Cl MPAKRADBVATBMQ-UHFFFAOYSA-N 0.000 description 1
- VWZINROLVVODOZ-UHFFFAOYSA-N 1-(3-aminophenyl)-2,2,2-trifluoroethanone Chemical compound NC1=CC=CC(C(=O)C(F)(F)F)=C1 VWZINROLVVODOZ-UHFFFAOYSA-N 0.000 description 1
- IDTZTLCYGXLOHJ-UHFFFAOYSA-N 1-(3-aminophenyl)-2,2,2-trifluoroethanone 2,2,2-trifluoro-1-(3-nitrophenyl)ethanone Chemical compound FC(C(=O)C1=CC(=CC=C1)[N+](=O)[O-])(F)F.NC=1C=C(C=CC1)C(C(F)(F)F)=O IDTZTLCYGXLOHJ-UHFFFAOYSA-N 0.000 description 1
- GPRYKVSEZCQIHD-UHFFFAOYSA-N 1-(4-aminophenyl)ethanone Chemical compound CC(=O)C1=CC=C(N)C=C1 GPRYKVSEZCQIHD-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- ZFARJJGGGWHLDQ-UHFFFAOYSA-N 1-(6-aminoindazol-1-yl)ethanone Chemical compound C1=C(N)C=C2N(C(=O)C)N=CC2=C1 ZFARJJGGGWHLDQ-UHFFFAOYSA-N 0.000 description 1
- FYKFYSAOIYBANM-UHFFFAOYSA-N 1-(bromomethyl)-4-nitro-2-(trifluoromethyl)benzene;1-ethyl-4-[[4-nitro-2-(trifluoromethyl)phenyl]methyl]piperazine Chemical compound [O-][N+](=O)C1=CC=C(CBr)C(C(F)(F)F)=C1.C1CN(CC)CCN1CC1=CC=C([N+]([O-])=O)C=C1C(F)(F)F FYKFYSAOIYBANM-UHFFFAOYSA-N 0.000 description 1
- UXRBIXZEWJJGIC-UHFFFAOYSA-N 1-(fluoromethoxy)-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(OCF)C=C1 UXRBIXZEWJJGIC-UHFFFAOYSA-N 0.000 description 1
- QXYJYXCLWRDZOG-UHFFFAOYSA-N 1-(fluoromethoxy)-4-nitrobenzene (4-nitrophenyl)methanol Chemical compound [N+](=O)([O-])C1=CC=C(CO)C=C1.FCOC1=CC=C(C=C1)[N+](=O)[O-] QXYJYXCLWRDZOG-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- HQEANSPJHFFHEO-UHFFFAOYSA-N 1-bromo-5-nitronaphthalene N-(4-chlorophenyl)-5-nitronaphthalen-1-amine Chemical compound BrC1=CC=CC2=C(C=CC=C12)[N+](=O)[O-].ClC1=CC=C(C=C1)NC1=CC=CC2=C(C=CC=C12)[N+](=O)[O-] HQEANSPJHFFHEO-UHFFFAOYSA-N 0.000 description 1
- VEGJXUQQFQWQMP-UHFFFAOYSA-N 1-chloro-6-methyl-5-nitroisoquinoline 6-methyl-5-nitroisoquinoline Chemical compound CC=1C(=C2C=CN=CC2=CC1)[N+](=O)[O-].ClC1=NC=CC2=C(C(=CC=C12)C)[N+](=O)[O-] VEGJXUQQFQWQMP-UHFFFAOYSA-N 0.000 description 1
- VLJSJFKIGHYITE-UHFFFAOYSA-N 1-ethyl-4-[[4-nitro-2-(trifluoromethyl)phenyl]methyl]piperazine Chemical compound C1CN(CC)CCN1CC1=CC=C([N+]([O-])=O)C=C1C(F)(F)F VLJSJFKIGHYITE-UHFFFAOYSA-N 0.000 description 1
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 1
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 description 1
- TUWHJYXETJCCPJ-UHFFFAOYSA-N 1-methyl-6-nitroindazole Chemical compound C1=C([N+]([O-])=O)C=C2N(C)N=CC2=C1 TUWHJYXETJCCPJ-UHFFFAOYSA-N 0.000 description 1
- YTKNUPJYGSOVLV-UHFFFAOYSA-N 1-methylindazol-6-amine Chemical compound C1=C(N)C=C2N(C)N=CC2=C1 YTKNUPJYGSOVLV-UHFFFAOYSA-N 0.000 description 1
- PBYMYAJONQZORL-UHFFFAOYSA-N 1-methylisoquinoline Chemical compound C1=CC=C2C(C)=NC=CC2=C1 PBYMYAJONQZORL-UHFFFAOYSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- KEJFADGISRFLFO-UHFFFAOYSA-N 1H-indazol-6-amine Chemical compound NC1=CC=C2C=NNC2=C1 KEJFADGISRFLFO-UHFFFAOYSA-N 0.000 description 1
- XBTOSRUBOXQWBO-UHFFFAOYSA-N 1h-indazol-5-amine Chemical compound NC1=CC=C2NN=CC2=C1 XBTOSRUBOXQWBO-UHFFFAOYSA-N 0.000 description 1
- MIMYTSWNVBMNRH-UHFFFAOYSA-N 1h-indol-6-amine Chemical compound NC1=CC=C2C=CNC2=C1 MIMYTSWNVBMNRH-UHFFFAOYSA-N 0.000 description 1
- KZJRKRQSDZGHEC-UHFFFAOYSA-N 2,2,2-trifluoro-1-phenylethanone Chemical compound FC(F)(F)C(=O)C1=CC=CC=C1 KZJRKRQSDZGHEC-UHFFFAOYSA-N 0.000 description 1
- RRJUYQOFOMFVQS-UHFFFAOYSA-N 2,3,4-trichloroaniline Chemical compound NC1=CC=C(Cl)C(Cl)=C1Cl RRJUYQOFOMFVQS-UHFFFAOYSA-N 0.000 description 1
- BZKOZYWGZKRTIB-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-6-amine Chemical compound O1CCOC2=CC(N)=CC=C21 BZKOZYWGZKRTIB-UHFFFAOYSA-N 0.000 description 1
- KQCMTOWTPBNWDB-UHFFFAOYSA-N 2,4-dichloroaniline Chemical compound NC1=CC=C(Cl)C=C1Cl KQCMTOWTPBNWDB-UHFFFAOYSA-N 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- JEGLWVZRGFONCW-UHFFFAOYSA-N 2-aminothieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=C(N)N=C2C(C(=O)N)=CSC2=C1 JEGLWVZRGFONCW-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- BQTMHUUWYHEPNQ-UHFFFAOYSA-N 2-methoxy-4-morpholin-4-ylaniline Chemical compound C1=C(N)C(OC)=CC(N2CCOCC2)=C1 BQTMHUUWYHEPNQ-UHFFFAOYSA-N 0.000 description 1
- IWPBWVZEOVCZRX-UHFFFAOYSA-N 2-methyl-5-nitroindazole Chemical compound C1=C([N+]([O-])=O)C=CC2=NN(C)C=C21 IWPBWVZEOVCZRX-UHFFFAOYSA-N 0.000 description 1
- RJFYXEGJMSZKIR-UHFFFAOYSA-N 2-methyl-6-nitroindazole Chemical compound C1=CC([N+]([O-])=O)=CC2=NN(C)C=C21 RJFYXEGJMSZKIR-UHFFFAOYSA-N 0.000 description 1
- 239000001431 2-methylbenzaldehyde Substances 0.000 description 1
- CKQHAYFOPRIUOM-UHFFFAOYSA-N 3'-Aminoacetophenone Chemical compound CC(=O)C1=CC=CC(N)=C1 CKQHAYFOPRIUOM-UHFFFAOYSA-N 0.000 description 1
- XEFRNCLPPFDWAC-UHFFFAOYSA-N 3,4,5-trimethoxyaniline Chemical compound COC1=CC(N)=CC(OC)=C1OC XEFRNCLPPFDWAC-UHFFFAOYSA-N 0.000 description 1
- SDYWXFYBZPNOFX-UHFFFAOYSA-N 3,4-dichloroaniline Chemical compound NC1=CC=C(Cl)C(Cl)=C1 SDYWXFYBZPNOFX-UHFFFAOYSA-N 0.000 description 1
- LGDHZCLREKIGKJ-UHFFFAOYSA-N 3,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C=C1OC LGDHZCLREKIGKJ-UHFFFAOYSA-N 0.000 description 1
- UQRLKWGPEVNVHT-UHFFFAOYSA-N 3,5-dichloroaniline Chemical compound NC1=CC(Cl)=CC(Cl)=C1 UQRLKWGPEVNVHT-UHFFFAOYSA-N 0.000 description 1
- WWTGXYAJVXKEKL-UHFFFAOYSA-N 3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)aniline Chemical compound C1=NC(C)=CN1C1=CC(N)=CC(C(F)(F)F)=C1 WWTGXYAJVXKEKL-UHFFFAOYSA-N 0.000 description 1
- SADHVOSOZBAAGL-UHFFFAOYSA-N 3-(trifluoromethoxy)aniline Chemical compound NC1=CC=CC(OC(F)(F)F)=C1 SADHVOSOZBAAGL-UHFFFAOYSA-N 0.000 description 1
- VIUDTWATMPPKEL-UHFFFAOYSA-N 3-(trifluoromethyl)aniline Chemical compound NC1=CC=CC(C(F)(F)F)=C1 VIUDTWATMPPKEL-UHFFFAOYSA-N 0.000 description 1
- WOJBIBHVUSZAGS-UHFFFAOYSA-N 3-[(dimethylamino)methyl]aniline Chemical compound CN(C)CC1=CC=CC(N)=C1 WOJBIBHVUSZAGS-UHFFFAOYSA-N 0.000 description 1
- LZPLRAXAVPPVSX-UHFFFAOYSA-N 3-amino-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC(N)=C1 LZPLRAXAVPPVSX-UHFFFAOYSA-N 0.000 description 1
- PYDQTASEULDNRL-UHFFFAOYSA-N 3-amino-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(N)=C1 PYDQTASEULDNRL-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FVZODFVCIDBDGS-UHFFFAOYSA-N 3-bromo-4-chloroaniline Chemical compound NC1=CC=C(Cl)C(Br)=C1 FVZODFVCIDBDGS-UHFFFAOYSA-N 0.000 description 1
- PPXLRJUETYYCHW-UHFFFAOYSA-N 3-chloro-1-methylindazol-6-amine Chemical compound C1=C(N)C=C2N(C)N=C(Cl)C2=C1 PPXLRJUETYYCHW-UHFFFAOYSA-N 0.000 description 1
- BNTNWQPIBPBJOO-UHFFFAOYSA-N 3-chloro-2,4-difluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1F BNTNWQPIBPBJOO-UHFFFAOYSA-N 0.000 description 1
- XWBTZHDDWRNOQH-UHFFFAOYSA-N 3-chloro-2-fluoroaniline Chemical compound NC1=CC=CC(Cl)=C1F XWBTZHDDWRNOQH-UHFFFAOYSA-N 0.000 description 1
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 1
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 1
- GOPUCAPKOUZKPS-UHFFFAOYSA-N 3-fluoro-4-(4-methylpiperazin-1-yl)aniline Chemical compound C1CN(C)CCN1C1=CC=C(N)C=C1F GOPUCAPKOUZKPS-UHFFFAOYSA-N 0.000 description 1
- LJWAPDSCYTZUJU-UHFFFAOYSA-N 3-fluoro-4-methoxyaniline Chemical compound COC1=CC=C(N)C=C1F LJWAPDSCYTZUJU-UHFFFAOYSA-N 0.000 description 1
- MBNPJRQKQLLRIS-UHFFFAOYSA-N 3-methylsulfonylaniline Chemical compound CS(=O)(=O)C1=CC=CC(N)=C1 MBNPJRQKQLLRIS-UHFFFAOYSA-N 0.000 description 1
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 1
- DIOBEQCFVVJJBU-UHFFFAOYSA-N 4-(2-methoxyethoxy)aniline Chemical compound COCCOC1=CC=C(N)C=C1 DIOBEQCFVVJJBU-UHFFFAOYSA-N 0.000 description 1
- KEPUOYACJXZYTQ-UHFFFAOYSA-N 4-(4-ethylpiperazin-1-yl)aniline Chemical compound C1CN(CC)CCN1C1=CC=C(N)C=C1 KEPUOYACJXZYTQ-UHFFFAOYSA-N 0.000 description 1
- NDEZTSHWEPQVBX-UHFFFAOYSA-N 4-(difluoromethoxy)aniline Chemical compound NC1=CC=C(OC(F)F)C=C1 NDEZTSHWEPQVBX-UHFFFAOYSA-N 0.000 description 1
- HLIHWPGWKQEMAJ-UHFFFAOYSA-N 4-(methylamino)thieno[3,2-d]pyrimidine-7-carboxylic acid Chemical compound CNC1=NC=NC2=C1SC=C2C(O)=O HLIHWPGWKQEMAJ-UHFFFAOYSA-N 0.000 description 1
- XUJFOSLZQITUOI-UHFFFAOYSA-N 4-(trifluoromethoxy)aniline Chemical compound NC1=CC=C(OC(F)(F)F)C=C1 XUJFOSLZQITUOI-UHFFFAOYSA-N 0.000 description 1
- BLBDTBCGPHPIJK-UHFFFAOYSA-N 4-Amino-2-chloropyridine Chemical compound NC1=CC=NC(Cl)=C1 BLBDTBCGPHPIJK-UHFFFAOYSA-N 0.000 description 1
- LNKBDFVSILQKSI-UHFFFAOYSA-N 4-Chloro-3-methoxyaniline Chemical compound COC1=CC(N)=CC=C1Cl LNKBDFVSILQKSI-UHFFFAOYSA-N 0.000 description 1
- QYNKSEMCQMGSMM-UHFFFAOYSA-N 4-amino-1-phenylhexan-1-one Chemical compound CCC(N)CCC(=O)C1=CC=CC=C1 QYNKSEMCQMGSMM-UHFFFAOYSA-N 0.000 description 1
- MPIBSKMFPDGQJB-UHFFFAOYSA-N 4-amino-N-[1-(1H-indazol-5-ylamino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide hydrochloride Chemical compound Cl.Cc1ccc2c(Nc3ccc4[nH]ncc4c3)nccc2c1NC(=O)c1csc2c(N)ncnc12 MPIBSKMFPDGQJB-UHFFFAOYSA-N 0.000 description 1
- LHQDXSJKFRUKHD-UHFFFAOYSA-N 4-amino-n-[1-(1h-indazol-6-ylamino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide;hydrochloride Chemical compound Cl.N1=CN=C2C(C(=O)NC3=C4C=CN=C(NC=5C=C6NN=CC6=CC=5)C4=CC=C3C)=CSC2=C1N LHQDXSJKFRUKHD-UHFFFAOYSA-N 0.000 description 1
- QHTUJVQPEAAQDO-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2,4-difluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(F)C(Cl)=C1F QHTUJVQPEAAQDO-UHFFFAOYSA-N 0.000 description 1
- RFEWCQAWLXXDQI-UHFFFAOYSA-N 4-amino-n-[1-(3-chloroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1 RFEWCQAWLXXDQI-UHFFFAOYSA-N 0.000 description 1
- LBTOJFBUWMCHKS-UHFFFAOYSA-N 4-amino-n-[1-(4-cyanoanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(C#N)C=C1 LBTOJFBUWMCHKS-UHFFFAOYSA-N 0.000 description 1
- RDTGVMRPFRKENL-UHFFFAOYSA-N 4-amino-n-[1-(4-ethynylanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(C#C)C=C1 RDTGVMRPFRKENL-UHFFFAOYSA-N 0.000 description 1
- RFHHLEZYZLIMMI-UHFFFAOYSA-N 4-amino-n-[1-(4-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(F)C=C1 RFHHLEZYZLIMMI-UHFFFAOYSA-N 0.000 description 1
- OHVMYBPZTUUQOD-UHFFFAOYSA-N 4-amino-n-[1-(4-hydroxyanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(O)C=C1 OHVMYBPZTUUQOD-UHFFFAOYSA-N 0.000 description 1
- BMPSHNCDAQWDEZ-UHFFFAOYSA-N 4-amino-n-[1-[(3-chloro-1-methylindazol-6-yl)amino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CN=C(NC=5C=C6N(C)N=C(Cl)C6=CC=5)C4=CC=C3C)=CSC2=C1N BMPSHNCDAQWDEZ-UHFFFAOYSA-N 0.000 description 1
- WVRKCFNVCYCMNJ-UHFFFAOYSA-N 4-amino-n-[1-[(4-chlorophenyl)methylamino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NCC1=CC=C(Cl)C=C1 WVRKCFNVCYCMNJ-UHFFFAOYSA-N 0.000 description 1
- VOWRLHZYAXTEIT-UHFFFAOYSA-N 4-amino-n-[1-[(5-tert-butyl-1,2-oxazol-3-yl)amino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC=1C=C(C(C)(C)C)ON=1 VOWRLHZYAXTEIT-UHFFFAOYSA-N 0.000 description 1
- IHOGYXZVZKMMAX-UHFFFAOYSA-N 4-amino-n-[1-[3-(methanesulfonamido)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(NS(C)(=O)=O)=C1 IHOGYXZVZKMMAX-UHFFFAOYSA-N 0.000 description 1
- PIGVTYWKKVCOFL-UHFFFAOYSA-N 4-amino-n-[1-[3-[(dimethylamino)methyl]anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound CN(C)CC1=CC=CC(NC=2C3=CC=C(C)C(NC(=O)C=4C5=NC=NC(N)=C5SC=4)=C3C=CN=2)=C1 PIGVTYWKKVCOFL-UHFFFAOYSA-N 0.000 description 1
- BJROBPFGHZHXHY-UHFFFAOYSA-N 4-amino-n-[1-[3-fluoro-4-(4-methylpiperazin-1-yl)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC=C1NC(C1=CC=C2C)=NC=CC1=C2NC(=O)C1=CSC2=C(N)N=CN=C12 BJROBPFGHZHXHY-UHFFFAOYSA-N 0.000 description 1
- SUXLUDBBSIDEGN-UHFFFAOYSA-N 4-amino-n-[1-[4-(methanesulfonamidomethyl)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(CNS(C)(=O)=O)C=C1 SUXLUDBBSIDEGN-UHFFFAOYSA-N 0.000 description 1
- UJDUZMAVAYQZND-UHFFFAOYSA-N 4-amino-n-[1-[4-chloro-3-(piperazin-1-ylmethyl)anilino]-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide;hydrochloride Chemical compound Cl.N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC(C=1)=CC=C(Cl)C=1CN1CCNCC1 UJDUZMAVAYQZND-UHFFFAOYSA-N 0.000 description 1
- GBHWXSBVMSXCEW-UHFFFAOYSA-N 4-amino-n-[5-(4-chloroanilino)naphthalen-1-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound C=1SC=2C(N)=NC=NC=2C=1C(=O)NC(C1=CC=C2)=CC=CC1=C2NC1=CC=C(Cl)C=C1 GBHWXSBVMSXCEW-UHFFFAOYSA-N 0.000 description 1
- BFHAPXDHSKCMFH-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-(4-prop-2-ynoxyanilino)isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=C(OCC#C)C=C1 BFHAPXDHSKCMFH-UHFFFAOYSA-N 0.000 description 1
- NPDMFWZSWPKFFJ-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-(quinolin-5-ylamino)isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CN=C(NC=5C6=CC=CN=C6C=CC=5)C4=CC=C3C)=CSC2=C1N NPDMFWZSWPKFFJ-UHFFFAOYSA-N 0.000 description 1
- UNIVUMQYZQDLTB-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-[(1-methylindol-6-yl)amino]isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CN=C(NC=5C=C6N(C)C=CC6=CC=5)C4=CC=C3C)=CSC2=C1N UNIVUMQYZQDLTB-UHFFFAOYSA-N 0.000 description 1
- XFIHRWUMRXPGKO-UHFFFAOYSA-N 4-amino-n-[6-methyl-1-[(4-oxochromen-6-yl)amino]isoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CN=C(NC=5C=C6C(=O)C=COC6=CC=5)C4=CC=C3C)=CSC2=C1N XFIHRWUMRXPGKO-UHFFFAOYSA-N 0.000 description 1
- YBAZINRZQSAIAY-UHFFFAOYSA-N 4-aminobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1 YBAZINRZQSAIAY-UHFFFAOYSA-N 0.000 description 1
- GZRMNMGWNKSANY-UHFFFAOYSA-N 4-bromo-2-fluoroaniline Chemical compound NC1=CC=C(Br)C=C1F GZRMNMGWNKSANY-UHFFFAOYSA-N 0.000 description 1
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
- CSFDTBRRIBJILD-UHFFFAOYSA-N 4-chloro-2-fluoroaniline Chemical compound NC1=CC=C(Cl)C=C1F CSFDTBRRIBJILD-UHFFFAOYSA-N 0.000 description 1
- AKNSTVMTJIIGEX-UHFFFAOYSA-N 4-chloro-3-(methoxymethyl)aniline Chemical compound COCC1=CC(N)=CC=C1Cl AKNSTVMTJIIGEX-UHFFFAOYSA-N 0.000 description 1
- MQWNBMBBDXMIHJ-UHFFFAOYSA-N 4-chloro-3-(piperidin-1-ylmethyl)aniline Chemical compound NC1=CC=C(Cl)C(CN2CCCCC2)=C1 MQWNBMBBDXMIHJ-UHFFFAOYSA-N 0.000 description 1
- IJPJYADTQATOIX-UHFFFAOYSA-N 4-chloro-3-(pyrrolidin-1-ylmethyl)aniline Chemical compound NC1=CC=C(Cl)C(CN2CCCC2)=C1 IJPJYADTQATOIX-UHFFFAOYSA-N 0.000 description 1
- LRDMKYBYGCHWIM-UHFFFAOYSA-N 4-chloro-3-[(dimethylamino)methyl]aniline N-[4-chloro-3-[(dimethylamino)methyl]phenyl]-6-methyl-5-nitroisoquinolin-1-amine Chemical compound ClC1=C(C=C(N)C=C1)CN(C)C.ClC1=C(C=C(C=C1)NC1=NC=CC2=C(C(=CC=C12)C)[N+](=O)[O-])CN(C)C LRDMKYBYGCHWIM-UHFFFAOYSA-N 0.000 description 1
- ACMJJQYSPUPMPN-UHFFFAOYSA-N 4-chloro-3-fluoroaniline Chemical compound NC1=CC=C(Cl)C(F)=C1 ACMJJQYSPUPMPN-UHFFFAOYSA-N 0.000 description 1
- XXNOGQJZAOXWAQ-UHFFFAOYSA-N 4-chlorophenylhydrazine Chemical compound NNC1=CC=C(Cl)C=C1 XXNOGQJZAOXWAQ-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- IMPPGHMHELILKG-UHFFFAOYSA-N 4-ethoxyaniline Chemical compound CCOC1=CC=C(N)C=C1 IMPPGHMHELILKG-UHFFFAOYSA-N 0.000 description 1
- JXYITCJMBRETQX-UHFFFAOYSA-N 4-ethynylaniline Chemical compound NC1=CC=C(C#C)C=C1 JXYITCJMBRETQX-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- SULNLNVYOGZGNK-UHFFFAOYSA-N 4-methylsulfinylaniline Chemical compound CS(=O)C1=CC=C(N)C=C1 SULNLNVYOGZGNK-UHFFFAOYSA-N 0.000 description 1
- PHNDZBFLOPIMSM-UHFFFAOYSA-N 4-morpholin-4-ylaniline Chemical compound C1=CC(N)=CC=C1N1CCOCC1 PHNDZBFLOPIMSM-UHFFFAOYSA-N 0.000 description 1
- FPLSLCJCSKFAMA-UHFFFAOYSA-N 4-prop-2-ynoxyaniline Chemical compound NC1=CC=C(OCC#C)C=C1 FPLSLCJCSKFAMA-UHFFFAOYSA-N 0.000 description 1
- MLNFMFAMNBGAQT-UHFFFAOYSA-N 4-propan-2-yloxyaniline Chemical compound CC(C)OC1=CC=C(N)C=C1 MLNFMFAMNBGAQT-UHFFFAOYSA-N 0.000 description 1
- NHLHWHRXMZZWGA-UHFFFAOYSA-N 4-pyrrol-1-ylaniline Chemical compound C1=CC(N)=CC=C1N1C=CC=C1 NHLHWHRXMZZWGA-UHFFFAOYSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 description 1
- ASPDJZINBYYZRU-UHFFFAOYSA-N 5-amino-2-chlorobenzotrifluoride Chemical compound NC1=CC=C(Cl)C(C(F)(F)F)=C1 ASPDJZINBYYZRU-UHFFFAOYSA-N 0.000 description 1
- KMEBUNSLFRQSEM-UHFFFAOYSA-N 5-amino-2-methylisoindole-1,3-dione Chemical compound C1=C(N)C=C2C(=O)N(C)C(=O)C2=C1 KMEBUNSLFRQSEM-UHFFFAOYSA-N 0.000 description 1
- WSGURAYTCUVDQL-UHFFFAOYSA-N 5-nitro-1h-indazole Chemical compound [O-][N+](=O)C1=CC=C2NN=CC2=C1 WSGURAYTCUVDQL-UHFFFAOYSA-N 0.000 description 1
- GGXGVZJHUKEJHO-UHFFFAOYSA-N 5-tert-butyl-1,2-oxazol-3-amine Chemical compound CC(C)(C)C1=CC(N)=NO1 GGXGVZJHUKEJHO-UHFFFAOYSA-N 0.000 description 1
- BEVVUJBVEXJGKM-UHFFFAOYSA-N 6-amino-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(N)=CC=C21 BEVVUJBVEXJGKM-UHFFFAOYSA-N 0.000 description 1
- MBBFNMNVDPOREX-UHFFFAOYSA-N 6-aminochromen-4-one Chemical compound O1C=CC(=O)C2=CC(N)=CC=C21 MBBFNMNVDPOREX-UHFFFAOYSA-N 0.000 description 1
- IGRNCJMPZCWJAG-UHFFFAOYSA-N 6-bromo-n-(4-chlorophenyl)-7-methyl-8-nitroquinazolin-4-amine Chemical compound N=1C=NC2=C([N+]([O-])=O)C(C)=C(Br)C=C2C=1NC1=CC=C(Cl)C=C1 IGRNCJMPZCWJAG-UHFFFAOYSA-N 0.000 description 1
- QAJYCQZQLVENRZ-UHFFFAOYSA-N 6-chloropyridin-3-amine Chemical compound NC1=CC=C(Cl)N=C1 QAJYCQZQLVENRZ-UHFFFAOYSA-N 0.000 description 1
- UUVDJIWRSIJEBS-UHFFFAOYSA-N 6-methoxypyridin-3-amine Chemical compound COC1=CC=C(N)C=N1 UUVDJIWRSIJEBS-UHFFFAOYSA-N 0.000 description 1
- FZKQIUFNSYCJNS-UHFFFAOYSA-N 6-methyl-5-n-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]isoquinoline-1,5-diamine Chemical compound C1=NC(C)=CN1C1=CC(NC=2C3=CC=NC(N)=C3C=CC=2C)=CC(C(F)(F)F)=C1 FZKQIUFNSYCJNS-UHFFFAOYSA-N 0.000 description 1
- AZNSQTRNMYYEAT-UHFFFAOYSA-N 6-methyl-5-n-[3-(trifluoromethyl)phenyl]isoquinoline-1,5-diamine Chemical compound CC1=CC=C2C(N)=NC=CC2=C1NC1=CC=CC(C(F)(F)F)=C1 AZNSQTRNMYYEAT-UHFFFAOYSA-N 0.000 description 1
- XNKLDBHXRXKNOR-UHFFFAOYSA-N 6-methylisoquinolin-5-amine Chemical compound C1=NC=CC2=C(N)C(C)=CC=C21 XNKLDBHXRXKNOR-UHFFFAOYSA-N 0.000 description 1
- UENBBJXGCWILBM-UHFFFAOYSA-N 6-methylpyridin-3-amine Chemical compound CC1=CC=C(N)C=N1 UENBBJXGCWILBM-UHFFFAOYSA-N 0.000 description 1
- LTNYDSMDSLOMSM-UHFFFAOYSA-N 6-nitro-2,3-dihydro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2CCNC2=C1 LTNYDSMDSLOMSM-UHFFFAOYSA-N 0.000 description 1
- SFFNZDXKMOSLNK-UHFFFAOYSA-N 7-bromo-1h-thieno[3,2-d]pyrimidin-4-one Chemical compound N1C=NC(=O)C2=C1C(Br)=CS2 SFFNZDXKMOSLNK-UHFFFAOYSA-N 0.000 description 1
- FHPLLDPRJUHXOG-UHFFFAOYSA-N 7-bromothieno[3,2-d]pyrimidin-4-amine 7-ethenylthieno[3,2-d]pyrimidin-4-amine Chemical compound BrC1=CSC2=C1N=CN=C2N.C(=C)C2=CSC1=C2N=CN=C1N FHPLLDPRJUHXOG-UHFFFAOYSA-N 0.000 description 1
- APPHSAIPZPYEGB-UHFFFAOYSA-N 7-methyl-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C=2C1=CC(C)=CC=2 APPHSAIPZPYEGB-UHFFFAOYSA-N 0.000 description 1
- KJTYNZWEAIRZHT-UHFFFAOYSA-N 7-methyl-1h-thieno[3,2-d]pyrimidin-4-one Chemical compound N1C=NC(=O)C2=C1C(C)=CS2 KJTYNZWEAIRZHT-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- MVPMPMRWHSIWLQ-UHFFFAOYSA-N BrC=1C=C2C(NC=NC2=C(C1C)[N+](=O)[O-])=O.BrC=1C=C2C(=NC=NC2=C(C1C)[N+](=O)[O-])Cl Chemical compound BrC=1C=C2C(NC=NC2=C(C1C)[N+](=O)[O-])=O.BrC=1C=C2C(=NC=NC2=C(C1C)[N+](=O)[O-])Cl MVPMPMRWHSIWLQ-UHFFFAOYSA-N 0.000 description 1
- YDHFMTHANUWLEK-UHFFFAOYSA-N BrC=1C=C2C(NC=NC2=CC1C)=O.BrC=1C=C2C(NC=NC2=C(C1C)[N+](=O)[O-])=O Chemical compound BrC=1C=C2C(NC=NC2=CC1C)=O.BrC=1C=C2C(NC=NC2=C(C1C)[N+](=O)[O-])=O YDHFMTHANUWLEK-UHFFFAOYSA-N 0.000 description 1
- NJSSRENPRJYGGW-UHFFFAOYSA-N CC(C(CC#N)=O)(C)C.C(C)(C)(C)C1=CC(=NO1)N Chemical compound CC(C(CC#N)=O)(C)C.C(C)(C)(C)C1=CC(=NO1)N NJSSRENPRJYGGW-UHFFFAOYSA-N 0.000 description 1
- WUSFRCZXOBADBF-UHFFFAOYSA-N CC1=C(C=C(C=C1)[N+](=O)[O-])C(F)(F)F.BrCC1=C(C=C(C=C1)[N+](=O)[O-])C(F)(F)F Chemical compound CC1=C(C=C(C=C1)[N+](=O)[O-])C(F)(F)F.BrCC1=C(C=C(C=C1)[N+](=O)[O-])C(F)(F)F WUSFRCZXOBADBF-UHFFFAOYSA-N 0.000 description 1
- BMUCCYXXHLJAIY-UHFFFAOYSA-N CC1=CC=C2C(NC=NC2=C1)=O.BrC=1C=C2C(NC=NC2=CC1C)=O Chemical compound CC1=CC=C2C(NC=NC2=C1)=O.BrC=1C=C2C(NC=NC2=CC1C)=O BMUCCYXXHLJAIY-UHFFFAOYSA-N 0.000 description 1
- PUDDDNFRYAVNLB-UHFFFAOYSA-N CC=1C(=C2C=CN=CC2=CC1)[N+](=O)[O-].CC1=C(C=2C=CN=CC2C=C1)N Chemical compound CC=1C(=C2C=CN=CC2=CC1)[N+](=O)[O-].CC1=C(C=2C=CN=CC2C=C1)N PUDDDNFRYAVNLB-UHFFFAOYSA-N 0.000 description 1
- SBRLNXGZCZOZBR-UHFFFAOYSA-N CC=1C(=C2C=CN=CC2=CC1)[N+](=O)[O-].CC=1C(=C2C=C[N+](=CC2=CC1)[O-])[N+](=O)[O-] Chemical compound CC=1C(=C2C=CN=CC2=CC1)[N+](=O)[O-].CC=1C(=C2C=C[N+](=CC2=CC1)[O-])[N+](=O)[O-] SBRLNXGZCZOZBR-UHFFFAOYSA-N 0.000 description 1
- GLBJPDSSSRFZEE-UHFFFAOYSA-N CN1N=CC2=CC=C(C=C12)[N+](=O)[O-].CN1N=C(C2=CC=CC=C12)N Chemical compound CN1N=CC2=CC=C(C=C12)[N+](=O)[O-].CN1N=C(C2=CC=CC=C12)N GLBJPDSSSRFZEE-UHFFFAOYSA-N 0.000 description 1
- NGVFTFAETXRDDB-UHFFFAOYSA-N COC(=O)C=1SC=C(C1N)C.CC1=CSC2=C1N=CNC2=O Chemical compound COC(=O)C=1SC=C(C1N)C.CC1=CSC2=C1N=CNC2=O NGVFTFAETXRDDB-UHFFFAOYSA-N 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- CJEANBTUHRZRPV-UHFFFAOYSA-N ClC1=C(C=O)C=C(C=C1)[N+](=O)[O-].ClC1=C(CN2CCN(CC2)C(=O)OC(C)(C)C)C=C(C=C1)[N+](=O)[O-] Chemical compound ClC1=C(C=O)C=C(C=C1)[N+](=O)[O-].ClC1=C(CN2CCN(CC2)C(=O)OC(C)(C)C)C=C(C=C1)[N+](=O)[O-] CJEANBTUHRZRPV-UHFFFAOYSA-N 0.000 description 1
- PNFTUFNTHILUBX-UHFFFAOYSA-N ClC1=NC=CC2=C(C(=CC=C12)C)[N+](=O)[O-].ClC1=CC=C(C=C1)NC1=NC=CC2=C(C(=CC=C12)C)[N+](=O)[O-] Chemical compound ClC1=NC=CC2=C(C(=CC=C12)C)[N+](=O)[O-].ClC1=CC=C(C=C1)NC1=NC=CC2=C(C(=CC=C12)C)[N+](=O)[O-] PNFTUFNTHILUBX-UHFFFAOYSA-N 0.000 description 1
- HBFZYKJYEZOCAC-UHFFFAOYSA-N ClC=1C2=C(N=CN1)C(=CS2)C.CC2=CSC1=C2N=CN=C1 Chemical compound ClC=1C2=C(N=CN1)C(=CS2)C.CC2=CSC1=C2N=CN=C1 HBFZYKJYEZOCAC-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WVXNSAVVKYZVOE-UHFFFAOYSA-N DCC-2036 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=C4C=CC=NC4=CC=3)=CC=2)=C1 WVXNSAVVKYZVOE-UHFFFAOYSA-N 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010049959 Discoidins Proteins 0.000 description 1
- 101100508533 Drosophila melanogaster IKKbeta gene Proteins 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 101000944251 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) Calcium/calmodulin-dependent protein kinase cmkA Proteins 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000714174 Feline sarcoma virus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102100032822 Homeodomain-interacting protein kinase 1 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 description 1
- 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 description 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101001066404 Homo sapiens Homeodomain-interacting protein kinase 1 Proteins 0.000 description 1
- 101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 description 1
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 101000601441 Homo sapiens Serine/threonine-protein kinase Nek2 Proteins 0.000 description 1
- 101000987310 Homo sapiens Serine/threonine-protein kinase PAK 2 Proteins 0.000 description 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 1
- 101710141394 MAP kinase-activated protein kinase 2 Proteins 0.000 description 1
- 108700012928 MAPK14 Proteins 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 208000026680 Metabolic Brain disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 101100180319 Mus musculus Itk gene Proteins 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 description 1
- 101710198035 Myosin light chain kinase, smooth muscle Proteins 0.000 description 1
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 1
- 102100022437 Myotonin-protein kinase Human genes 0.000 description 1
- FQOUCIYLPASENR-UHFFFAOYSA-N N-(4-chlorophenyl)-5-nitronaphthalen-1-amine Chemical compound [O-][N+](=O)c1cccc2c(Nc3ccc(Cl)cc3)cccc12 FQOUCIYLPASENR-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 229940123690 Raf kinase inhibitor Drugs 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 102100039313 Rho-associated protein kinase 1 Human genes 0.000 description 1
- 101710088411 Rho-associated protein kinase 1 Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 102100037703 Serine/threonine-protein kinase Nek2 Human genes 0.000 description 1
- 102100027939 Serine/threonine-protein kinase PAK 2 Human genes 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 description 1
- GDAOWNAUCMIBIP-UHFFFAOYSA-N [N+](=O)([O-])C1=CC=C2C=NN(C2=C1)C(C)=O.NC1=CC=C2C=NN(C2=C1)C(C)=O Chemical compound [N+](=O)([O-])C1=CC=C2C=NN(C2=C1)C(C)=O.NC1=CC=C2C=NN(C2=C1)C(C)=O GDAOWNAUCMIBIP-UHFFFAOYSA-N 0.000 description 1
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- 229910001634 calcium fluoride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 150000004653 carbonic acids Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical compound CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000004212 difluorophenyl group Chemical group 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- DIDJZJDDXQPTLN-UHFFFAOYSA-N indazole-1-carboxylic acid Chemical compound C1=CC=C2N(C(=O)O)N=CC2=C1 DIDJZJDDXQPTLN-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- TWEQNZZOOFKOER-UHFFFAOYSA-N methyl 3-aminothiophene-2-carboxylate Chemical compound COC(=O)C=1SC=CC=1N TWEQNZZOOFKOER-UHFFFAOYSA-N 0.000 description 1
- LZXXNPOYQCLXRS-UHFFFAOYSA-N methyl 4-aminobenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1 LZXXNPOYQCLXRS-UHFFFAOYSA-N 0.000 description 1
- BUFZZXCVOFBHLS-UHFFFAOYSA-N methyl 4-aminothiophene-3-carboxylate Chemical compound COC(=O)C1=CSC=C1N BUFZZXCVOFBHLS-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- PEMGGJDINLGTON-UHFFFAOYSA-N n-(3-aminophenyl)acetamide Chemical compound CC(=O)NC1=CC=CC(N)=C1 PEMGGJDINLGTON-UHFFFAOYSA-N 0.000 description 1
- UQRRCQRFQGOHAI-UHFFFAOYSA-N n-(3-aminophenyl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC(N)=C1 UQRRCQRFQGOHAI-UHFFFAOYSA-N 0.000 description 1
- ZGZFEDUYJFEJAW-UHFFFAOYSA-N n-(4-aminophenyl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=C(N)C=C1 ZGZFEDUYJFEJAW-UHFFFAOYSA-N 0.000 description 1
- OHRWLUAIBLJRNI-UHFFFAOYSA-N n-(5-amino-2-chlorophenyl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC(N)=CC=C1Cl OHRWLUAIBLJRNI-UHFFFAOYSA-N 0.000 description 1
- ZFBWWGLKRMKNGN-UHFFFAOYSA-N n-(5-amino-2-methoxyphenyl)methanesulfonamide Chemical compound COC1=CC=C(N)C=C1NS(C)(=O)=O ZFBWWGLKRMKNGN-UHFFFAOYSA-N 0.000 description 1
- SLFVYFOEHHLHDW-UHFFFAOYSA-N n-(trifluoromethyl)aniline Chemical compound FC(F)(F)NC1=CC=CC=C1 SLFVYFOEHHLHDW-UHFFFAOYSA-N 0.000 description 1
- NERJYEUDZIHCNK-UHFFFAOYSA-N n-[(3-aminophenyl)methyl]methanesulfonamide Chemical compound CS(=O)(=O)NCC1=CC=CC(N)=C1 NERJYEUDZIHCNK-UHFFFAOYSA-N 0.000 description 1
- TUAUDVGBJMBLTF-UHFFFAOYSA-N n-[(4-aminophenyl)methyl]methanesulfonamide Chemical compound CS(=O)(=O)NCC1=CC=C(N)C=C1 TUAUDVGBJMBLTF-UHFFFAOYSA-N 0.000 description 1
- OGOOIMIIZARYGZ-UHFFFAOYSA-N n-[1-(3-acetylanilino)-6-methylisoquinolin-5-yl]-4-aminothieno[3,2-d]pyrimidine-7-carboxamide Chemical compound CC(=O)C1=CC=CC(NC=2C3=CC=C(C)C(NC(=O)C=4C5=NC=NC(N)=C5SC=4)=C3C=CN=2)=C1 OGOOIMIIZARYGZ-UHFFFAOYSA-N 0.000 description 1
- YNYZVJHCMJDDEK-UHFFFAOYSA-N n-[1-[(1-acetylindazol-6-yl)amino]-6-methylisoquinolin-5-yl]-4-aminothieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N1=CN=C2C(C(=O)NC3=C4C=CN=C(C4=CC=C3C)NC3=CC=C4C=NN(C4=C3)C(=O)C)=CSC2=C1N YNYZVJHCMJDDEK-UHFFFAOYSA-N 0.000 description 1
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 1
- XMKKDZFLEISDBE-UHFFFAOYSA-N n-[3-[(6-methyl-5-nitroisoquinolin-1-yl)amino]phenyl]methanesulfonamide Chemical compound N=1C=CC2=C([N+]([O-])=O)C(C)=CC=C2C=1NC1=CC=CC(NS(C)(=O)=O)=C1 XMKKDZFLEISDBE-UHFFFAOYSA-N 0.000 description 1
- AUWQVBQQIZEMLD-UHFFFAOYSA-N n-[4-chloro-3-[(dimethylamino)methyl]phenyl]-6-methyl-5-nitroisoquinolin-1-amine Chemical compound C1=C(Cl)C(CN(C)C)=CC(NC=2C3=CC=C(C)C(=C3C=CN=2)[N+]([O-])=O)=C1 AUWQVBQQIZEMLD-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229940080607 nexavar Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- FXLOVSHXALFLKQ-UHFFFAOYSA-N p-tolualdehyde Chemical compound CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 1
- RZXMPPFPUUCRFN-UHFFFAOYSA-N p-toluidine Chemical compound CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 1
- LRTFPLFDLJYEKT-UHFFFAOYSA-N para-isopropylaniline Chemical compound CC(C)C1=CC=C(N)C=C1 LRTFPLFDLJYEKT-UHFFFAOYSA-N 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 102000051624 phosphatidylethanolamine binding protein Human genes 0.000 description 1
- 108700021017 phosphatidylethanolamine binding protein Proteins 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical class [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical class [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- VBJGJHBYWREJQD-UHFFFAOYSA-M sodium;dihydrogen phosphate;dihydrate Chemical compound O.O.[Na+].OP(O)([O-])=O VBJGJHBYWREJQD-UHFFFAOYSA-M 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- MLFFIJPTVSVNPA-UHFFFAOYSA-N tert-butyl 4-[(2-chloro-5-nitrophenyl)methyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC1=CC([N+]([O-])=O)=CC=C1Cl MLFFIJPTVSVNPA-UHFFFAOYSA-N 0.000 description 1
- CQWOFJHYELPDPL-UHFFFAOYSA-N tert-butyl 4-[(5-amino-2-chlorophenyl)methyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC1=CC(N)=CC=C1Cl CQWOFJHYELPDPL-UHFFFAOYSA-N 0.000 description 1
- ZUICVUBVMOQUFW-UHFFFAOYSA-N tert-butyl 4-[(5-amino-2-chlorophenyl)methyl]piperazine-1-carboxylate tert-butyl 4-[[2-chloro-5-[(6-methyl-5-nitroisoquinolin-1-yl)amino]phenyl]methyl]piperazine-1-carboxylate Chemical compound NC=1C=CC(=C(CN2CCN(CC2)C(=O)OC(C)(C)C)C1)Cl.ClC1=C(CN2CCN(CC2)C(=O)OC(C)(C)C)C=C(C=C1)NC1=NC=CC2=C(C(=CC=C12)C)[N+](=O)[O-] ZUICVUBVMOQUFW-UHFFFAOYSA-N 0.000 description 1
- ZOEGRRYBIBTUIY-UHFFFAOYSA-N tert-butyl 4-[[2-chloro-5-[(6-methyl-5-nitroisoquinolin-1-yl)amino]phenyl]methyl]piperazine-1-carboxylate Chemical compound N=1C=CC2=C([N+]([O-])=O)C(C)=CC=C2C=1NC(C=1)=CC=C(Cl)C=1CN1CCN(C(=O)OC(C)(C)C)CC1 ZOEGRRYBIBTUIY-UHFFFAOYSA-N 0.000 description 1
- OUXDYWVVAVNTHS-UHFFFAOYSA-N tert-butyl 4-[[5-[(5-amino-6-methylisoquinolin-1-yl)amino]-2-chlorophenyl]methyl]piperazine-1-carboxylate Chemical compound Cc1ccc2c(Nc3ccc(Cl)c(CN4CCN(CC4)C(=O)OC(C)(C)C)c3)nccc2c1N OUXDYWVVAVNTHS-UHFFFAOYSA-N 0.000 description 1
- BFHIPZRCKRPULM-UHFFFAOYSA-N tert-butyl 6-[(6-methyl-5-nitroisoquinolin-1-yl)amino]indazole-1-carboxylate Chemical compound C1=C2C=NN(C(=O)OC(C)(C)C)C2=CC(NC=2C3=CC=C(C(=C3C=CN=2)[N+]([O-])=O)C)=C1 BFHIPZRCKRPULM-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- AROWMXGGAHTZPG-UHFFFAOYSA-N thieno[3,2-d]pyrimidine-7-carbaldehyde Chemical compound N1=CN=C2C(C=O)=CSC2=C1 AROWMXGGAHTZPG-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.
Description
THIENO(3,2-d][PYRIMIDINE DERIVATIVES HAVING #1: | 5 PY 3:33
INHIBITORY ACTIVITY FOR PROTEIN KINASES ;
The present invention relates to thieno[3,2-d]-pyrimidine derivatives and pharmaceutically acceptable salts thereof having inhibitory activity for protein kinases, and a pharmaceutical composition comprising same as an active ingredient for prevention and treatment of diseases caused by abnormal cell growth of protein kinases. :
A protein kinase is an enzyme, which plays a key role in mediation of signal transduction via phosphorylation of a hydroxyl group present in a tyrosine, serine or threonine residue, and; thus; is deeply involved in the regulation of cell growth, differentiation, proliferation, etc. oo
As is well known, a balance between “on-states” and “off-states” of an intracellular signaling pathway is essential for maintenance of homeostasis of a cell. When a normal intracellular signaling pathway of, e.g., mostly continuation of “on-state” of intracellular signals is interrupted due to overexpression or mutation of a specific protein kinase, it may lead to an outbreak of various diseases such as cancer, inflammatory disease, metabolic disease and brain disease.
It is estimated that human genome contains 518 protein kinases which constitute approximately 1.7% of all human genes [Manning et al., Science, 298,(2002), : 1912]; and the protein kinases can be divided into tyrosine protein kinases (90 or more types) and serine/threonine protein kinases. The tyrosine protein kinases can be divided into receptor tyrosine kinases including 58 distinct kinases which can be further categorized into 20 subtypes, and cytoplasmic/non-receptor tyrosine kinases including 32 distinct kinases which can be further categorized into 10 subtypes. A receptor tyrosine kinase has a kinase domain on the surface where it can bind a growth factor, and an active site where phosphorylation of a tyrosine residue takes place. Binding of a growth factor to the extracellular domain of the receptor may cause the receptor tyrosine kinase to form a polymer, which may result in autophosphorylation of specific tyrosine residues in the cytoplasmic domain. This may trigger a cascade of events through phosphorylation of intracellular proteins that ultimately transmit the extracellular signal to the nucleus, thereby causing transcription and synthesis of various genes that may be involved in cell growth, differentiation, proliferation and the like.
Among the various cytoplasmic kinases, RAF is one of the kinases that participate in the linear Ras-RAF-MEK-ERK mitogen-activated protein kinase (MAPK) pathway initiated by a receptor protein kinase, which is activated by a growth factor [Solit, D. B. et al., Nature, 439,(2006), 358]. Currently, there are known three types of isoforms thereof, i.e., A-RAF, B-RAF and C-RAF (RAF-1) : [Jansen HW, et al., EMBO J, 2, (1983), 1969; Marais R. et al., Cancer Surv, 27,(1996), 101]. Since abnormal activation in the MAPK pathway has been observed in approximately 30% of human cancer tissues and gene mutation of B-
RAF and C-RAF showing aberrant activation has been confirmed in cancer tissues, it is generally accepted that RAF plays a very important role in the MAPK pathway of cancer tissues.
Accordingly, there have been suggested methods of using a compound having an inhibitory effect against abnormal activities of RAF kinases for treatment of cancer. Hence, a number of RAF and modified RAF kinase inhibitors are currently under development or being tested in ongoing clinical studies. Examples of such RAF kinase inhibitors include: sorafenib (Nexavar®,
Bayer) which is used for treatment of liver cancer, vemurafenib (PLX-4032, :
RG7204, Roche) which has been recently approved for treatment of melanoma;
and examples that are currently being tested in clinical trials include: regorafenib and RDEA119 by Bayer, RAF265 by Novartis, E3810 by Advan Chem, DCC2036 by Deciphera Pharma., CKI-27 by Chugai Pharma., RO-5126766 by Roche, etc.
However, efficacy of such drugs has been questioned when they are administered over a duration of time despite their good initial performance as drug resistance has been observed in some patients about 7 months after the initial administration of the drug.
It has been postulated that such degradation may be due to the drug resistance of B-RAF inhibitor which is caused by abnormal activation of MAPK pathway due to changes in RAF, activation of complementary signaling system among different RAF isoforms, or activation of various receptor kinases other than MAPK as a result of activation of different pathways of Ras, a key protein used in the signal-transducing cascade which consists of K-Ras, N-Ras and H-Ras subtypes.
One of the signaling pathways that the RAF kinases do not get involved is
C-FMS (cellular feline McDonough sarcoma), also known as colony-stimulating factor-1 receptor (CSF-1R), which is a member of the family of genes originally isolated from the Susan McDonough strain of feline sarcoma viruses. FMS is a receptor for macrophage-colony-stimulating factor (M-CSF) encoded by the C-
FMS proto-oncogene, which belongs to a class III RTK along with Kit, Flt-3 and
PDGFR. It has been reported that FMS tyrosine kinase is involved in cancer metastasis.
Another example is a receptor protein tyrosine kinase called discoidin domain receptor (DDR), which is a subfamily of receptor tyrosine kinases that possess an extracellular domain related to the lectin discoidin. In case of animals such as humans, there are two types of DDR proteins, DDR1 type and DDR2 type, which have similar amino acid sequences and are encoded by different genes from each other. It has been reported that DDR proteins may be implicated in the process of cancer growth and metastasis. In addition, an upregulated expression of DDR has been observed in some tumor cells, along with a report that an upregulated expression of DDR raised expression of MMP-1 and MMP-2 which are known to be implicated in cancer growth. Thus, it is expected that inhibition of such kinases can lead to a therapeutic effect against various types of cancer.
Therefore, a compound having an inhibitory activity against not only RAF, but also FMS, DDR1 and DDR2 kinases can be more useful for treatment of various cancers including resistant cancer, as compared with a conventional RAF kinase inhibitor.
Accordingly, it is an object of the present invention to provide a compound and a pharmaceutical composition comprising same for prevention or treatment of intractable cancer such as resistant cancer by inhibiting not only RAF, which is a key regulator of cell growth, differentiation and proliferation, but also FMS,
DDR1 and DDR?2 kinases.
MEANS FOR SOLVING THE PROBLEM
In accordance with one aspect of the present invention, there is provided a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity against RAF, FMS, DDR1 and DDR2 kinases: :
R?
NTN f Ln (ay. 0 (CH);
Zz S Xo ¥
Wy wherein,
A is hydrogen, Cis alkyl, Css cycloalkyl, 3- to 6-membered heterocycloalkyl, Ce.jparyl or 5- to 10-membered heteroaryl, wherein said aryl or heteroaryl is optionally reduced or substituted with hydrogen;
W is O, S, S(O), S(O), NH, -NHNH- or 3- to 6-membered ; heterocycloalkyl;
X and Y are each independently CH or N;
Z is hydrogen, C,.; alkyl or NR3R*, wherein said R® and R* are each independently hydrogen, Ci, alkyl or -(CH,)q-B-, B representing NR’RS, Ci alkoxy, Cs. cycloalkyl or 3- to 6-membered heterocycloalkyl;
R! is hydrogen, halogen, C;.; alkyl or C.; alkoxy, wherein said alkyl or alkoxy is unsubstituted or substituted with one or more halogen atoms;
R?is hydrogen, halogen, -CF3, -NO,, -OH, -CN, C,. alkoxy, Ci. alkyl, C24 alkenyl, Co4 alkynyl, -NR'R®, -NHSO,R®, -SO,R"’, -C(O)R", -NHC(O)RY, -
NHC(O)OR" , -S(O)RM, Cj. cycloalkyl, 3- to 6-membered heterocycloalkyl, Ce. 10 aryl, Ce.10 aryloxy, 5- to 10-membered heteroaryl or 5- to 10-membered heteroaryloxy, wherein said R? is connected to A by -(CH,)p- or substituted with
Ci.salkyl, Cy4alkyl, C4 alkylcarbonyl or one or more halogen atoms,
R’, RS, R’, R®, R’, RY, R", R", R" and R"™ are each independently hydrogen, -NH,, C,¢ alkyl, C,¢ alkoxy, Cs cycloalkyl or 3- to 6-membered heterocycloalkyl, said alkyl, alkoxy, cycloalkyl or heterocycloalkyl being unsubstituted or substituted with one or more halogen atoms; q is an integer ranging from 0 to 3; p is an integer ranging from 0 to 3;
m is an integer ranging from 0 to 5; n is an integer ranging from 0 to 2; and when A is hydrogen, m is 0.
In accordance with another aspect of the present invention, there is provided a pharmaceutical composition comprising a compound selected from the group consisting of a thieno[3,2-d]pyrimidine derivative of formula (I), a pharmaceutically acceptable salt, a stereoisomer, a hydrate and a solvate thereof as an active ingredient for prevention or treatment of diseases caused by abnormal activation of a protein kinase.
The pharmaceutical composition comprising a compound selected from the group consisting of a thieno[3,2-dJpyrimidine derivative of formula (I), a pharmaceutically acceptable salt, a stereoisomer, a hydrate and a solvate thereof in accordance with the present invention is effective for prevention or treatment of abnormal cell growth diseases caused by abnormal activation of a protein kinase.
The term ‘halogen’ as used herein refers to fluorine, chlorine, bromine or iodine, unless otherwise indicated.
The term ‘alkyl’ as used herein refers to a straight, cyclic, or branched hydrocarbon residue, unless otherwise indicated.
The term ‘cycloalkyl’ as used herein refers to a cyclic alkyl, e.g. cyclopropyl, unless otherwise indicated.
The term ‘aryl’ as used herein refers to a monocyclic or bicyclic aromatic group, e.g., phenyl and naphthyl, unless otherwise indicated.
The term ‘heterocycloalkyl’ as used herein refers to a cyclic alkyl, e.g., monocyclic or bicyclic alkyl, which contains one or more heteroatoms, preferably :
one to four heteroatoms, selected from O, N and S, unless otherwise indicated.
Examples of monoheterocycloalkyl include piperidinyl, morpholinyl, thiamorpholinyl, pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, piperazinyl and similar groups thereof, but not limited thereto. ;
The term ‘heteroaryl’ as used herein refers to an aromatic group, e.g., monocyclic or bicyclic group, which contains one to four heteroatoms selected from O, N and S, and one or more of ring member carbon may be substituted with
C=0, unless otherwise indicated. Examples of monocyclic heteroaryl include thiazolyl, oxazolyl, thiophenyl, furanyl, pyrrolyl, imidazolyl, isooxazolyl, pyrazolyl, triazolyl, thiadiazolyl, tetrazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl and similar groups thereof, but not limited thereto.
Examples of bicyclic heteroaryl include indolyl, benzothiophenyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benzthiadiazolyl, benztriazolyl, quinolinyl, isoquinolinyl, furinyl, furopyridinyl, oxochromene, dioxoisoindoline and similar groups thereof, but not limited thereto.
The compound of the present invention may also form a pharmaceutically acceptable salt. Such salt may be a pharmaceutically acceptable nontoxic acid addition salt containing anion, but not limited thereto. For example, the salt may include acid addition salts formed by inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydriodic acid, and others; organic carbonic acids such as tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, and others; and sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalensulfonic acid, and others. Among them, acid addition salts formed by sulfuric acid, methanesulfonic acid or hydrohalogenic acid, and others are preferred.
Further, the compound of the present invention can have an asymmetric carbon center, and thus may be present in the form of R or S isomer, racemic compounds, diastereomeric mixture, or individual diastereomer, such entire isomers and mixtures being included within the scope of the present invention.
In addition, solvates and hydrates of the compound of formula (I) are encompassed within the scope of the present invention. :
A preferred embodiment of the present invention is represented by the thieno[3,2-d]pyrimidine derivatives of formula (I), ; wherein:
Ais aryl or heteroaryl;
W is NH;
Z is NR’RY;
X is CH; and
YisN.
The preferred thieno[3,2-d]pyrimidine derivatives of the present invention are further exemplified below. In addition to the derivatives, pharmaceutically acceptable salts, isomers, hydrates or solvates thereof may also be used. 1) 4-amino-N-(1-((4-chlorophenyl)amino)-6-methylisoquinolin-5- yDthieno[3,2-d]pyrimidine-7-carboxamide; 2) 4-amino-N-(6-methyl-1-((3- (trifluoromethyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide; 3) N-(1-((4-chlorophenyl)amino)-6-methylisoquinolin-5-y1)-4- (cyclopropylamino)thieno[3,2-d]pyrimidine-7-carboxamide; : 4) 4~(cyclopropylamino)-N-(6-methyl-1-((3-
(trifluoromethyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide; 5) 4-amino-N-(6-methyl-1-((3-(4-methyl-1H-imidazol-1-yl)-5- (trifluoromethyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide; 6) 4-(cyclopropylamino)-N-(6-methyl-1-((3-(4-methyl-1H- imidazol-1-yl)-5-(trifluoromethyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide; 7 4-amino-N-(1-((4-((4-ethylpiperazin-1-yl)methyl)-3- (trifluoromethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide;
8) 4-(cyclopropylamino)-N-(1-((4-((4-ethylpiperazin-1-yl)methyl)- 3-(trifluoromethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide; 9) N-(1-((4-((4-ethylpiperazin-1-yl)methyl)-3- (trifluoromethyl)phenyl)amino)-6-methylisoquinolin-5-yl)-4- (methylamino)thieno[3,2-d]pyrimidine-7-carboxamide; 10) 4-amino-N-(1-((4-(4-ethylpiperazin-1-yl)phenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 11) 4-amino-N-(1-((4-((4-ethylpiperazin-1- : yl)methyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide; 12) 4-amino-N-(6-methyl-1-((3- (trifluoromethyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide; 13) 4-amino-N-(1-((4-chloro-3-(trifluoromethyl)phenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 14) 4-amino-N-(1-((2-methoxy-5-(trifluoromethyl)phenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;
15) 4-amino-N-(6-methyl-1-((4- (trifluoromethyl)phenyl)amino)isoquinolin-5-yl)thieno(3,2-d]pyrimidine-7- carboxamide; 16) 4-amino-N-(1-((4-methoxyphenyl)amino)-6-methylisoquinolin- S5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;
17) 4-amino-N-(6-methyl-1-(p-tolylamino)isoquinolin-5- ylthieno[3,2-d]pyrimidine-7-carboxamide; 18) 4-amino-N-(1-((4-isopropylphenyl)amino)-6-methylisoquinolin- 5-yD)thieno[3,2-d]pyrimidine-7-carboxamide; 19) 4-amino-N-(1-((5-(t-butyl)isoxazol-3-yl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 20) 4-amino-N-(1-((4-fluorophenyl)amino)-6-methylisoquinolin-5- yDthieno[3,2-d]pyrimidine-7-carboxamide;
21) 4-amino-N-(6-methyl-1-(thiazol-2-ylamino)isoquinolin-5-
yDthieno[3,2-d]pyrimidine-7-carboxamide; 22) 4-amino-N-(1-((4-cyanophenyl)amino)-6-methylisoquinolin-5- yDthieno[3,2-d]pyrimidine-7-carboxamide;
23) 4-amino-N-(6-methyl-1-(quinolin-5-ylamino)isoquinolin-5- yl)thienof3,2-d]pyrimidine-7-carboxamide; 24) 4-amino-N-(1-((4-ethoxyphenyl)amino)-6-methylisoquinolin-5- yl)thieno[3,2-d]pyrimidine-7-carboxamide; 25) 4-amino-N-(6-methyl-1-((4-phenoxyphenyl)amino)isoquinolin- 5-yDthieno[3,2-d]pyrimidine-7-carboxamide;
26) 4-amino-N-(1-((4-hydroxyphenyl)amino)-6-methylisoquinolin-
S-yDthieno[3,2-d]pyrimidine-7-carboxamide; 27) 4-amino-N-(1-((4-isopropoxyphenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 28) 4-amino-N-(1-((4-(dimethylamino)-6-methylisoquinolin-5- yD)thieno[3,2-d]pyrimidine-7-carboxamide;
29) 4-amino-N-(1-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 30) 4-amino-N-(1-((3,4-dimethoxyphenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 3D) 4-amino-N-(1-((3-fluoro-4-methoxyphenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 32) 4-amino-N-(6-methyl-1-((3,4,5- ] trimethoxyphenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide; 33) 4-amino-N-(6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine- 7-carboxamide; 34) 4-amino-N-(1-(benzo[d][1,3]dioxol-5-ylamino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 35) 4-amino-N-(6-methyl-1-((5,6,7,8-tetrahydronaphthalen-2- yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 36) 4-amino-N-(4-((4-chlorophenyl)amino)-7-methylquinazolin-8- yDthieno[3,2-d]pyrimidine-7-carboxamide; 37) 4-(cyclopropylamino)-N-(1-((4-methoxyphenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 38) 4-amino-N-(1-((3-chlorophenyl)amino)-6-methylisoquinolin-5- yDthieno[3,2-d]pyrimidine-7-carboxamide; 39) 4-amino-N-(1-((3-bromophenyl)amino)-6-methylisoquinolin-5- yDthieno[3,2-d]pyrimidine-7-carboxamide; 40) 4-amino-N-(1-((2,4-dichlorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 41) 4-amino-N-(1-((3,4-dichlorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 42) 4-amino-N-(1-((3,5-dichlorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;
43) 4-amino-N-(6-methyl-1-((3,4,5- trichlorophenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 44) 4-amino-N-(1-((4-chloro-3-methoxyphenyl)amino)-6- methylisoquinolin-5-yl)thieno{3,2-d]pyrimidine-7-carboxamide; 45) 4-amino-N-(1-benzylamino-6-methylisoquinolin-5- yl)thieno[3,2-d]pyrimidine-7-carboxamide; 46) 4-amino-N-(6-methyl-1-phenoxyisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide;
47) 4-amino-N-(6-methyl-1-((4- morpholinophenyl)amino)isoquinolin-5-yl)thieno([3,2-d]pyrimidine-7- carboxamide;
48) N-(1-((4-(1H-pyrrol-1-yl)phenyl)amino)-6-methylisoquinolin-5- yl)-4-aminothieno(3,2-d]pyrimidine-7-carboxamide; 49) 4-amino-N-(6-methyl-1-(pyrimidin-4-ylamino)isoquinolin-5- yl)thieno|3,2-d]pyrimidine-7-carboxamide; 50) 4-amino-N-(1-((4-(difluoromethoxy)phenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 51) 4-amino-N-(6-methyl-1-((4- (trifluoromethoxy)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide; 52) 4-amino-N-(1-((4-chlorophenyl)amino)isoquinolin-5- yDthieno[3,2-d]pyrimidine-7-carboxamide; 53) 4-amino-N-(5-((4-chlorophenyl)amino)naphthalen-1- yDthieno[3,2-d]pyrimidine-7-carboxamide; 54) 4-amino-N-(1-((4-ethynylphenyl)amino)-6-methylisoquinolin-5- yl)thieno[3,2-d}pyrimidine-7-carboxamide; 55) 4-amino-N-(1-(isopropylamino)-6-methylisoquinolin-5- yDthieno[3,2-d]pyrimidine-7-carboxamide; 56) 4-amino-N-(1-(indolin-6-ylamino)-6-methylisoquinolin-5-
yDthieno[3,2-d]pyrimidine-7-carboxamide;
57) 4-amino-N-(1-((4-(fluoromethoxy)phenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;
58) N-(1-(4-chlorophenylamino)-6-methylisoquinolin-5-
ybthieno[3,2-d]pyrimidine-7-carboxamide;
59) 4-amino-N-(1-((4-chloro-3- ((dimethylamino)methyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide; 60) 4-amino-N-(1-((4-chloro-3-(pyrrolidin-1-
ylmethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide;
61) 4-amino-N-(1-((4-chloro-3- ((diethylamino)methyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide;
62) 4-amino-N-(1-((1,4-diethyl-1,2,3,4-tetrahydroquinoxalin-6- yl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;
63) 4-amino-N-(1-((4-chloro-3-(piperidin-1- ylmethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide;
64) 4-amino-N-(1-((4-chloro-3-(morpholinomethyl)phenyl)amino)- 6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;
65) 4-amino-N-(1-((4-chloro-3-((4-methylpiperazin-1- yDmethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide;
66) 4-amino-N-(1-((4-chloro-3- ((diisopropylamino)methyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide;
67) 4-amino-N-(6-methyl-1-((3- (methylsulfonamido)phenyl)amino)isoquinolin-5 -yDthieno[3,2-d]pyrimidine-7-
carboxamide;
68) tert-butyl 4-(5-((5-(4-aminothieno[3,2-d]pyrimidine-7- carboxamido)-6-methylisoquinolin-1-yl)amino)-2-chlorobenzyl)piperazine-1- carboxylate;
69) 4-amino-N-(1-((4-chloro-3-(piperazin-1- ylmethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide; 70) 4-amino-N-(1-((3-chloro-4-methoxyphenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;
71) 4-amino-N-(1-((3-(dimethylcarbamoyl)phenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;
72) 4-amino-N-(6-methyl-1-((3- (methylcarbamoyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide;
73) 4-amino-N-(1-((4-chloro-2-fluorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 74) 4-amino-N-(1-((4-bromo-2-fluorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;
75) 4-amino-N-(1-((4-methoxybenzyl)amino)-6-methylisoquinolin-
5-ylthieno[3,2-d]pyrimidine-7-carboxamide;
76) 4-amino-N-(1-((4-chlorobenzyl)amino)-6-methylisoquinolin-5- ybthieno[3,2-d]pyrimidine-7-carboxamide;
77) 4-amino-N-(1-(2-(4-chlorophenyl)hydrazinyl)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 78) 4-amino-N-(1-((3-((dimethylamino)methyl)phenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]Jpyrimidine-7-carboxamide;
79) 4-amino-N-(6-methyl-1-((4-ox0-4H-chromen-6- : yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 80) N-(1-((3-acetylphenyl)amino)-6-methylisoquinolin-5-yl)-4-
aminothieno[3,2-d]pyrimidine-7-carboxamide;
81) 4-amino-N-(1-((4-(2-methoxyethoxy)phenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;
82) 4-amino-N-(6-methyl-1-((3-
(trifluoromethoxy)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide; 83) N-(1-((4-acetylphenyl)amino)-6-methylisoquinolin-5-y1)-4- aminothieno[3,2-d]pyrimidine-7-carboxamide; 84) 4-amino-N-(6-methyl-1-((4-
(methylsulfonamido)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide;
85) 4-amino-N-(6-methyl-1-((3- (methylsulfonyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide; 86) 4-amino-N-(1-((4-chloro-3-(methoxymethyl)phenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;
87) 4-amino-N-(1-((4-methoxy-3- (methylsulfonamido)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide; 88) 4-amino-N-(1-((4-chloro-3-(methylsulfonamido)phenyl)amino)- 6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;
89) 4-amino-N-(1-((6-chloropyridin-3-yl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;
90) 4-amino-N-(1-((2-chloropyridin-4-yl)amino)-6- :
methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 91) 4-amino-N-(6-methyl(4- (methylsulfonamidomethyl)phenyl)amino)isoquinolin-5 -yDthieno[3,2- d]pyrimidine-7-carboxamide;
92) 4-amino-N-(6-methyl-1-((3-
(methylsulfonamidomethyl)phenyl)amino)isoquinolin-5-yl)thieno{3,2- d]pyrimidine-7-carboxamide; 93) 4-amino-N-(1-((4-chloro-3-fluorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 94) 4-amino-N-(1-((3-bromo-4-chlorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 95) 4-amino-N-(1-((4-(dimethylcarbamoyl)phenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; : 96) N-(1-((3-acetamidophenyl)amino)-6-methylisoquinolin-5-yl)-4- aminothieno[3,2-d]pyrimidine-7-carboxamide; 97) 4-amino-N-(6-methyl-1-((1-methyl-1H-indazol-6- yDamino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 98) 4-amino-N-(6-methyl-1-((4- (methylsulfinyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d}pyrimidine-7- carboxamide; 99) 4-amino-N-(6-methyl-1-((2-methyl-1,3-dioxoisoindolin-5- yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 100) 4-amino-N-(1-((6-methoxypyridin-3-yl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 101) 4-amino-N-(6-methyl-1-((3-(2,2,2- trifluoroacetyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide; 102) 4-amino-N-(6-methyl-1-((4-propionylphenyl)amino)isoquinolin-
S-yDthieno[3,2-d]pyrimidine-7-carboxamide; 103) 4-amino-N-(1-((4-hexanoylphenyl)amino)-6-methylisoquinolin- yDthieno[3,2-d]pyrimidine-7-carboxamide; 104) N-(1-((1-acetyl-1H-indazol-6-yl)amino)-6-methylisoquinolin-5- yl)-4-aminothieno[3,2-d]pyrimidine-7-carboxamide; 105) 4-amino-N-(1-((3-chloro-4-fluorophenyl)amino)-6-
methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 106) 4-amino-N-(6-methyl-1-((5-0x0-5,6,7,8-tetrahydronaphthalen-2- yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 107) 4-amino-N-(6-methyl-1-((2-methyl-2H-indazol-6- yDamino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 108) methyl 4-((5-(4-aminothieno[3,2-d]pyrimidine-7-carboxamido)- 6-methylisoquinolin-1-yl)amino)benzoate; 109) 4-amino-N-(6-methyl-1-((1-methyl-1H-indazol-5- yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 110) 4-amino-N-(6-methyl-1-((2-methyl-2H-indazol-5- yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 111) 4-amino-N-(6-methyl-1-((6-methylpyridin-3- yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 112) 4-amino-N-(6-methyl-1-((1-methyl-1H-indol-6- yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 113) tert-butyl 6-((5-(4-aminothieno[3,2-d]pyrimidine-7-carboxamido)-6- methylisoquinolin-1-yl)amino)-1H-indazol- 1-carboxylate; 114) N-(1-((1H-indazol-6-yl)amino)-6-methylisoquinolin-5-y1)-4- aminothieno[3,2-d]pyrimidine-7-carboxamide hydrochloride; 115) 4-amino-N-(1-((5-chloro-2-fluorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 116) 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 117) 4-amino-N-(1-((3-fluoro-4-(4-methylpiperazin-1- yl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide; 118) 4-amino-N-(1-((3-chloro-1 -methyl-1H-indazol-6-yl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 119) 4-amino-N-(6-methyl-1-((4-(prop-2-yn-1- ;
yloxy)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 120) 4-amino-N-(1-((2-methoxy-4-morpholinophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 121) 4-amino-N-(1-(benzo[d]thiazol-6-ylamino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 122) N-(1-((1H-indazol-5-yl)amino)-6-methylisoquinolin-5-yl)-4- aminothieno[3,2-d]pyrimidine-7-carboxamide; 123) 4-amino-N-(1-((3-chloro-2,4-difluorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 124) 4-amino-N-(1-((3-(dimethylamino)propyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d}pyrimidine-7-carboxamide; and 125) 4-amino-N-(6-methyl-1-(piperidin-1-yl)isoquinolin-5- yDthieno[3,2-d]pyrimidine-7-carboxamide.
The derivatives of the present invention may be obtained via Reaction
Scheme 3 by using intermediates obtained in Reaction Scheme 1 and Reaction
Scheme 2 shown below, or intermediates which are commercially available, respectively. Further, mass analysis of the obtained thieno[3,2-d]pyrimidine derivatives may be performed by using MicroMass ZQ™ (Waters).
The pharmaceutical composition comprising, as an active ingredient, the thieno[3,2-d]pyrimidine derivatives or salts, isomers, hydrates or solvates thereof may be used for prevention or treatment of abnormal cell growth diseases caused by abnormal activation of a protein kinase.
Examples of the protein kinase include ALK, AMPK, Aurora A, Aurora B,
Aurora C, Axl, Blk, Bmx, BTK, CaMK, CDK2/cyclinE, CDK5/p25, CHK, CK2, c-RAF, DDR1, DDR2, DMPK, EGFRI1, Her2, Her4, EphAl, EphBl, FAK,
FGFR2, FGFR3, FGFR4, Flt-1, Fit-3, Flt-4, Fms (CSF-1), Fyn, GSK3beta,
HIPK1, IKKbeta, IGFR-1R, IR, Itk, JAK2, JAK3, KDR, Kit, Lck, Lyn, MAPK,
MAPKAP-K2, MEK1, Met, MKK6, MLCK, NEK2, p70S6K, PAK2, PDGFR alpha, PDGFR beta, PDK1, Pim-1, PKA, PKBalpha, PKCalpha, Plkl, Ret,
ROCK-I, Rskl, SAPK2a, SGK, Src, Syk, Tie-2, Tec, Trk or ZAP-70. The pharmaceutical composition in accordance with the present invention has good inhibitory activity against the above kinases.
Examples of the abnormal cell growth diseases caused by abnormal activation of protein kinase in which the inventive pharmaceutical composition is effective against include gastric cancer, lung cancer, liver cancer, colorectal cancer, small intestine cancer, pancreatic cancer, brain cancer, bone cancer, melanoma, breast cancer, sclerosing adenosis, uterine cancer, cervical cancer, head and neck cancer, esophagus cancer, thyroid cancer, parathyroid cancer, renal cancer, sarcoma, prostate cancer, urethral cancer, bladder cancer, blood cancer, lymphoma, fibroadenoma, inflammation, diabetes, obesity, psoriasis, rheumatoid arthritis, ; hemangioma, acute or chronic kidney disease, coronary restenosis, autoimmune diseases, asthma, neurodegenerative diseases, acute infection or ocular diseases caused by angiogenesis.
The inventive pharmaceutical composition may comprise pharmaceutically acceptable carriers, excipients or additives. The pharmaceutical composition may comprise a drug selected from the group consisting of cell signal transduction inhibitors, mitosis inhibitors, alkylating agents, antimetabolites, antibiotics, growth factor inhibitors, cell cycle inhibitors, topoisomerase inhibitors, biological reaction modifiers, antihormonal agents, antiandrogen, cell differentiation/proliferation/survival inhibitors, apoptosis inhibitors, inflammation inhibitors and P-glycoprotein inhibitors. In case where the inventive pharmaceutical composition is developed into a formulation, it may be used in combination with said drug or developed into a combined formulation.
The inventive pharmaceutical composition may comprise conventional pharmaceutically acceptable carriers, excipients or additives. The pharmaceutical composition may be formulated in accordance with conventional methods, and may be prepared in the form of oral formulations such as a tablet, pill, powder, capsule, syrup, an emulsion, a microemulsion and others or parenteral formulations such as intramuscular, intravenous or subcutaneous administration.
For oral formulations, additives or carriers such as cellulose, calcium silicate, corn starch, lactose, sucrose, dextrose, calcium phosphate, stearic acid, magnesium stearate, calcium stearate, gelatin, talc, surfactants, suspending agents, emulsifying agents, diluting agents and others. For injectable formulations, additives or carriers such as water, saline, glucose solution, glucose solution analogs, alcohols, glycols, ethers (e.g., polyethylene glycol 400), oils, fatty acids, fatty acid esters, glycerides, surfactants, suspending agents, emulsifying agents and others may be used.
Hereinafter, an exemplary method for preparing the compound of the present invention is explained.
The following abbreviations are used in Preparation Examples, Preparation
Methods and Examples below:
DECP: diethyl chlorophosphate
DIPEA: N,N-diisopropylethylamine
HATU: [2-(1H-9-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uranium hexafluorophosphate]
HOBT: N-hydroxybenzotriazole
DMF: N,N-dimethyl formamide
DMSO: dimethyl sulfoxide EA: ethyl acetate
CH,Cl,: dichloromethane EtOAc: ethylacetate
Na;SO4: anhydrous sodium sulfate NaOH: sodium hydroxide
NaBH(OAc);: sodium triacetoxyborohydride =~ THF: tetrahydrofuran
Cs,COj3: cesium carbonate
AIBN: azobisisobutyronitrile
Pd,(dba)s: tris(dibenzylideneacetone)dipalladium(0)
The compound of formula (I) in accordance with the present invention may be prepared via Reaction Scheme 3 by using intermediates obtained in
Preparation Examples 1 and 2 as shown in Reaction Schemes 1 and 2, respectively.
Reaction Scheme 1
Br
HN Mu Step 2 MNo{ ~~ Step3 # Step4 oD Step 1 J oe tep . Ig oe ep £0 cp
Ag - - a —_— 0 ct 0 oO
NC NT N H N OH
0 Step 5 ax Step 6 0 ) ° Step 7 r ] $
Zz z z wherein Z is the same as defined in formula (I).
The above reaction processes are exemplified in the following stepwise reactions. <Step 1-1>
Anhydrous acetic acid (12 to 13 equivalents) and formic acid (12 to 15
L/mol, based on a standard equivalent unit) are mixed. Methyl-3- aminothiophene-4-carboxylate (1.0 equivalent, standard equivalent unit) is added to the resulting reaction solution, and stirred for about 2 to 4 hours at room ;
temperature. The reaction solution is removed under reduced pressure.
Separately, ammonium formate (8/0 to 9/0 equivalents) and formamide (150 mL, 3.76 mol) are added, and the mixture is stirred for about 20 to 40 minutes. The synthesized material is added to the resulting reaction mixture, and stirred for about 7 to 9 hours at a temperature in the range of 140 to 160°C. The reaction mixture is cooled to room temperature and further stirred for about 11 to 13 hours.
The resulting solid is filtered and washed with water to obtain the desired compound. <Step 12>
The compound (1.0 equivalent, standard equivalent unit) obtained in <Step 1-1> is dissolved in acetic acid (9.0 to 11.0 equivalents). Separately, bromine (3.0 to 4.0 equivalents) is diluted in acetic acid (9.0 to 11.0 equivalents) and resulting solution is slowly added to the solution prepared. The reaction solution is placed in a sealed reactor and stirred for 17 to 19 hours at a temperature in the range of 110 to 130°C. The reaction mixture is cooled to room temperature, and acetic acid is removed under reduced pressure. An ice water is poured to the mixture, and the resulting solid compound is filtered, followed by drying. The desired compound is obtained without further purification. <Step 1-3>
Dimethylformamide (2.0 to 3.0 equivalents) and dichloromethane (3.0 to 4.0 L/mol, based on a standard equivalent unit) are added to a reactor. Separately, oxalyl chloride (3.0 to 4.0 L/mol, based on a standard equivalent unit) is diluted in dichloromethane (3.0 to 4.0 L/mol, based on a standard equivalent unit) and resulting solution is added to the solution prepared over a period of about 20 to 40 minutes. The compound (1.0 equivalent, standard equivalent unit 35 g, 0.15 : mol) obtained in <Step 1-2> is added thereto, heated, and refluxed for 2.5 to 4.0 : hours. The temperature is lowered and water is slowly added. The resulting organic layer is separated and aqueous layer is subjected to extraction using dichloromethane. The resulting organic layer is dried over anhydrous sodium sulfate. The dried organic layer is filtered and distilled under reduced pressure, and dried under nitrogen atmosphere to obtain the desired compound. <Step 1-4>
The compound (1.0 equivalent, standard equivalent unit) obtained in <Step 1-3> and 2.0 M ammonia (15 to 25 mL/g, based on the standard equivalent unit) are dissolved in a 2-propanol solvent, sealed in a container, and stirred. The external temperature is raised to a range of 95 to 100°C, followed by stirring for 7 hours. The reaction mixture was cooled to room temperature, and the solvent is distilled under reduced pressure. Distilled water (40 to 55 mL/g, based on the standard equivalent unit) is added to the concentrate, followed by stirring for 20 to 40 minutes. The resulting solid is filtered, and washed with distilled water (15 to 25 ml/g, based on the standard equivalent unit) twice. The compound is dried in an oven at 45 to 55°C to obtain the desired compound. <Step 1-5> :
The compound (1.0 equivalent, standard equivalent unit) obtained in <Step 1-4>, tetrakis(triphenylphosphine)palladium (0.05 to 0.08 equivalents) and copper iodide (1.0 to 1.2 equivalents) are dissolved in 1.4-dioxane (1.5 to 2.5 L/mol, based on the standard equivalent unit) solvent and stirred. Tributyl(vinyl)tin (1.1 to 1.5 equivalents) is slowly added to the resulting reaction solution and refluxed for 6 hours or more, preferably about 6 to 8 hours. The reaction solution is cooled to room temperature, and potassium fluoride aqueous solution (3.0 to 4.0
L/mol, based on the standard equivalent unit) and ethylacetate (3.0 to 4.0 L/mol, : based on the standard equivalent unit) are added thereto, followed by intense : stirring for 2.5 hours or more, preferably about 2.5 to 3.5 hours. The reaction solution is filtered through a Celite pad under reduced pressure, washed with ethyl acetate (0.5 to 0.8 L/mol, based on the standard equivalent unit). The organic layer of the filtrate is separated and dried over anhydrous sodium sulfate. The dried organic layer is filtered and distilled under reduced pressure, added with a mixed solution of ethylacetate/hexane = 1/1 (v/v) (0.8 to 1.2 L/mol, based on the standard equivalent unit), followed by stirring for 1 hour. The resulting reaction solution is filtered under reduced pressure, and washed with a mixed solution of ethylacetate/hexane = 1/1 (v/v) (0.4 to 0.6 L/mol, based on the standard equivalent unit). The resulting solid is dried with warm wind in an oven (45 to 55°C) for 2.5 hour or more, preferably about 2.5 to 3.5 hours, to obtain the desired compound. <Step 1-6>
The compound (1.0 equivalent, standard equivalent unit) obtained in <Step 1-5> is stirred with a mixed solution of chloroform (0.8 to 1.2 L/mol, based on the standard equivalent unit) and methanol (0.8 to 1.2 L/mol, based on the standard equivalent unit). The resulting reaction solution is cooled to -65 to -78°C as : nitrogen gas is introduced, followed by supplying ozone gas for 2.5 hours or more, preferably about 2.5 to 3.5 hours. The ozone generator is removed and the reaction solution is raised to room temperature while nitrogen gas is introduced, dimethyl sulfide (0.2 to 0.4 L/mol, based on the standard equivalent unit) is added thereto, followed by stirring for 2.5 hours or more, preferably about 2.5 to 3.5 hours, at room temperature. The reaction solution is concentrated under reduced i pressure, and ethyl acetate (0.3 to 0.5 L/mol, based on the standard equivalent : unit) is added to the concentrate, followed by stirring for 1.0 to 1.5 hours. The resulting solution is filtered under reduced pressure, and filtered solid is washed wish ethyl acetate (0.04 to 0.06 L/mol, based on the standard equivalent unit).
The filtered solid dried with warm wind in an oven (45 to 55°C) for 2.5 hours or more, preferably about 2.5 to 3.5 hours, to obtain the desired compound. : <Step 1-7>
Disodium hydrogen phosphate (48.2 g, 0.402 mol) is dissolved in distilled water (180 mL), and the reaction solution is cooled to 5°C or below, preferably about 5 to -3°C. The compound (1.0 equivalent, standard equivalent unit) obtained in <Step 1-6> is dissolved in a mixed solution of acetone (0.8 to 1.2 L/mol, based on the standard equivalent unit) and dimethyl sulfoxide (0.8 to 1.2
L/mol), followed by slowly adding the resulting solution to the reaction solution prepared at 5°C or below, preferably in the temperature range of about 5.0 to 3.0°C. Separately, sodium chlorite (1.0 to 1.3 equivalents) is dissolved in distilled water (0.8 to 1.2 L/mol, based on the standard equivalent unit), followed by slowly adding the resulting solution to the reaction solution prepared at 5°C or below, preferably in the temperature range of about 5.0 to 1.0°C. The reaction solution is raised to room temperature, followed by stirring for 2.5 or more, preferably about 2.5 to 3.5 hours. Distilled water (8.0 to 12 L/mol, based on the standard equivalent unit) is added thereto, followed by further stirring for 4.5 hours or more, preferably about 4.5 to 5.5 hours. The reaction solution was filtered under reduced pressure, and the resulting solid is washed with diethyl ether (0.3 to 0.5 L/mol). Ethanol (0.8 to 1.2 L/mol, based on the standard equivalent unit) is added to the filtered solid, and the solution is distilled under reduced pressure, dried with warm wind in an oven (45 to 55°C) for 2.5 hours or more, preferably about 2.5 to 3.5 hours, to obtain the desired compound.
Reaction Scheme 2 :
L | PI q ?
CX 8 3
HiStep 3 or Step 4 \ N
SL uN ;
Reaction Scheme 2 illustrates a reaction process when X = CH and Y=N in the compound of formula (I), wherein R' is same as defined in formula (I).
The above reaction processes are exemplified in the following stepwise reactions. <Step 2-1>
Aldehyde (1.0 equivalent, standard equivalent unit) substituted with R® is stirred in a solvent of chloroform (1.6 to 2.0 L/mol, based on the standard equivalent unit), and aminoacetaldehyde dimethyl acetal (1.0 to 1.2 equivalents) is slowly added thereto, followed by stirring at 80 to 95°C until about one-half of the reaction solution is evaporated. The reaction solution is cooled to room temperature, and the resulting yellow reaction solution is dissolved in chloroform (0.8 to 1.0 L/mol, based on the standard equivalent unit), followed by cooling the reaction solution to 5°C or below, preferably about 5 to 0°C. Ethyl chloroformate (1.0 to 1.2 equivalents) and triethylphosphite (1.2 to 1.4 equivalents) are slowly added to the reaction solution for 0.5 to 1.0 hour. The resulting reaction solution is stirred for 20 to 28 hours at room temperature.
Subsequently, the reaction solution is cooled to 5°C or below, preferably about 5 to 0°C, and then titanium tetrachloride (3.8 to 4.2 equivalents) is slowly added thereto for 0.5 to 1.0 hour, and refluxed for 10 hours or more, preferably about 10 to 14 hours. The reaction solution is cooled to room temperature, followed by stirring for 10 hours or more, preferably, 10 to 14 hours. An ice water is poured to the reaction mixture to separate the organic layer and aqueous layer, and the aqueous layer is washed with dichloromethane. The aqueous layer is poured into a saturated sodium potassium tartrate solution and adjusted to pH 8.0 to 9.5 by adding ammonia solution, and subjected to extraction with CH,Cl,. The : obtained organic layers are dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the desired compound. <Step 2-2>
Sulfuric acid (300 to 400 L/mol, based on the standard equivalent unit) is added to the compound (1.0 equivalent, standard equivalent unit) obtained in <Step 2-1> and stirred. The reaction solution is cooled to 5°C or below, preferably about 5 to 0°C, followed by slowly adding potassium nitrate (2.0 to 2.2 equivalents). The reaction solution is stirred for 3 hours or more, preferably about 3 to 4 hours, at a temperature of 5 to 0°C. The reaction mixture poured into an ice water and adjusted to pH 11 to 12 by adding 5 N NaOH solution, followed by stirring for 11 hours or more, preferably about 11 to 13 hours, at room temperature. The generated solid is filtered under reduced pressure, followed by washing with water. The filtered solid is dried with warm wind in an oven (35 to 45°C) for 3 hours or more, preferably about 3 to 4 hours to obtain the desired compound. <Step 2-3>
The compound (1.0 equivalent, standard equivalent unit) obtained in <Step 2-2> is dissolved in CHCl, (2.8 to 3.3 L/mol, based on the standard equivalent unit), and the reaction solution is cooled to 5°C or below, preferably about 5 to 0°C. Subsequently, mCPBA (1.5 to 1.7 equivalents) is slowly added to the reaction solution for 0.5 to 1 hour, followed by stirring for 10 hours or more, preferably about 10 to 11 hours at a temperature of 5 to 0°C. The reaction mixture is adjusted to pH of 10 to 11 by adding 1 N NaOH solution, and subjected : to extraction with CH,Cl,. The obtained organic layers are dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the desired compound. <Step 2-4>
The compound (1.0 equivalent, standard equivalent unit) obtained in <Step 2-3> is dissolved in 1,2-dichloroethane (8 to 9 L/mol, based on the standard equivalent unit), and POCl; (4.5 to 5.5 equivalents) is added to the reaction solution at room temperature. And then, the reaction solution is refluxed for 6 hours or more, preferably about 6 to 7 hours. The reaction solution is cooled to room temperature, and concentrated by distilling the solvent under reduced pressure. The concentrated solid is dissolved in dichloromethane. An ice water is added thereto, and the mixed solution is subjected to extraction with dichloromethane. The obtained organic layer is dried over anhydrous sodium sulfate, and concentrated under reduced pressure. A mixed solution of ethyl acetate/hexane = 1/1 (v/v) is added to the concentrated solid, followed by stirring for 2 hours or more, preferably about 2 to 2.5 hours at room temperature. The resulting solid is filtered under reduced pressure, and washed with a mixed solution of ethyl acetate/hexane = 1/1 (v/v). The filtered solid is dried with warm wind in an oven (35 to 45°C) for 3 hours or more, preferably about 3 to 4 hours to obtain the desired compound.
Reaction Scheme 3
R rR! wy + aug A Rn el RUSE, ®lm
MN uN : " 2 OH oer we ® 4 os aN Nog .
P~CT 8 SE
Reaction Scheme 3 illustrates a reaction process when W is NH in the compound of formula (I), wherein A, R!, R?, n and m are same as defined in formula (I).
The above reaction processes are exemplified in the following stepwise reactions. <Step 3-1>
The compound (1.0 equivalent, standard equivalent unit) obtained in <Step 2-4> is dissolved in 2-propanol (2.0 to 4.0 L/mol, based on the standard equivalent unit), and amine containing ring A (0.6 to 0.9 equivalents) is added to the reaction solution at room temperature. The reaction solution is sealed, and stirred for 9 hours or more, preferably about 9 to 11 hours, at a temperature of 85 to 95°C. The reaction mixture is cooled to room temperature, and the generated solid is filtered under reduced pressure, followed by washing with ethyl acetate. :
The filtered solid is dried with warm wind in an oven (45 to 55°C) for 2.5 hours or more, preferably about 2.5 to 3.5 hours to obtain the desired compound. <Step 3-2>
Iron (3.0 to 5.0 equivalents) and concentrated hydrochloric acid (0.04 to 0.06 mL/mmol) are added to a mixed solution of ethanol/water = 1/1 (v/v) (3.0 to 5.0 L/mol, based on the standard equivalent unit), and refluxed for 0.5 to 1.5 hours.
The compound (1.0 equivalent, standard equivalent unit) obtained in <Step 3-1> is added to a reaction mixture, and refluxed for 1.5 hours or more, preferably about 1.5 to 2.5 hours. The reaction mixture is filtered through a Celite pad under : reduced pressure, and washed with a mixed solution of chloroform/2-propanol = 4/1 (v/v). The filtrate obtained was distilled under reduced pressure, and dissolved in a mixed solution of chloroform/2-propanol = 4/1 (v/v). The organic 29 5 layer is washed with an aqueous solution of sodium bicarbonate and brine. The obtained organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the desired compound. <Step 3-3>
The compound (1.0 equivalent, standard equivalent unit) obtained in <Step 1-7> is dissolved in dimethylformamide (1.0 to 3.0 L/mol, based on the standard equivalent unit), and DECP (1.8 to 2.2 equivalents) and DIPEA (3.6 to 4.4 equivalents) are added to the reaction solution at a temperature of 4 to -4°C. The reaction solution is stirred for 5 to 15 minutes. The compound (0.45 to 0.55 equivalent) obtained in <Step 3-2> is added to the reaction mixture, and the mixture is stirred for 11 hours or more, preferably about 11 to 13 hours. The reaction mixture is diluted with ethyl acetate, and washed with a saturated aqueous solution of sodium bicarbonate and brine. The organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
Ethyl acetate is added to the concentrated solid, followed by stirring for 1.5 hours or more, preferably about 1.5 to 2.5 hours. The resulting solid is filtered under reduced pressure, and washed with ethyl acetate and methanol. The filtered solid is dried with warm wind in an oven (35 to 45°C) for 2.5 hours or more, preferably about 2.5 to 3.5 hours to obtain the desired compound.
The synthesis of derivatives of the present invention may be performed by employing a general reaction scheme such as Reaction Schemes 1, 2 and 3 shown above, and mass analysis may be performed by using MicroMass ZQ™ (Waters).
The present invention provides a pharmaceutical composition comprising the compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient to prevent or treat abnormal cell growth diseases caused by overactivity (abnormal activation) of a protein kinase.
A dosage of the compound of formula (I) or pharmaceutically acceptable salt thereof may be determined in light of various relevant factors including the condition, age, body weight and sex of the subject to be treated, administration route and disease severity. For example, the compound of formula (I) may be administered in a range of 0.01 to 200 mg/kg (body weight), preferably 10 to 100 mg/kg (body weight) once or twice a day orally or parenterally.
Further, the present invention provides a compound library comprising one or more of the compounds selected from the group consisting of the compound of formula (I), pharmaceutically acceptable salt, isomer, hydrate and solvate thereof.
The following Examples are provided to illustrate preferred embodiments of the present invention, and are not intended to limit the scope of the present invention.
Preparation Example 1: Preparation of 4-aminothieno[3,2-d]pyrimidine-7- carboxylic acid <Step 1> Preparation of 3H-thieno[3.2-d]pyrimidin-4-one
Acetic anhydride (185 mL, 1.96 mol) and formic acid (85 mL, 2.22 mmol) were mixed and stirred. Methyl-3-aminothiophene-2-carboxylate (50 g, 0.16 mol) was added to the reaction mixture, followed by stirring for about 3 hours at room temperature. The reaction solvent was removed under reduced pressure.
Separately, ammonium formate (90 g, 1.43 mol) and formamide (150 mL, 3.76 mol) were mixed and stirred for about 30 minutes. The synthesized material in the above was added to the resulting reaction solution, followed by stirring 8 hours at 150°C.
The reaction solution was cooled to room temperature and stirred for about 12 hours.
The generated solid was filtered, and washed with water to obtain the title compound (39 g, 81%). "H-NMR Spectrum (300 MHz, DMSO-ds): 5 12.48 (br, 1H), 8.18 (d, 1H), 8.14 (s, 1H), 7.40 (d, 1H) <Step 2> Preparation of 7-bromothieno{3.2-d]pyrimidin-4(3H)-one
Thieno[3,2-d]pyrimidin-4(3H)-one (38.0 g, 0.25 mol) was dissolved in acetic acid (143 mL, 2.5 mol), and bromine (40.4 mL, 0.78 mol) diluted with acetic acid (122 mL, 2.1 mol) was slowly added to the solution prepared. The reaction solution was stirred in a sealed reactor for 18 hours at 120°C. The reaction solution was cooled to room temperature and acetic acid was removed by distillation under reduced pressure. The reaction mixture was poured into an ice water to generate a solid compound, and the resulting solid compound was filtered and dried. The title compound was obtained without purification (37.5 g, 65%). "H-NMR Spectrum (300 MHz, DMSO-dy): § 12.75 (brs, 1H), 8.36 (s, 1h), 8.24 (s, 1H) <Step 3> Preparation of 7-bromo-4-chlorothieno{3.2-d]pyrimidine
Dimethylformamide (25.8 mL, 0.33 mol) and dichloromethane (150 mL) were added to a reactor. Oxalyl chloride (46.4 mL, 0.53 mol) diluted with dichloromethane (150 mL) at room temperature was added to the reactor for about 30 minutes. 7-bromothieno[3,2-d]pyrimidin-4(3H)-one (35 g, 0.15 mol) was added thereto, and then, the reaction solution was heated to reflux for 3 hours. The i temperature of the reaction solution was lowered and water was carefully added thereto. The organic layer was separated, and the aqueous layer was subjected to extraction using dichloromethane. The extracted organic layer was dried over anhydrous sodium sulfate. The dried organic layer was filtered and distilled under reduced pressure, and dried with nitrogen gas to obtain the title compound (30.5 g,
"H-NMR Spectrum (300 MHz, DMSO-dj): 8 9.16 (s, 1H), 8.79 (s, 1H) <Step 4> Preparation of 7-bromothieno[3.2-d]pyrimidine-4-amine 7-bromo-4-chlorothieno[3,2-d]pyrimidine (84.0 g) obtained in <Step 3> and 2.0 M ammonia (672 mL) were stirred under a solvent of 2-propanol in a sealed condition.
The external temperature was raised to a range of 95 to 100°C, followed by stirring for 7 hours.
The reaction solution was cooled to room temperature and the solvent was distilled under reduced pressure.
Distilled water (400 mL) was added to the concentrated solution, followed by stirring for 30 minutes.
The solid compound was filtered and washed with distilled water (168 mL) twice.
The resulting compound was dried in an oven at 50°C to obtain the title compound (75 g, 97%).
"H-NMR Spectrum (300 MHz, DMSO-d): 8 7.71 (s, 2H), 8.33 (s, 1H), 8.47 (s, 1H)
<Step 5> Preparation of 7-vinylthieno[3.2-d]pyrimidine-4-amine 7-bromothieno[3,2-d]pyrimidine-4-amine (53.0 g, 0.23 mol) obtained in <Step 4>, tetrakis(triphenylphosphine)palladium (15.8 g, 0.014 mol) and copper iodide (5.3 g, 0.028 mol) were stirred under a solvent of 1,4-dioxane (530 mL).
Tributyl(vinyl)tin (83.2 mL, 0.276 mL) was slowly added to the resulting mixture, followed by refluxing for 7 hours or more.
The reaction solution was cooled to room temperature.
An aqueous solution of calcium fluoride (795 mL) and ethyl acetate (795 mL) are added to the reaction solution and stirred vigorously for 3 hours or more.
The reaction solution was filtered through a Celite pad under reduced pressure, and washed with ethyl acetate (105 mL). The organic layer of the filtrate was separated, and dried over anhydrous sodium sulfate.
The dried organic layer was filtered and distilled under reduced pressure, and a mixed solution of ethyl acetate (106 mL)/hexane (106 mL) was added thereto, followed by stirring for 1 hour.
The reaction solution was filtered under reduced pressure and washed with a mixed solution of ethyl acetate (27 mL)/hexane (27 mL). The filtered solid was dried with warm wind in an oven (50°C) for 3 hours or more to obtain title compound (34.2 g, 83.8%). 'H-NMR Spectrum (300 MHz, DMSO-d): 8 8.40 (s, 1H), 8.13 (s, 1H), 7.44 (s, 2H), 6.94 (dd, 1H), 6.34 (dd, 1H), 5.37 (dd, 1H) <Step 6> Preparation of 4-aminothieno[3.2-d]pyrimidine-7-carboaldehyde 7-vinylthieno[3,2-d]pyrimidine-4-amine (40.0 g, 0.226 mol) obtained in <Step 5> was stirred under solvents of chloroform (280 mL) and methanol (280 mL).
The reaction solution was cooled to -78°C by introducing nitrogen gas and supplied by ozone gas for 3 hours or more. The ozone generator was removed and the temperature of the reaction solution was raised to room temperature while nitrogen gas was introduced. Dimethyl sulfide (60 mL) was added to the reaction mixture, followed by stirring for 3 hours or more at room temperature. The reaction solution was concentrated under reduced pressure, and ethyl acetate (80 mL) was added to the concentrated solution, followed by stirring for one hour. The reaction solution was filtered under reduced pressure, and the filtered solid was washed with ethyl acetate (10 mL). The filtered solid was dried with warm wind in an oven (50°C) for 3 hours or more to obtain the title compound (36 g, 89%). "H-NMR Spectrum (300 MHz, CDCl3): § 10.25 (s, 1H), 8.99 (s, 1H), 8.50 (s, 1H), 7.82 (s, 2H) <Step 7> Preparation of 4-aminothieno[3.2-d]pyrimidine-7-carboxylic acid
Sodium phosphate monobasic dihydrate (48.2 g, 0.402 mol) was dissolved in distilled water (180 mL), and the reaction solution was cooled to 0°C or below.
Separately, 4-aminothieno[3,2-d]pyrimidine-7-carboaldehyde (36.0 g, 0.201 mol) obtained in <Step 6> was dissolved in a mixed solution of acetone (244 mL)/dimethylsulfoxide (176 mL), and the resulting solution was slowly added to a reaction solution at 3°C or below. Separately, sodium chlorite (30.3 g, 0.268 mol) was dissolved in distilled water (180 mL), and the resulting solution was slowly added to the reaction solution at 3°C or below. Distilled water (1,280 mL) was added to the reaction solution, followed by stirring for 5 hours or more.
The reaction solution was filtered under reduced pressure, and the filtered solid was washed with diethyl ether (72 mL). The filtered solid was added with ethanol (180 mL), and the resulting solution was distilled under reduced pressure.
The concentrated solid was dried with warm wind in an oven (50°C) for 3 hours or more to obtain the title compound (36 g, 91.8%). "H-NMR Spectrum (300 MHz, DMSO-dq): 8 8.92 (s, 1H), 8.50 (s, 1H), 7.94 (s, 2H)
Preparation Example 2: Preparation of 1-chloro-6-methyl-S-nitroisoquinoline ] <Step 1> Preparation of 6-methylisoquinoline
Para-tolualdehyde (53 mL, 0.486 mol) was stirred in a solvent of chloroform (900 mL). Aminoacetaldehyde dimethyl acetal (59.3 mL, 0.486 mol) was slowly added thereto, followed by stirring at 90°C until about one-half of the reaction solution was evaporated. The reaction solution was cooled to room temperature, and the resulting yellow reaction solution was dissolved in chloroform (400 mL), followed by cooling the solution to 0°C or below. Ethyl chloroformate (48 mL, 0.486 mol) and triethylphosphite (104 mL, 0.583 mol) were slowly added to the reaction solution. The reaction solution was stirred for 24 hours at room temperature. The reaction solution was cooled to 0°C or below, slowly added with titanium tetrachloride (213.6 mL, 1.94 mol), and refluxed for 12 hours or more.
The reaction solution was cooled to room temperature, and stirred for 12 hours or more. The reaction mixture was poured to an ice water to separate the organic layer and the aqueous layer, and the aqueous layer was washed with dichloromethane. A saturated sodium tartrate solution was added to the aqueous layer, adjusted to pH 9 by adding ammonia water, and subjected to extraction with dichloromethane. The obtained organic layer was dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the title compound (46.3 g, 66%).
H-NMR Spectrum (300 MHz, DMSO-d): § 9.23 (s, 1H), 8.45 (d, 1H), 8.02(d, 1H), 7.72 (d, 2H), 7.54 (d, 1H), 2.49 (s, 3H) <Step 2> Preparation of 6-methyl-5-nitroisoquinoline
Sulfuric acid (400 mL) was added to 6-methylisoquinoline (46.3 g, 0.323 mol) obtained in <Step 1> above and the mixture was stirred. The reaction solution was cooled to 0°C or below, followed by slowly adding potassium nitrate (65.3 g, 0.646 mol). The reaction solution was stirred for 3 hours or more at 0°C. An ice water was poured to the reaction mixture, adjusted to pH 12 by adding 5 N NaOH solution, followed by stirring for 12 hours or more at room temperature. The generated solid was filtered under reduced pressure, and the filtered solid was washed with water. The filtered solid was dried with warm wind in an oven (40°C) for 3 hours or more to obtain the title compound (43.3 g, 71%). "H-NMR Spectrum (300 MHz, DMSO-ds): & 9.46 (s, 1H), 8.67 (d, 1H), 8.37 (d, 1H), 7.79 (d, 1H), 7.62 (d, 1H), 2.54 (s, 3H) <Step 3> Preparation of 6-methyl-5-nitroisoquinolin-2-oxide 6-methyl-5-nitroisoquinoline (43.3 g, 0.230 mol) obtained in <Step 2> above was dissolved in dichloromethane (650 mL), and the reaction solution was cooled to 0°C or below. Subsequently, mCPBA (67.5 g, 0.390 mol) was slowly added to the reaction solution, followed by stirring for 10 hours or more at 0°C. The reaction mixture was adjusted to pH 10 by adding 1 N NaOH solution, and subjected to extraction with dichloromethane. The obtained organic layer was dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the title compound (46.5 g, 99%). "H-NMR Spectrum (300 MHz, CDCl): 6 8.80 (s, 1H), 8.24 (d, 1H), 7.80
(d, 1H), 7.66 (d, 1H), 7.56 (d, 1H), 2.55 (s, 3H) <Step 4> Preparation of 1-chloro-6-methyl-5-nitroisoquinoline 6-methyl-5-nitroisoquinoline (46.5 g, 0.228 mol) obtained in <Step 3> above was dissolved in 1,2-dichloroethane (1.8 L), and added with POCl; (107 mL, 1.14 mol) at room temperature. The reaction solution was refluxed for 7 hours or more.
The reaction solution was cooled to room temperature, and the reaction solution was concentrated by distilling the solvent under reduced pressure. The concentrated solid was dissolved in dichloromethane, and then, an ice water was added thereto.
The reaction mixture was subjected to extraction with dichloromethane. The obtained organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The concentrated solid was added with a mixed solution of ethyl acetate/hexane = 1/1 (v/v), followed by stirring for 2 hours or more at room temperature. The resulting solid was filtered under reduced pressure, and washed with a mixed solution of ethyl acetate/hexane = 1/1 (v/v). The filtered solid was dried with warm wind in an oven (40°C) for 3 hours or more to obtain the title compound (28 g, 55%). 'H-NMR Spectrum (300 MHz, DMSO-d): 8 8.53 (m, 2H), 7.92 (d, 1H), 7.67 (d, 1H), 2.72 (s, 3H)
Example 1: Preparation of 4-amino-N-(1-((4-chlorophenyl)amino)-6- methylisoquinolin-S-yl)thieno[3,2-d]pyrimidine-7-carboxamide : <Step 1> Preparation of N-(4-chlorophenyl)-6-methyl-5-nitroisoquinolin-1- amine 1-chloro-6-methyl-5-nitroisoquinoline (5.0 g, 22.5 mmol) obtained in <Step 4> of Preparation Example 2 was dissolved in 2-propanol (70 mL), and added with : 4-chloroaniline (2.6, 20.4 mmol) at room temperature. The reaction solution was placed in a sealed reactor, and stirred for 10 hours or more at 90°C. The reaction mixture was cooled to room temperature, and the resulting solid was filtered under reduced pressure, followed by washing with ethyl acetate. The filtered solid was dried with warm wind in an oven (40°C) for 3 hours or more to obtain the title compound (6.1 g, 95%). "H-NMR Spectrum (300 MHz, DMSO-d): § 8.53 (m, 2H), 7.92 (d, 1H), 7.67 (d, 1H), 2.72 (s, 3H)
MS(ESI’, m/z): 314 [M+H]" <Step 2> Preparation of N'-(4-chlorophenyl)-6-methylisoquinolin-1,5- diamine
Iron (5.4 g, 97.2 mmol) and concentrated hydrochloric acid (0.1 mL) were added to a mixed solution of ethanol/water (50 mL/ 50 mL), and refluxed for 1 hour.
N-(4-chlorophenyl)-6-methyl-5-nitroisoquinolin-1-amine (6.1 g, 19.4 mmol) obtained in <Step 1> above was added to the mixed reaction solution, and further refluxed for 2 hours or more. The reaction mixture was filtered through a Celite pad under reduced pressure, and washed with a mixed solution of chloroform/2- propanol = 4/1 (v/v). The filtrate obtained was distilled under reduced pressure, and dissolved in a mixed solution of chloroform/2-propanol = 4/1 (v/v). The organic layer was separated, and washed with an aqueous solution of sodium bicarbonate and brine. The obtained organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound (4.6 g, 84%). 'H-NMR Spectrum (300 MHz, DMSO-dj): § 8.96 (s, 1H), 7.96 (d, 2H), 7.88 (d, 1H), 7.63 (d, 1H), 7.43 (d, 1H), 7.33 (d, 2H), 7.26 (d, 1H), 5.48 (s, 2H), 225d, 3H)
MS(ESI', m/z): 284 [M+H]" methylisoquinolin-5-yl)thieno[3.2-d]pyrimidine-7-carboxamide
4-aminothieno[3,2-d]pyrimidine-7-carboxylic acid (7.9 g, 40.5 mmol) obtained in <Step 7> of Preparation Example 1 was dissolved in dimethylformamide, added with DECP (11.7 mL, 81.1 mmol) and DIPEA (17.7 mL, 97.3 mmol) at 0°C, stirred for 10 minutes. The mixed reaction solution was added with N'-(4- chlorophenyl)-6-methylisoquinolin-1,5-diamine (4.6 g, 16.2 mmol) obtained in <Step 2> above, followed by stirring for 12 hours or more. The reaction mixture was diluted with ethyl acetate, and washed with a saturated aqueous solution of sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrated solid was added with ethyl acetate, followed by stirring for 2 hours or more. The resulting solid was dried with warm wind in an oven for 3 hours or more to obtain the title compound (2.7 g, 36%). "H-NMR Spectrum (300 MHz, DMSO-ds): § 11.56 (s, 1H), 9.33 (s, 1H), 9.14 (s, 1H), 8.58 (s, 1H), 8.47 (d, 1H), 8.00 (m, 5H), 7.63 (d, 1H), 7.38 (d, 2H), 7.19 (d, 1H), 2.42 (s, 3H)
MS(ESI', m/z): 461 [M+H]"
Example 2: Preparation of 4-amino-N-(6-methyl-1-((3- (trifluoromethyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 3-trifluoromethylaniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (22 mg, 26%).
MS(EST', m/z): 495 [M+H]*
Example 3: Preparation of N-(1-((4-chlorophenyl)amino)-6-methylisoquinolin-
S-y)-4-(cyclopropylamino)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Step 3> of Example 1 were repeated, except for using
N'-(4-chlorophenyl)-6-methylisoquinolin-1,5-diamine (0.04 g, 0.14 mmol) and 4- cyclopropylamino-thieno[3,2-d]pyrimidine-7-carboxylic acid (see WO 2011009687, 0.18 mmol) obtained in <Step 2> of Example 1 to obtain the title compound (27 mg, 38%).
MS(EST', m/z): 501 [M+H]"
Example 4: Preparation of 4-(cyclopropylamino)-N-(6-methyl-1-((3- (trifluoromethyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide
The procedures of Example 3 were repeated, except for using 6-methyl-N'- (3-trifluoromethyl-phenyl)-isoquinolin-1,5-diamine (0.05 g, 0.16 mmol) obtained in <Step 2> of Example 2 instead of N'-(4-chlorophenyl)-6-methylisoquinolin-1,5- diamine obtained in <Step 2> of Example 1 to obtain the title compound (27 mg, 26%).
MS(EST', m/z): 535 [M+H]"
Example 5: Preparation of 4-amino-N-(6-methyl-1-((3-(4-methyl-1H-imidazol- 1-yl)-5-(trifluoromethyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl- phenylamine (see WO 2006135640, 1.62 mmol) instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (7 mg, 42%).
MS(EST, m/z): 575 [M+H]"
Example 6: Preparation of 4-(cyclopropylamino)-N-(6-methyl-1-((3-(4-methyl-
1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)amino)isoquinolin-S-yl)thieno[3,2- d]pyrimidine-7-carboxamide
The procedures of <Step 3> of Example 1 were repeated, except for using 6- methyl-N'-(3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl)-isoquinolin-1,5- diamine (0.012 g, 0.03 mmol) obtained in Example 5 and 4-cyclopropylamino- thieno[3,2-d]pyrimidine-7-carboxylic acid (see WO 2011009687, 0.04 mmol) to obtain the title compound (10 mg, 57%).
MS(ESI’, m/z): 615 [M+H]"
Example 7: Preparation of 4-amino-N-(1-((4-((4-ethylpiperazin-1-yl)methyl)-3- (trifluoromethyl)phenyl)amino)-6-methylisoquinolin-S-yl)thieno[3,2- djpyrimidine-7-carboxamide <Step 1> Preparation of 1-(bromomethyl)-4-nitro-2-(trifluoromethyl)benzene 1-methyl-4-nitro-2-(trifluoromethyl)benzene (25 g, 122 mmol) was dissolved in dichloroethane (300 mL), followed by stirring. NBS (21.7 g, 122 mmol) and
AIBN (2.0 g, 12.2 mmol) were added thereto, followed by further stirring for about 12 hours at 80°C. The resulting solid was filtered under reduced pressure, and dried with warm wind in an oven (40°C) for 3 hours or more to obtain the title compound (34 g, 98%). "H-NMR Spectrum (300 MHz, DMSO-d;): § 8.53 (d, 1H), 8.42 (s, 1H), 8.06 (d, 1H), 4.88 (s, 2H)
MS(ESI", m/z): 284 [M+H]" <Step 2> Preparation of 1-ethyl-4-(4-nitro-2- (trifluoromethyl)benzyl)piperazine 1-(bromomethyl)-4-nitro-2-(trifluoromethyl)benzene (34 g, 120 mmol) obtained in <Step 1> above was dissolved in dichloromethane (300 mL), followed a1 by stirring. The reaction solution was added with 1-ethylpiperazine (15.97 mL, 126 mmol) and DIPEA (27.2 mL, 156 mmol), followed by further stirring for about 3 hours at room temperature. The reaction mixture was diluted with dichloromethane, and washed with a saturated aqueous solution of sodium bicarbonate and brine.
The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound (21.7 g, 57%). "H-NMR Spectrum (300 MHz, DMSO-ds): § 8.52 (d, 1H), 8.40 (s, 1H), 8.09 (d, 1H), 3.71 (s, 2H), 2.35 (m, 10H), 1.00 (t, 3H)
MS(EST, m/z): 318 [M+H]* <Step _3> Preparation of _ 4-((4-ethylpiperazin-1-yl)methyl)-3- ; (trifluoromethyl)aniline : 1-ethyl-4-(4-nitro-2-(trifluoromethyl)benzyl)piperazine (21.7 g, 68.3 mmol) obtained in <Step 2> above was dissolved in methanol, followed by stirring. The reaction solution was added with Pd/C (1.8 g, 17.08 mmol), followed by stirring under hydrogen conditions for about 12 hours at room temperature. The reaction mixture was filtered through a Celite pad under reduced pressure, washed with methanol. The filtrate was concentrated under reduced pressure to obtain the title compound (19.4 g, 99%). "H-NMR Spectrum (300 MHz, DMSO-dg): § 7.30 (d, 1H), 6.85 (s, 1H), : 6.76 (d, 1H), 5.42 (s, 2H), 3.37 (s, 2H), 2.33 (m, 10H) 1.01 (t, 3H)
MS(ESI, m/z): 288 [M+H]" <Step 4> Preparation of 4-amino-N-( 1-((4-((4-ethylpiperazin-1-yl)methyl)-3- trifluoromethyl)phenyl)amino )-6-methylisoquinolin-5-yl)thieno[3.2-d [pyrimidine-7- carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in : sequence, except for using 4-((4-ethylpiperazin-1-yl)methyl)-3- } (trifluoromethyl)aniline obtained in <Step3> above instead of 4-chloroaniline in
<Step 1> of Example 1 to obtain the title compound (7 mg, 30%).
MS(EST", m/z): 621 [M+H]"
Example 8: Preparation of 4-(cyclopropylamino)-N-(1-((4-((4-ethylpiperazin-1- yDmethyl)-3-(trifluoromethyl)phenyl)amino)-6-methylisoquinolin-5- yDthieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Step 3> of Example 1 were repeated in sequence, except for using N'-(4-(4-ethyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl)-6-methyl- isoquinolin-1,5-diamine (0.015 g, 0.03 mmol) and 4-cyclopropylamino-thieno[3,2- d]pyrimidine-7-carboxylic acid (see WO 2011009687, 0.04 mmol) to obtain the title compound (10 mg, 46%). "H-NMR Spectrum (300 MHz, DMSO-dp): § 11.59 (s, 1H), 9.48 (s, 1H), 8.94 (s, 1H), 8.64 (m, 2H), 8.48 (m, 2H), 8.31 (s, 1H), 8.24 (d, 1H), 8.01 (d, 1H), 7.63 (d, 2H), 7.20 (d, 1H), 3.62 (s, 2H), 3.06 (m, 1H), 2.70 (m, 10H), 2.42 (s, 3H), 1.13 (m, 3H), 0.87 (br, 2H), 0.7 (br, 2H)
MS(EST', m/z): 661 [M-+H]"
Example 9: Preparation of N-(1-((4-((4-ethylpiperazin-1-yl)methyl)-3- (trifluoromethyl)phenyl)amino)-6-methylisoquinolin-5-ylI)-4- (methylamino)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Step 3> of Example 1 were repeated in sequence, except for using N'-(4-(4-ethyl-piperazin-1-ylmethyl)-3-trifluoromethyl-phenyl)-6-methyl- isoquinolin-1,5-diamine (0.020 g, 0.05 mmol) obtained in Example 7 and 4- methylamino-thieno[3,2-d]pyrimidine-7-carboxylic acid (see WO 2011009687, 0.05 mmol) to obtain the title compound (4 mg, 13%). :
MS(EST', m/z): 635 [M+H]" :
Example 10: Preparation of 4-amino-N-(1-((4-(4-ethylpiperazin-1- yl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-(4-ethyl-piperazin-1-yl)phenylamine (see WO 2009141386, 0.37 mmol) instead of 4-chloroaniline obtained in <Step 1> of
Example 1 to obtain the title compound (1.2 mg, 37%). "H-NMR Spectrum (300 MHz, DMSO-dp): & 11.54 (s, 1H), 9.04 (s, 1H), 8.96 (s, 1H), 8.60 (s, 1H), 8.44 (d, 1H), 7.97 (s, 2H), 7.91 (d, 1H), 7.69 (d, 2H), 7.57 (d, 1H), 7.07 (d, 1H), 6.95 (d, 2H), 3.07 (m, 4H), 2.50 (m, 4H), 2.37 (m, 5H), 1.03 (t, 3H)
MS(ESI’, m/z): 539 [M+H]" [Example 11: Preparation of 4-amino-N-(1-((4-((4-ethylpiperazin-1- yDmethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-(4-ethyl-piperazin-1-ylmthyl)-phenylamine (see WO 2006000420, 0.37 mmol) instead of 4-chloroaniline obtained in <Step 1> of
Example 1 to obtain the title compound (4 mg, 8%). "H-NMR Spectrum (300 MHz, DMSO-dg): 8 11.56 (s, 1H), 9.20 (s, 1H), 8.96 (s, 1H), 8.60 (s, 1H), 8.47 (d, 1H), 7.98 (m, 3H), 7.82 (d, 2H), 7.61 (d, 1H), 7.24 (d, 1H), 7.15 (d, 1H), 3.43 (s, 2H), 2.43 (s, 3H), 2.35 (m, 10H), 0.99 (t, 3H) :
MS(ESI', m/z): 553 [M+H]*
Example 12: Preparation of 4-amino-N-(6-methyl-1-(phenylamino)isoquinolin-
S-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using aniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (112 mg, 65.5%). "H-NMR Spectrum (300 MHz, DMSO-dg): 8 11.55 (s, 1H), 9.21 (s, 1H), 8.96 (s, 1H), 8.58 (s, 1H), 8.50 (d, 1H), 7.98 (m, 3H), 7.91 (d, 2H), 7.61 (d, 1H), 7.36 (m, 2H), 7.15 (d, 1H), 7.01 (t, 1H), 2.48 (s, 3H)
MS(ESI", m/z): 427 [M+H]"
Example 13: Preparation of 4-amino-N-(1-((4-chloro-3- (trifluoromethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno(3,2- d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-chloro-3-(trifluoromethyl)aniline instead of 4- chloroaniline in <Step 1> of Example 1 to obtain the title compound (75 mg, 50%). "H-NMR Spectrum (300 MHz, DMSO-d): § 11.58 (s, 1H), 9.62 (s, 1H), 8.94 (s, 1H), 8.58 (s, 1H), 8.50 (s, 1H), 8.35 (d, 1H), 8.07 (d, 1H), 7.94 (s, 2H), 7.67 (dd, 2H), 7.27 (d, 1H), 2.48 (s, 3H)
MS(ESI', m/z): 529 [M+H]"
Example 14: Preparation of 4-amino-N-(1-((2-methoxy-5- : (trifluoromethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 2-methoxy-5-(trifluoromethyl)analine instead of 4- chloroaniline in <Step 1> of Example 1 to obtain the title compound (53 mg, 35%). "H-NMR Spectrum (300 MHz, DMSO-dg): 8 11.60 (s, 1H), 8.94 (s, 1H),
8.69 (s, 1H), 8.58 (s, 1H), 8.52 (d, 1H), 8.26 (d, 1H), 8.00 (d, 1H), 7.90 (s, 2H), 7.63 (d, 1H), 7.45 (d, 1H), 7.28 (d, 1H), 7.19 (d, 1H), 3.96 (s, 3H), 2.49 (s, 3H)
MS(ESI', m/z): 525 [M+H]"
Example 15: Preparation of 4-amino-N-(6-methyl-1-((4- (trifluoromethyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide <Step 1> Preparation of 6-methyl-5-nitro-N-(4-(trifluoromethyl)pyridin-2- yDisoquinolin-1-amine 1-chloro-6-methyl-5-nitroisoquinoline (580 mg, 2.61 mmol) obtained in <Step 4> of Preparation Example 2 was dissolved in 1,4-dioxane (15 mL), and added with 4-(trifluoromethyl)pyridin-2-amine (352 mg, 2.17 mmol), Xantphos (126 mg, 0.214 mmol), Pd,(dba); (80 mg, 0.087 mmol) and CsCO; (1.4 g, 4.34 mmol).
The reaction solution was sealed and stirred for 4 hours or more at 110°C. The reaction mixture was cooled to room temperature, diluted with ethyl acetate, and washed with a saturated aqueous solution of sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The concentrated compound was purified using silica gel chromatography (ethyl acetate:hexane = 1:3 (v/v)) to obtain the title compound (321 mg, 42%). "H-NMR Spectrum (300 MHz, DMSO-dy): § 10.50 (s, 1H), 8.79 (d, 1H), 8.65 (m, 2H), 8.26 (s, 1H), 7.70 (d, 1H), 7.35 (d, 1H), 7.07 (s, 1H)
MS(ESI’, m/z): 349 [M+H]" <Step 2> Preparation of 4-amino-N-(6-methyl-1-((4-trifluoromethyl)pyridin- 2-yl)amino)isoquinolin-5-yl)thieno[3.2-d]pyrimidine-7-carboxamide
The procedures of <Steps 2 and 3> of Example 1 were repeated in sequence, except for using 6-methyl-5-nitro-N-(4-(trifluoromethyl)pyridin-2-yl)isoquinolin-1-
amine obtained in <Step 1> above instead of N-(4-chlorophenyl)-6-methyl-5- nitroisoquinolin-1-amine in <Step 2> of Example 1 to obtain the title compound (19 mg, 17%). "H-NMR Spectrum (300 MHz, DMSO-dj): 8 11.59 (s, 1H), 10.67 (s, 1H), 9.06 (s, 1H), 8.64 (s, 1H), 8.58 (m, 3H), 8.14 (d, 1H), 7.96 (s, 2H), 7.63 (d, 1H), 7.38 (d, 1H), 7.32 (d, 1H), 2.43 (s, 3H)
MS(EST', m/z): 496 [M+H]"
Example 16: Preparation of 4-amino-N-(1-((4-methoxyphenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using para-anisidine instead of 4-chloroaniline in <Step 1> of
Example 1 to obtain the title compound (35 mg, 8%). "H-NMR Spectrum (300 MHz, DMSO-dq): 8 11.53 (s, 1H), 9.08 (s, 1H), 8.93 (s, 1H), 8.58 (s, 1H), 8.44 (d, 1H), 7.95 (s, 2H), 7.91 (d, 1H), 7.74 (d, 2H), 7.58 (d, 1H), 7.07 (d, 1H), 6.93 (d, 2H), 3.74 (s, 3H), 2.40 (s, 3H)
MS(EST', m/z): 457 [M+H]"
Example 17: Preparation of 4-amino-N-(6-methyl-1-(p-tolylamino)isoquinolin- 5-yDthieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using para-toluidine instead of 4-chloroaniline in <Step 1> of
Example 1 to obtain the title compound.
MS(ESI', m/z): 441 [M+H]"
Example 18: Preparation of 4-amino-N-(1-((4-isopropylphenyl)amino)-6-
methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-isopropylaniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (150 mg, 31%). "H-NMR Spectrum (300 MHz, DMSO-d): § 11.67 (s, 1H), 8.97 (s, 1H), 8.59 (m, 2H), 8.02 (m, 2H), 7.92 (d, 1H), 7.79 (d, 1H), 7.70 (d, 2H), 7.22 (m, 2H), 7.05 (d, 2H), 3.52 (m, 1H), 2.40 (s, 3H), 1.27 (m, 6H)
MS(ESI", m/z): 469 [M+H]"
Example 19: Preparation of 4-amino-N-(1-((5-(t-butyl)isoxazol-3-yl)amino-6- methylisoquinolin-S-yl)thieno[3,2-d]pyrimidine-7-carboxamide <Step 1> Preparation of 5-(t-butyl)isoxazol-3-amine 4,4-dimethyl-3-oxopentanenitrile (3 g, 23.97 mmol) was dissolved in distilled ; water, stirred, and added with NaOH (1.06 g, 26.4 mmol) and NH,OH-HCI (1.83 g, : 26.4 mmol). The reaction solution was stirred for about 30 minutes at room temperature. The reaction mixture was calibrated to yield pH in a range of 8 to 9 by adding an aqueous solution of 1 N NaOH, followed by further stirring for 10 hours or more at 50°C. The reaction mixture was washed 2 to 3 times with carbon tetrachloride, and aqueous layer was calibrated to yield pH in a range of 4 to 5 by adding concentrated HCl. The reaction mixture was further stirred for about 3 hours at 50°C. The reaction mixture was cooled to room temperature, and calibrated to yield pH 12 by adding an aqueous solution of 1 N NaOH. The resulting solid was filtered under reduced pressure, and washed with distilled water.
The filtered solid was dried with warm wind in an oven (40°C) for 3 hours or more to obtain the title compound (2.6 g, 77%). "H-NMR Spectrum (300 MHz, DMSO-dg): 6 5.49 (s, 1H), 5.40 (s, 2H), 1.21 (s, 9H) 48 i
MS(EST’, m/z): 141 [M+H]" <Step 2> Preparation of 4-amino-N-(1-((5-t-butyl)isoxazol-3-yl)amino)-6- : methylisoquinolin-S-yl)thieno[3.2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 5-(t-butyl)isoxazol-3-amine obtained in <Step 1> above, ] instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (7 mg, 7%). "H-NMR Spectrum (300 MHz, DMSO-ds): 8 11.56 (s, 1H), 10.20 (s, 1H), 8.94 (s, 1H), 8.58 (s, 1H), 8.52 (d, 1H), 8.07 (d, 1H), 7.95 (m, 1H), 7.60 (d, 1H), 7.25 (d, 1H), 6.85 (s, 1H), 2.20 (s, 3H), 1.33 (s, 9H)
MS(ESI', m/z): 474 [M+H]"
Example 20: Preparation of 4-amino-N-(1-((4-fluorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-fluoroaniline instead of 4-chloroaniline in <Step 1> of
Example 1 to obtain the title compound (25 mg, 13%).
MS(ESI*, m/z): 445 [M+H]"
Example 21: Preparation of 4-amino-N-(6-methyl-1-(thiazol-2- ylamino)isoquinolin-S-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Step 1> of Example 15 and <Steps 2 and 3> of Example 1 were repeated in sequence, except for using 2-aminothiazole instead of 4- (trifluoromethyl)pyridin-2-amine in <Step 1> of Example 15 to obtain the title compound (29 mg, 7.4%). "H-NMR Spectrum (300 MHz, DMSO-dp): & 11.59 (s, 1H), 8.95 (s, 1H),
8.58 (s, 1H), 8.50 (s, 1H), 8.15 (d, 1H), 7.97 (s, 2H), 7.69 (m, 1H), 7.60 (m, 1H), 7.29 (m, 2H), 7.11 (m, 1H), 2.42 (s, 3H)
MS(ESI', m/z): 434 [M+H]"
Example 22: Preparation of 4-amino-N-(1-((4-cyanophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-aminobenzonitrile instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (41 mg, 25%). "H-NMR Spectrum (300 MHz, DMSO-d): § 11.59 (s, 1H), 9.69 (s, 1H), 8.94 (s, 1H), 8.58 (s, 1H), 8.48 (d, 1H), 8.13 (m, 3H), 7.96 (s, 2H), 7.76 (d, 2H), 7.68 (d, 1H), 7.32 (d, 1H), 2.43 (s, 3H)
MS(ESI', m/z): 452 [M+H]"
Example 23: Preparation of 4-amino-N-(6-methyl-1-(quinolin-5- ylamino)isoquinolin-5-yl)thieno{3,2-d]pyrimidine-7-carboxamide
The procedures of <Step 1> of Example 15 and <Steps 2 and 3> of Example 1 were repeated in sequence, except for using S-aminoquinoline instead of 4- (trifluoromethyl)pyridin-2-amine in <Step 1> of Example 15 to obtain the title compound (15 mg, 8.6%). "H-NMR Spectrum (300 MHz, DMSO-d): 8 11.56 (s, 1H), 9.49 (s, 1H), 8.94 (s, 1H), 8.89 (d, 1H), 8.58 (s, 1H), 8.52 (d, 1H), 8.28 (d, 1H), 7.94 (m, 3H), 7.89 (t, 1H), 7.79 (m, 3H), 7.46 (d, 1H), 7.10 (d, 1H), 2.45 (s, 3H)
MS(EST, m/z): 478 [M+H]*
Example 24: Preparation of 4-amino-N-(1-((4-ethoxyphenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in : sequence, except for using 4-ethoxyaniline instead of 4-chloroaniline in <Step 1> of
Example 1 to obtain the title compound (52 mg, 33%). "H-NMR Spectrum (300 MHz, DMSO-d): § 11.53 (s, 1H), 9.08 (s, 1H), 8.93 (s, 1H), 8.41 (s, 1H), 8.44 (d, 1H), 7.94 (m, 3H), 7.72 (d, 2H), 7.58 (d, 1H), 7.63 (d, 1H), 7.07 (d, 1H), 6.92 (d, 2H), 3.41 (q, 2H), 2.40 (s, 3H), 1.35 (t, 3H)
MS(EST’, m/z): 471 [M+H]"
Example 25: Preparation of 4-amino-N-(6-methyl-1-((4- phenoxyphenyl)amino)isoquinolin-5-yl)thieno{3,2-d]pyrimidine-7- carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-phenoxyphenyl instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (71 mg, 47%). "H-NMR Spectrum (300 MHz, DMSO-dy): § 11.55 (s, 1H), 9.24 (s, 1H), 8.94 (s, 1H), 8.47 (s, 1H), 7.97 (m, SH), 7.61 (d, 1H), 7.39 (m, 3H), 7.14 (m, 6H), 2.42 (s, 3H)
MS(ESI’, m/z): 519 [M+H]"
Example 26: Preparation of 4-amino-N-(1-((4-hydroxyphenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-aminophenol instead of 4-chloroaniline in <Step 1> of
Example 1 to obtain the title compound.
MS(ESI", m/z): 443 [M+H]"
Example 27: Preparation of 4-amino-N-(1-((4-isopropoxyphenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-isopropoxyaniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound. "H-NMR Spectrum (300 MHz, DMSO-dg): § 11.55 (s, 1H), 8.95 (s, 1H), 8.59 (s, 1H), 8.47 (d, 1H), 7.96 (s, 2H), 7.85 (d, 1H), 7.69 (d, 2H), 7.10 (d, 1H), 6.95 (d, 2H), 4.60 (m, 1H), 2.42 (s, 3H), 1.13 (m, 6H)
MS(ESI’, m/z): 485 [M+H]"
Example 28: Preparation of 4-amino-N-(1-((4-(dimethylamino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using N,N-dimethyl-p-phenylenediamine instead of 4- chloroaniline in <Step 1> of Example 1 to obtain the title compound (32 mg, 15%). "H-NMR Spectrum (300 MHz, DMSO-d): 8 11.51 (s, 1H), 8.96 (s, 1H), 8.93 (s, 1H), 8.58 (s, 1H), 8.42 (d, 1H), 7.94 (s, 2H), 7.87 (d, 1H), 7.61 (d, 2H), 7.55(d, 1H), 7.02 (d, 1H), 6.76 (d, 2H), 2.86 (s, 3H), 2.40 (s, 3H)
MS(ESI’, m/z): 470 [M+H]"
Example 29: Preparation of 4-amino-N-(1-((2,3-dihydrobenzo[b][1,4]dioxin-6- yl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 1,4-benzodioxan-6-amine instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (21 mg, 13%). "H-NMR Spectrum (300 MHz, DMSO-d): § 11.57 (s, 1H), 8.94 (s, 1H),
8.58 (s, 1H), 8.51 (d, 1H), 7.97 (m, 2H), 7.68 (d, 1H), 7.62 (d, 1H), 7.39 (s, 1H), 7.19 (m, 2H), 6.73 (d, 2H), 4.12 (m, 4H), 2.44 (s, 3H)
MS(ESI", m/z): 485 [M+H]"
Example 30: Preparation of 4-amino-N-(1-((3,4-dimethoxyphenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 3,4-dimethoxyaniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (40 mg, 25%). "H-NMR Spectrum (300 MHz, DMSO-dy): 8 11.59 (s, 1H), 9.41 (s, 1H), 8.94 (s, 1H), 8.80 (s, 1H), 8.51 (m, 2H), 8.13 (s, 2H), 7.87 (m, 2H), 7.78 (m, 1H), 7.34 (m, 1H), 7.05 (m, 1H), 3.76 (d, 6H), 2.36 (s, 3H)
MS(EST', m/z): 487 [M+H]"
Example 31: Preparation of 4-amino-N-(1-((3-fluoro-4- methoxyphenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 3-fluoro-4-methoxyaniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound.
MS(EST', m/z): 475 [M+H]"
Example 32: Preparation of 4-amino-N-(6-methyl-1-((3,4,5- trimethoxyphenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- ; carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 3,4,5-trimethoxyaniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound. "H-NMR Spectrum (300 MHz, DMSO-d): § 11.77 (s, 1H), 9.45 (s, 1H), 8.89 (s, 1H), 8.60 (s, 1H), 8.52 (s, 1H), 7.95 (m, 3H), 7.57 (m, 2H), 7.12 (m, 2H), 3.63 (s, 6H), 3.39 (s, 3H)
MS(ESI', m/z): 517 [M+H]"
Example 33: Preparation of 4-amino-N-(6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide <Step 1> Preparation of 6-methylisoquinolin-5-amine 6-methyl-5-nitroisoquinoline (1 g, 5.31 mmol) obtained in <Step 2> of
Preparation Example 2 was dissolved in ethanol (70 mL), and added with tin(Il) chloride (5.46 g, 26.5 mmol) at room temperature. The reaction solution was stirred for 4 hours or more at 100°C. The reaction mixture was cooled to room temperature, diluted with ethyl acetate, and washed with a saturated aqueous solution of sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The concentrated solid was added with diethyl ether, followed by stirring for 1 hour. The resulting solid was filtered under reduced pressure to obtain the title compound (320 mg, 38%). "H-NMR Spectrum (300 MHz, DMSO-dy): 6 9.05 (s, 1H), 8.33 (d, 1H), 8.01 (d, 1H), 7.32 (d, 1H), 7.22 (d, 1H), 5.65 (s, 2H), 2.22 (s, 3H)
MS(ESI’, m/z): 159 [M+H]" <Step 2> Preparation of 4-amino-N-(6-methylisoquinolin-5-yl)thieno[3.2- d]pyrimidine-7-carboxamide
The procedures of <Step 3> of Example 1 were repeated, except for using 6- methylisoquinolin-5-amine obtained in <Step 1> above instead of N'-(4-
chlorophenyl)-6-methylisoquinolin-1,5-diamine in <Step 3> of Example 1 to obtain the title compound. "H-NMR Spectrum (300 MHz, DMSO-dg): 8 11.64 (s, 1H), 9.35 (s, 1H), 8.95 (s, 1H), 8.58 (s, 1H), 8.48 (d, 1H), 8.07 (d, 1H), 7.94 (s, 2H), 7.75 (m, 2H), 242s, 3H)
MS(EST', m/z): 336 [M+H]"
Example 34: Preparation of 4-amino-N-(1-(benzo[d][1,3]dioxol-5-ylamino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 3,4-(methylenedioxy)aniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (39 mg, 24%). "H-NMR Spectrum (300 MHz, DMSO-d): § 11.54 (s, 1H), 9.10 (s, 1H), 8.93 (s, 1H), 8.58 (s, 1H), 8.42 (d, 1H), 7.95 (m, 3H), 7.59 (m, 2H), 7.23 (d, 1H), 7.10 (d, 1H), 6.89 (d, 1H), 5.99 (s, 2H), 2.40 (s, 3H)
MS(ESI', m/z): 471 [M+H]"
Example 35: Preparation of 4-amino-N-(6-methyl-1-((5,6,7,8- tetrahydronaphthalen-2-yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 5,6,7,8-tetrahydronaphthylamine instead of 4- chloroaniline in <Step 1> of Example 1 to obtain the title compound. "H-NMR Spectrum (300 MHz, DMSO-d): § 11.60 (s, 1H), 9.44 (s, 1H), 8.93 (s, 1H), 8.57 (m, 3H), 7.94 (m, 2H), 7.54 (m, 3H), 7.00 (m, 2H), 2.41 (s, 3H), 1.74 (s, 4H), 1.00 (s, 4H)
MS(ESI', m/z): 481 [M+H]"
Example 36: Preparation of 4-amino-N-(4-((4-chlorophenyl)amino)-7- methylquinazolin-8-yl)thieno[3,2-d]pyrimidine-7-carboxamide 2-amino-4-methylbenzonitrile (10 g, 75.7 mmol) was dissolved in ethanol, added with potassium hydroxide (21.2 g, 378 mmol), followed by refluxing for 8 hours. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, and dissolved in ethyl acetate. The organic layer formed was washed with a saturated aqueous solution of sodium bicarbonate and brine. The obtained organic layer is dried over anhydrous sodium sulfate, concentrated under reduced pressure, and recrystallized from ethanol to obtain the title compound (4.9 g, 43%). "H-NMR Spectrum (300 MHz, DMSO-dg): 8 7.40 (d, 1H), 6.52 (s, 2H), 6.45 (s, 1H), 6.28 (d, 1H), 2.14 (s, 3H) <Step 2> Preparation of 7-methylquinazolin-4-(3H)-one 2-amino-4-mthylbenzamide (4.93 g, 32.8 mmol) obtained in <Step 1> above was added with formic acid (30 mL, 787.9 mmol), followed by stirring for 6 hours at 100°C. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, and washed with water. The filtered solid was dried with warm wind in an oven (40°C) for 6 hours or more to obtain the title compound (4.79 g, 91%). "H-NMR Spectrum (300 MHz, DMSO-ds): & 8.06 (s, 1H), 8.00 (d, 1H), 7.47 (s, 1H), 7.34 (d, 1H), 2.45 (s, 3H)
MS(ESI', m/z): 161 [M+H]" : <Step 3> Preparation of 6-bromo-7-methylquinazolin-4(3H)-one 7-methylquinazolin-4(3H)-one (4.78 g, 29.9 mmol) obtained in <Step 2> above and methanol (1.2 mL) were dissolved in acetic acid (23 mL, 397.5 mmol), and slowly added with bromine (3.1 mL, 59.8 mmol) over a period of 5 minutes at room temperature, followed by stirring for 5 hours at room temperature. The reaction mixture was concentrated under reduced pressure, and added with sodium thiosulfate, followed by stirring for a while. The resulting solid was filtered under reduced pressure, washed with water. The filtered solid was dried with warm wind in an oven (40°C) for 6 hours or more to obtain the title compound (4.62 g, 65%).
MS(EST*, m/z): 238 [M+H]" <Step 4> Preparation of 6-bromo-7-methyl-8-nitroquinazolin-4(3H)-one 6-bromo-7-methylquinazolin-4(3H)-one (2 g, 7.04 mmol) obtained in <Step 3> was added to sulfuric acid (15 mL), and heated to 80°C. The reaction mixture was added with potassium nitrate (1.1 g, 10.56 mmol), followed by stirring for 20 minutes at 80°C. The reaction mixture was cooled to room temperature, and ice water was added thereto. The resulting solid was filtered under reduced pressure, washed with water, and recrystallized from methanol to obtain the title compound (675 mg, 28%). "H-NMR Spectrum (300 MHz, DMSO-d): § 8.41 (s,1H), 8.25 (s,1H), 2.42 (s, 3H)
MS(EST", m/z): 283 [M+H]" <Step 5> Preparation of 6-bromo-4-chloro-7-methyl-8-nitroquinazoline 6-bromo-7-methyl-8-nitroquinazolin-4(3H)-one (672 mg, 2.366 mmol) obtain in <Step 4> was added to POCl; (10 mL), followed by stirring for 4 hours at 130°C. The reaction mixture was cooled to room temperature, and the reaction mixture was distilled under reduced pressure, followed by adding with ice water.
The reaction mixture was subjected to extraction with dichloromethane. The obtained organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound (420 mg, 59%).
MS(EST’, m/z): 301 [M+H]" <Step 6> _ Preparation of 6-bromo-N-(4-chlorophenyl)-7-methyl-8- nitroquinazolin-4-amine 6-bromo-4-chloro-7-methyl-8-nitroquinazoline (420 mg, 1.388 mmol) obtained in <Step 5> was dissolved in 2-propanol (8 mL), and 4-chloroaniline (195 mg, 1.527 mmol) was added thereto. The reaction solution was sealed, and stirred for 10 hours or more at 90°C. The reaction mixture was cooled to room temperature, and the resulting solid was filtered under reduced pressure, and washed with ethyl acetate. The filtered solid was dried with warm wind in an oven (40°C) for 3 hours or more to obtain the title compound (89 mg, 16%).
MS(ESI', m/z): 392 [M+H]" <Step 7> Preparation of N*-(4-chlorophenyl)-7-methylquinazolin-4,8- diamine 6-bromo-N-(4-chlorophenyl)-7-methyl-8-nitroquinazolin-4-amine (88 mg, 19.4 mmol) obtained in <Step 6> was dissolved in ethanol, added with 10% Pd/C (9 mg, 0.022 mmol), followed by stirring for 8 hours under hydrogen gas. The reaction mixture was filtered through a Celite pad under reduced pressure, and washed with a mixed solution of chloroform/2-propanol = 4/1 (v/v). The resulting filtrate was concentrated under reduced pressure and purified using silica gel chromatography to obtain the title compound (36 mg, 56%). 'H-NMR Spectrum (300 MHz, DMSO-dy): § 9.58 (s,1H), 8.54 (s,1H), 7.96 (d,2H), 7.62 (d,1H), 7.43 (d, 2H), 7.28 (d,1H), 5.61 (s,2H), 2.27 (s,3H)
MS(ESI', m/z): 285 [M+H]" <Step 8> Preparation of 4-amino-N-( 4-((4-chlorophenyl)amino)-7- methylquinazolin-8-yl)thieno[3,2-d]pyrimidine-7-carboxamide 4-aminothieno(3,2-d]pyrimidine-7-carboxylic acid (47 mg, 0.239 mmol)
obtained in <Step 7> of Example 1 was dissolved in dimethylformamide, added with
DECP (52 pL, 0.358 mmol) and DIPEA (0.1 mL, 0.597 mmol) at 0°C, followed by stirring for 10 minutes. The reaction mixture was added with N*-(4-chlorophenyl)- 7-methylquinazolin-4,8-diamine (34 mg, 0.119 mmol) obtained in <Step 7> above, followed by stirring for 10 hours at 40°C. The reaction mixture was diluted with ethyl acetate, and washed with a saturated aqueous solution of sodium bicarbonate and brine. The organic layer is dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrated solid was added with ethyl acetate, followed by stirring for 2 hours or more. The resulting solid was filtered under reduced pressure, washed with ethyl acetate and methanol. The filtered solid was dried with warm wind in an oven (40°C) for 3 hours or more to obtain the title compound (5.7 mg, 10%). "H-NMR Spectrum (300 MHz, DMSO-d): 8 11.74 (s,1H), 9.91 (s,1H), 8.93 (s,1H), 8.58 (d,1H), 8.42 (d,1H), 7.95 (d,2H), 7.90 (s,2H), 7.62 (d,1H), 7.46 (d,2H), 2.43 (s,3H)
MS(EST*, m/z): 462 [M+H]"
Example 37: Preparation of 4-(cyclopropylamino)-N-(1-((4- methoxyphenyl)amino)-6-methylisoquinolin-5-yl)thieno|3,2-d]pyrimidine-7- carboxamide
The procedures of Example 16 were repeated in sequence, except for using 4-(cyclopropylamino)thieno[3,2-d]pyrimidine-7-carboxylic acid (see Preparation
Example 4 of Korean Patent Publication Number. No. 10-2011-0089108) instead of carboxylic acid in Example 16 to obtain the title compound (32 mg, 24%). 'H-NMR Spectrum (300 MHz, DMSO-dy): § 11.55 (s, 1H), 9.13 (s, 1H), 9.07 (s, 1H), 8.65 (s, 1H), 8.51 (d, 1H), 8.44 (d, 1H), 7.91 (d, 1H), 7.74 (d, 2H), 7.58 (d, 1H), 7.07 (d, 1H), 6.93 (d, 2H), 3.08 (m, 1H), 2.41 (s, 3H), 0.86 (m, 2H), 0.71 (m, 2H)
MS(ESI', m/z): 497 [M+H]"
Example 38: Preparation of 4-amino-N-(1-((3-chlorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 3-chloroaniline instead of 4-chloroaniline in <Step 1> of
Example 1 to obtain the title compound (223 mg, 39%).
H-NMR Spectrum (300 MHz, DMSO-dg): 8 11.56 (s, 1H), 9.35 (s, 1H), 8.93 (s, 1H), 8.57 (s, 1H), 8.45 (d, 1H), 8.14 (m, 1H), 8.03 (d, 1H), 7.94 (s, 2H), 7.84 (d, 1H), 7.62 (4, 1H), 7.33 (t, 1H), 7.20 (d, 1H), 6.99 (dd, 1H), 2.41 (s, 3H)
MS(EST, m/z): 460 [M+H]"
Example 39: Preparation of 4-amino-N-(1-((3-bromophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-bromoaniline instead of 4-chloroaniline in <Step 1> of
Example 1 to obtain the title compound (65 mg, 15%). "H-NMR Spectrum (300 MHz, DMSO-dy): § 11.55 (s, 1H), 9.31 (s, 1H), 8.92 (s, 1H), 8.57 (s, 1H), 8.44 (d, 1H), 7.99 (d, 1H), 7.93 (m, 4H), 7.61 (d, 1H), 7.48 (d, 2H), 7.17 (d, 1H), 2.41 (s, 3H)
MS(EST', m/z): 504 [M+H]"
Example 40: Preparation of 4-amino-N-(1-((2,4-dichlorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example | were repeated in sequence, except for using 2,4-dichloroaniline instead of 4-chloroaniline in <Step 1> :
of Example 1 to obtain the title compound (45 mg, 42%). "H-NMR Spectrum (300 MHz, DMSO-dy): 8 11.56 (brs, 1H), 9.05 (brs, 1H), 8.94 (s, 1H), 8.59 (s, 1H), 8.35 (s, 1H), 7.95 (m, 4H), 7.27 (s, 1H), 7.14 (s, 1H), 2.43 (s, 3H)
MS(ESI?, m/z): 495 [M+H]"
Example 41: Preparation of 4-amino-N-(1-((3,4-dichlorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 3,4-dichloroaniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (47 mg, 43%). "H-NMR Spectrum (300 MHz, DMSO-d): § 11.58 (brs, 1H), 9.47 (brs, 1H), 8.94 (s, 1H), 8.59 (s, 1H), 8.46 (m, 4H), 7.63 (s, 1H), 7.56 (s, 1H), 7.25 (s, 1H), 2.43 (s, 3H)
MS(ESI, m/z): 495 [M+H]"
Example 42: Preparation of 4-amino-N-(1-((3,5-dichlorophenyl)amino)-6- methylisoquinolin-S-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 3,5-dichloroaniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (42 mg, 41%). 'H-NMR Spectrum (300 MHz, DMSO-d): § 11.59 (brs, 1H), 9.51 (brs, 1H), 8.94 (s, 1H), 5.60 (s, 1H), 8.44 (s, 1H), 8.11 (m, 3H), 7.67 (s, 1H), 7.27 (s, 1H), 7.14 (s, 1H), 2.44 (s, 3H)
MS(EST", m/z): 495 [M+H]"
Example 43: Preparation of 4-amino-N-(6-methyl-1-((3,4,5-
trichlorophenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 2,3,4-trichloroaniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (75 mg, 6%).
MS(ESI’, m/z): 529 [M+H]"
Example 44: Preparation of 4-amino-N-(1-((4-chloro-3- methoxyphenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-chloro-3-methoxyaniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (103 mg, 9%). 'H-NMR Spectrum (300 MHz, DMSO-d): § 11.57 (s,1H), 9.31 (s,1H), 8.94 (s,1H), 8.58 (s,1H), 8.47 (d,1H), 8.03 (d,1H), 7.95 (s,2H), 7.80 (s,1H), 7.65 (m,2H), 7.33 (d,2H), 7.19 (d,1H), 3.87 (s,3H), 2.42 (s, 3H)
MS(ESI', m/z): 491 [M+H]"
Example 45: Preparation of 4-amino-N-(1-benzylamino-6-methylisoquinolin- 5-yl)thieno[3,2-d]pyrimidine-7-carboxamide ;
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using benzylamine instead of 4-chloroaniline in <Step 1> of
Example 1 to obtain the title compound (32 mg, 32%).
MS(EST", m/z): 441 [M+H]"
Example 46: Preparation of 4-amino-N-(6-methyl-1-phenoxyisoquinolin-5-
yDthieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using phenol, KOH, Cu (powder) and 1,4-dioxane instead of 4- chloroaniline and 2-propanol in <Step 1> of Example 1 to obtain the title compound (62 mg, 17%). "H-NMR Spectrum (300 MHz, DMSO-d): § 11.64 (s, 1H), 8.94 (s, 1H), 8.57 (s, 1H), 8.29 (d, 1H), 7.94 (s, 2H), 7.90 (d, 1H), 7.70 (d, 1H), 7.45 (m, 3H), 7.26 (m, 3H), 2.46 (s, 3H)
MS(ESI", m/z): 427 [M+H]"
Example 47: Preparation of 4-amino-N-(6-methyl-1-((4- morpholinophenyl)amino)isoquinolin-5-yl)thieno3,2-d]pyrimidine-7- carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-morpholinoaniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (193 mg, 35%). "H-NMR Spectrum (300 MHz, DMSO-ds): & 9.03 (s, 1H), 8.92 (s, 1H), 8.57 (s, 1H), 8.41 (d, 1H), 7.93 (br, 2H), 7.88 (d, 1H), 7.68 (d, 2H), 7.55 (d, 1H), 7.04 (d, 1H), 6.92 (d, 2H), 3.74 (m, 4H), 3.05 (m, 4H), 2.39 (s, 3H)
MS(EST', m/z): 512 [M+H]"
Example 48: Preparation of N-(1-((4-(1H-pyrrol-1-yl)phenyl)amino)-6- methylisoquinolin-5-yl)-4-aminothieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-(1H-pyrrol-1-yl)aniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (110 mg, 21%).
"H-NMR Spectrum (300 MHz, DMSO-dy): § 11.59 (s, 1H), 9.30 (s, 1H), 8.93 (s, 1H), 8.57 (s, 1H), 8.48 (d, 1H), 7.97 (m, 4H), 7.62 (d, 1H), 7.51 (d, 2H), 7.30 (s, 2H), 7.16 (d, 1H), 6.23 (s, 2H), 2.41 (s, 3H)
MS(EST', m/z): 491 [M+H]"
Example 49: Preparation of 4-amino-N-(6-methyl-1-(pyrimidin-4- ylamino)isoquinolin-5-yl)thieno|3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-aminopyrimidine instead of 4- (trifluvoromethyl)pyridine-2-amine in <Step 1> of Example 15 to obtain the title compound (2.3 mg, 1.5%). "H-NMR Spectrum (300 MHz, DMSO-ds): § 11.61 (s, 1H), 10.50 (s, 1H), 8.94 (s, 1H), 8.78 (s, 1H), 8.58 (s, 1H), 8.49 (d, 1H), 8.38 (d, 1H), 8.21 (d, 1H), 8.13 (d, 1H), 7.95 (s, 2H), 7.64 (d, 1H), 7.42 (d, 1H), 2.43 (s, 3H)
MS(ESI', m/z): 429 [M+H]*
Example 50: Preparation of 4-amino-N-(1-((4- (difluoromethoxy)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-(difluoromethoxy)aniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (170 mg, 27%). 'H-NMR Spectrum (300 MHz, DMSO-d): 8 11.55 (s, 1H), 9.28 (s, 1H), 8.94 (s, 1H), 8.58 (s, 1H), 8.46 (d, 1H), 7.97 (m, 5H), 7.62 (d, 1H), 7.16 (m, 3H), 2.42 (s, 3H)
MS(EST, m/z): 493 [M-+H]*
Example 51: Preparation of 4-amino-N-(6-methyl-1-((4- (trifluoromethoxy)phenyl)amino)isoquinolin-5-yl)thieno{3,2-d]pyrimidine-7- carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-(trifluoromethoxy)aniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (30 mg, 20%). "H-NMR Spectrum (300 MHz, DMSO-ds): & 11.56 (s, 1H), 9.39 (s, 1H), 8.94 (s, 1H), 8.58 (s, 1H), 8.44 (d, 1H), 8.01 (m, SH), 7.64 (d, 1H), 7.33 (d, 2H), 7.21(d, 1H), 2.42 (s, 3H)
MS(ESI', m/z): 511 [M+H]"
Example 52: Preparation of 4-amino-N-(1-((4- chlorophenyl)amino)isoquinolin-5-yl)thieno|[3,2-d]pyrimidine-7-carboxamide <Step 1> Preparation of 1-chloro-5-nitroisoquinoline
The procedures of <Steps 3 and 4> of Preparation Example 2 were repeated in sequence, except for using S-nitroisoquinoline instead of 6-methyl-5- nitroisoquinoline in <Step 3> of Preparation Example 2 to obtain the title compound (1.35 g, 40%). 'H-NMR Spectrum (300 MHz, DMSO-dy): 6 8.77 (t, 2H), 8.56 (d, 1H), 8.31 (d, 1H), 8.05 (t, 1H)
MS(ESI', m/z): 209 [M+H]* <Step 2> Preparation of 4-amino-N-(1-((4-chlorophenyl)amino)isoquinolin-
S-yl)thieno[3.2-d]pyrimidine-7-carboxamide ;
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 1-chloro-5-nitroisoquinoline instead of 1-chloro-6- methyl-5-nitroisoquinoline in <Step 1> of Example 1 to obtain the title compound
(40 mg, 24%). 'H-NMR Spectrum (300 MHz, DMSO-d): § 12.42 (s, 1H), 9.34 (s, 1H), 9.00 (s, 1H), 8.76 (s, 1H), 8.71 (d, 1H), 8.35 (d, 1H), 8.20 (d, 1H), 8.01 (s, 2H), 7.97 (d, 2H), 7.74 (m, 2H), 7.39 (d, 2H)
MS(ESI", m/z): 447 [M+H]"
Example 53: Preparation of 4-amino-N-(5-((4-chlorophenyl)amino)naphthalen- 1-yl)thieno[3,2-d]pyrimidine-7-carboxamide <Step 1> Preparation of N-(4-chlorophenyl)-5-nitronaphthalen-1-amine 1-bromo-5-nitronaphthalene (131 mg, 0.52 mmol) was dissolved in DMA (5 mL), and added with 4-chloroaniline (60 mg, 0.47 mmol), Xantphos (27 mg, 0.047 mmol), Pdy(dba); (17.2 mg, 0.019 mmol) and CsCO; (306 mg, 0.94 mmol) at room temperature. The reaction solution was sealed and stirred for about 3 hours under microwave conditions at 140°C. The reaction mixture was cooled to room temperature, diluted with ethyl acetate, and washed with a saturated aqueous solution of sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrated compound purified using silica gel chromatography (ethyl acetate:hexane = 1:5 (v/v)) to obtain the title compound (92 mg, 66%). "H-NMR Spectrum (300 MHz, DMSO-dy): § 10.10 (s, 1H), 9.00 (d, 1H), 8.58 (d, 1H), 8.13 (d, 1H), 7.89 (m, 3H), 7.59 (d, 2H), 7.47 (d, 2H)
MS(ESI", m/z): 299 [M+H]" <Step 2> Preparation of 4-amino-N-(1-((4-chlorophenyl)amino)isoquinolin- 5-yhthieno[3.2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using N-(4-chlorophenyl)-5-nitronaphthalene-1-amine obtained in <Step 1> instead of N-(4-chlorophenyl)-6-methyl-5-nitroisoquinolin-1-amine in :
<Step 2> of Example 1 to obtain the title compound (10 mg, 8.2%). "H-NMR Spectrum (300 MHz, DMSO-ds): § 12.56 (s, 1H), 9.00 (s, 1H), 8.77 (s, 1H), 8.49 (d, 1H), 8.42 (s, 1H), 8.17 (d, 1H), 8.00 (m, 3H), 7.64 (m, 2H), 7.52 (d, 1H), 7.27 (d, 2H), 7.05 (d, 2H)
MS(EST*, m/z): 446 [M+H]"
Example 54: Preparation of 4-amino-N-(1-((4-ethynylphenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-ethynylaniline instead of 4-chloroaniline in <Step 1> of
Example 1 to obtain the title compound (114 mg, 46%). "H-NMR Spectrum (300 MHz, DMSO-ds): § 12.18 (s, 1H), 8.97 (s, 1H), 8.62 (s, 1H), 8.36 (d, 1H), 8.07 (d, 1H), 7.91 (m, 4H), 7.71 (d, 1H), 7.63 (d, 2H), 7.42(d, 1H), 5.77 (s, 1H), 5.76 (br, 1H), 2.29 (s, 3H)
MS(ESI', m/z): 450 [M+H]"
Example 55: Preparation of 4-amino-N-(1-(isopropylamino)-6- methylisoquinolin-5S-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using isopropylamine instead of 4-chloroaniline in <Step 1> of
Example 1 to obtain the title compound (4 mg, 1%). "H-NMR Spectrum (300 MHz, MeOD): § 8.89 (s,1H), 8.58 (s,1H), 8.16 (d,1H), 7.77 (d,1H), 7.50 (d,1H), 7.00 (d,1H), 4.34 (m,1H), 2.47 (s,3H), 1.25 (d, 6H) :
MS(ESI', m/z): 393 [M+H]" ;
Example 56: Preparation of 4-amino-N-(1-(indolin-6-ylamino)-6- ’
methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 6-nitroindoline instead of 4-chloroaniline in <Step 1> of
Example 1 to obtain the title compound (12 mg, 3%).
MS(EST", m/z): 468 [M+H]"
Example 57: Preparation of 4-amino-N-(1-((4-(fluoromethoxy)phenyl)amino)- 6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide <Step 1> Preparation of 1-(fluoromethoxy)-4-nitrobenzene 4-nitrobenzylalcohol (1 g, 6.53 mmol) was dissolved in dichloromethane (15 mL), and added with XeF; (1.1 g, 6.53 mmol) at 35°C. The reaction solution was stirred at a temperature in the range of 35 to 40°C until gas generation has come to ahalt. The reaction solution was cooled to room temperature and further stirred for about 7 hours. The reaction mixture was diluted with ethyl acetate, and washed with a saturated aqueous solution of sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The concentrated compound was purified using silica gel chromatography (ethyl acetate: hexane = 1:5 (v/v)) to obtain the title compound (670 mg, 61%). "H-NMR Spectrum (300 MHz, DMSO-ds): § 8.29 (d, 2H), 7.35 (d, 2H), 6.09 (s, 1H), 5.91 (s, 1H)
MS(ESI', m/z): 172 [M+H]" <Step 2> Preparation of 4-(fluoromethoxy)aniline
The procedures of <Step 2> of Example 1 were repeated, except for using 1- (fluoromethoxy)-4-nitrobenzene obtained in <Step 1> above instead of using N-(4- chlorophenyl)-6-methyl-5-nitroisoquinolin-1-amine in <Step 2> of Example 1 to :
obtain the title compound (510 mg, 92%). "H-NMR Spectrum (300 MHz, DMSO-dp): § 6.80 (d, 2H), 6.55 (d, 2H), 5.73 (s, 1H), 5.55 (s, 1H), 4.84 (s, 2H)
MS(EST, m/z): 142 [M+H]" <Step 3> Preparation of 4-amino-N-(1-((4-(fluoromethoxy)phenyl)amino)-6- methylisoquinolin-5-yhthieno[3.2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-(fluoromethoxy)aniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (17 mg, 11%). "H-NMR Spectrum (300 MHz, DMSO-d): § 11.54 (s, 1H), 9.19 (s, 1H), 8.93 (s, 1H), 8.58 (s, 1H), 8.45 (d, 1H), 7.95 (m, 3H), 7.85 (d, 1H), 7.60 (d, 1H), 7.12 (m, 3H), 5.91 (s, 1H), 5.73 (s, 1H), 2.41 (s, 3H)
MS(EST', m/z): 475 [M+H]"
Example 58: Preparation of N-(1-(4-chlorophenylamino)-6-methylisoquinolin- 5-yl)thieno|[3,2-d]pyrimidine-7-carboxamide <Step 1> Preparation of 7-methyl-3H-thieno[3.2-d]pyrimidin-4-one 3-amino-4-methyl-thiophene-2-carboxylic acid methyl ester (10.2 g, 59.6 mmol) was dissolved in formamide (25 mL), followed by refluxing for 24 hours at 200°C. The reaction solution was slowly cooled to room temperature. The resulting solid was filtered, washed with diethyl ether, and dried to obtain the title compound (9 g, 91%). "H-NMR Spectrum (300 MHz, DMSO-dy): & 8.17 (s, 1H), 7.81 (s, 1H), 2.31 (s, 3H) : 7-methyl-3H-thieno[3,2-d]pyrimidin-4-one (9 g, 54.2 mmol), DMF (ImL),
POCl; (80mL) were mixed and refluxed for 4 hours at 110°C. The reaction solution was cooled to room temperature, and the reaction mixture was concentrated under reduced pressure. The reaction mixture was added with toluene, and further concentrated under reduced pressure. The resulting residue was neutralized with sodium bicarbonate, subjected to extraction with ethyl acetate, dried, and filtered to obtain the title compound (8.1 g, 81%). "H-NMR Spectrum (300 MHz, CDCls): 8 9.01 (s, 1H), 7.69 (s, 1H), 2.53 (s, 3H) <Step 3> Preparation of 7-methyl-thieno[3.2-d]pyrimidine 4-chloro-7-methyl-thieno[3,2-d]pyrimidine (6.5 g, 35.2 mmol) was dissolved in methanol (200 mL), added with Pd(OH), (1.3 g) and triethylamine (4.9 mL, 35.2 mmol), and stirred for 5 hours under hydrogen pressure conditions. The reaction mixture was filtered through a Celite pad under reduced pressure, and concentrated.
The concentrated compound was purified using silica gel chromatography (ethyl acetate:hexane = 1:1 (v/v=1/1)) to obtain the title compound (4.5 g, 85%). "H-NMR Spectrum (300 MHz, CDCl): 8 9.24 (s, 2H), 7.65 (s, 1H), 2.54 (s, 3H) <Step 4> 7-acetyloxymethyl-thieno[3.2-d]pyrimidine 7-methyl-thieno[3,2-d]pyrimidine (500 mg, 3.33 mmol) was dissolved in : benzene (11 mL), added with NBS (539 mg, 3.33 mmol) and AIBN (27 mg, 0.17 mmol), and refluxed for 2 hours at 75°C. The reaction mixture was slowly cooled to room temperature, and added with potassium iodide (553 mg, 3.33 mmol) and DMF (5 mL), followed by stirring for 1 hour at 40°C. Sodium acetate (273 mg, 3.33 mmol) was added thereto, followed by further stirring for 3 hour at 40°C. Additionally, sodium acetate (273 mg, 3.33 mol) was added thereto, and the reaction mixture was stirred for 12 hours at 40°C. The reaction ] mixture was subjected to extraction with ethyl acetate, washed with water and
NaS;0; solution, dried and concentrated under reduced pressure. The concentrated compound was purified using silica gel chromatography (ethyl acetate:hexane = 1:1 (v/v)) to obtain the title compound (140 mg, 20%). "H-NMR Spectrum (300 MHz, CDCl3): 8 9.29 (s, 1H), 9.27 (s, 1H), 8.08 (s, 1H), 5.48 (s, 2H), 2.12 (s, 3H)
MS(EST’, m/z): 209 [M+H]" <Step 5> Preparation of 7-hydroxymethyl-thieno[3.2-d]pyrimidine 7-acetyloxymethyl-thieno[3,2-d]}pyrimidine (134 mg, 0.64 mmol) was dissolved in tetrahydrofuran/water (2 mL/2 mL), added with an aqueous solution of 1 N sodium hydroxide (0.97 mL, 0.97 mmol), followd by stirring for 2 hours at room temperature. The reaction solution was subjected to extraction with ethyl acetate, dried, and filtered to obtain the title compound (86 mg, 77%). "H-NMR Spectrum (300 MHz, CDCl): 8 9.25 (s, 1H), 9.17 (s, 1H), 7.92 (s, 1H), 5.04 (s, 2H) <Step 6> Preparation of thieno[3.2-d]pyrimidine-7-carboaldehyde 7-hydroxymethyl-thieno[3,2-d]pyrimidine (250 mg, 1.56 mmol) was dissolved in dichloromethane (10 mL), added with MnO, (1.36 g, 15.60 mmol), followed by stirring for 2 hours. The reaction mixture was filtered through a Celite pad under reduced pressure, and concentrated to obtain the title compound (80 mg, 30%). 'H-NMR Spectrum (300 MHz, CDCl): & 10.51 (s, 1H), 9.37 (s, 2H), 8.87 (s, 1H) <Step 7> Preparation of thieno[3.2-d]pyrimidine-7-carboxylic acid
The procedures of <Step 7> of Example 1 were repeated except for using thieno[3,2-d]pyrimidine-7-carboaldehyde (70 mg, 0.43 mmol) instead of 4- aminothieno[3,2-d]pyrimidine-7-carboaldehyde to obtain the title compound (37 mg,
"H-NMR Spectrum (300 MHz, DMSO-d): 8 13.06 (brs, 1H), 9.62 (s, 1H), 9.27 (s, 1H), 9.16 (s, 1H)
MS(EST’, m/z): 181 [M+H]" <Step 8> Preparation of N-(1-(4-chlorophenylamino)-6-methylisoquinolin-5- yDthieno[3.2-d]pyrimidine-7-carboxamide
The procedures of Example 1 were repeated except for using thieno[3,2- d]pyrimidine-7-carboxylic acid instead of 4-aminothieno[3,2-d]pyrimidine-7- carboxylic acid in <Step 3> of Example 1 to obtain the title compound (10 mg, 12%). "H-NMR Spectrum (300 MHz, DMSO-d): 5 11.01 (brs, 1H), 9.77 (s, 1H), 9.41 (s, 1H), 9.33 (brs, 1H), 9.29 (s, 1H), 8.47 (d, 1H), 7.98 (d, 1H), 7.95 (d, 2H), 7.63 (d, 1H), 7.36 (d, 2H), 7.23 (d, 1H), 2.45 (s, 3H)
MS(ESI', m/z): 446 [M+H]"
Example 59: Preparation of 4-amino-N-(1-((4-chloro-3- ((dimethylamino)methyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide <Step 1> Preparation of 1-(2-chloro-5-nitrophenyl)-N,N- dimethylmethanamine 2-chloro-5-nitrobenzaldehyde (1 g, 5.39 mmol) was dissolved in THF (10 mL), and added with dimethylamine (2 M THF solution, 2.7 mL, 5.39 mmol). The reaction solution was cooled to 0°C, and NaBH(OAc); (1.6 g, 7.55 mmol) was slowly added thereto, followed by stirring for 12 hours or more at room temperature.
The reaction mixture was added with water, and subjected to extraction with ethyl acetate. The separated organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound (940 mg, 81%). :
"H-NMR Spectrum (300 MHz, CDCls): 8.42 (d, 1H), 8.10 (dd, 1H), 7.55 (d, 1H), 3.70 (s, 2H), 2.37 (s, 6H)
MS(ESI', m/z): 215 [M+H]" <Step 2> Preparation of 4-chloro-3-((dimethylamino)methyl)aniline
Iron (1.36 g, 21.9 mmol) and concentrated hydrochloric acid (0.15 mL) was added to ethanol/water (20 mL/20 mL), followed by refluxing for 1 hour. The mixed reaction solution was added with 1-(2-chloro-5-nitrophenyl)-N,N- dimethylmethanamine (940 mg, 4.38 mmol) obtained in <Step 1> above, and refluxed for 1 hour. The reaction mixture was filtered through a Celite pad under reduced pressure, and washed with ethanol and chloroform/2-propanol = 3/1 (v/v).
The resulting filtrate was distilled under reduced pressure, and dissolved in ethyl acetate. The organic layer formed was washed with an aqueous solution of sodium bicarbonate and brine. The obtained organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The concentrated compound was purified using silica gel chromatography (chloroform:methanol = 30:1 — 15:1 (v/v)) to obtain the title compound (442 mg, 55%). "H-NMR Spectrum (300 MHz, CDCl): 6 7.12 (d, 1H), 6.79 (d, 1H), 6.54 (dd, 1H), 3.64 (brs, 2H), 3.45 (s, 2H), 2.30 (s, 6H)
MS(ESI', m/z): 185 [M+H]* <Step 3> Preparation of N-(4-chloro-3-((dimethylamino)methyl)phenyl)-6- methyl-5-nitroisoquinolin-1-amine 4-chloro-3-((dimethylamino)methyl)aniline (227 mg, 1.23 mmol) obtained in : <Step 2> above and 1-chloro-6-methyl-5-nitroisoquinoline (300 mg, 1.35 mmol) obtained in <Step 4> of Preparation Example 2 were dissolved in 1,4-dioxane (6 mL), and added with Xantphos (73 mg, 0.123 mmol), Pd,(dba); (75 mg, 0.0615 mmol) and Cs,CO; (801.5 mg, 2.46 mmol). The reaction solution was sealed, and stirred for 3 hours at 130°C. The reaction mixture was cooled to room temperature, and subjected to extraction with water and ethyl acetate. The separated organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrated compound was purified using silica gel chromatography (chloroform:methanol = 30:1 (v/v)) to obtain the title compound (241.5 mg, 53%). "H-NMR Spectrum (300 MHz, CDCl3): & 8.18 (d, 1H), 7.99 (d,1 H), 7.81 (dd, 1H), 7.55 (d, 1H), 7.46 (d, 1H), 7.38 (d, 1H), 6.99 (d, 1H), 3.58 (s, 2H), 2.53 (s, 3H), 2.35 (s, 6H)
MS(ESI", m/z): 371 [M+H]" <Step 4> Preparation of N1-(4-chloro-3-((dimethylamino)methyl)phenyl)-6- methylisoquinolin-1,5-diamine
Iron (202 mg, 3.25 mmol) and concentrated hydrochloric acid (0.02 mL) were added to ethanol/water (6.5 mL/6.5 mL), followed by refluxing for 1 hour.
The mixed reaction solution was added with N-(4-chloro-3- ((dimethylamino)methyl)phenyl)-6-methyl-5-nitroisoquinolin-1-amine (241.5 mg, 0.65 mmol) obtained in <Step 3> above, followed by refluxing for 1 hour. The reaction mixture was filtered through a Celite pad under reduced pressure, and washed with ethanol and chloroform/2-propanol = 3/1 (v/v). The resulting filtrate was distilled under reduced pressure, and dissolved in chloroform/2-propanol = 3/1 (v/v). The organic layer was washed with an aqueous solution of sodium bicarbonate and brine. The obtained organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrated compound was purified using silica gel chromatography (dichloromethane:methanol = 9:1 (v/v)) to obtain the title compound (130.9 mg, 59%). "H-NMR Spectrum (300 MHz, CDCl): 6 8.06 (d, 1H), 7.84 (dd, 1H), 7.54 (d, 1H), 7.35 (m, 3H), 7.11 (brs, 1H), 7.06 (d, 1H), 4.14 (brs, 2H), 3.57 (s, 2H),
2.35 (s, 3H), 2.34 (s, 6H)
MS(EST', m/z): 341 [M+H]* <Step > Preparation of 4-amino-N-(1-((4-chloro-3- ((dimethylamino)methyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide 4-aminothieno[3,2-d]pyrimidine-7-carboxylic acid (90 mg, 0.461 mmol) obtained in <Step 7> of Preparation Example 1 was dissolved in dimethylformamide, and added with HATU (350.6 mg, 0.922 mmol) and DIPEA (0.3 mL, 1.536 mmol), followed by stirring for 30 minutes. The mixed reaction solution was added with
N1-(4-chloro-3-((dimethylamino)methyl)phenyl)-6-methylisoquinolin-1,5-diamine (130.9 mg, 0.384 mmol) obtained <Step 4> above, followed by stirring for 12 hours or more. The reaction mixture was diluted with ethyl acetate, and washed with a saturated aqueous solution of sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrated solid was added with ethyl acetate, and stirred for 1 hour or more. The resulting solid was filtered under reduced pressure, and washed with ethyl acetate and diethyl ether. The filtered solid was dried under vacuum conditions for 3 hours or more to obtain the title compound (35.7 mg, 18%). "H-NMR Spectrum (300 MHz, DMSO-d): § 11.56 (s, 1H), 9.33 (s, 1H), 8.94 (s, 1H), 8.58 (s, 1H), 8.49 (d, 1H), 8.00 (m, 4H), 7.90 (s, 1H), 7.62 (d, 1H), 7.36 (d, 1H), 7.18 (d, 1H), 3.48 (s, 2H), 2.42 (s, 3H), 2.24 (s, 6H)
MS(ESI, m/z): 519 [M+H]*
Example 60: Preparation of 4-amino-N-(1-((4-chloro-3-(pyrrolidin-1- ; ylmethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide :
The procedures of <Steps 1 and 2> of Example 59 were repeated, except for using pyrrolidine instead of dimethylamine in <Step 1> of Example 59 to obtain the title compound (973.7 mg, 96%). "H-NMR Spectrum (300 MHz, CDCl3): § 7.11 (d, 1H), 6.84 (d, 1H), 6.52 (dd, 1H), 3.67 (s, 2H), 3.64 (brs, 2H), 2.62 (m, 4H), 1.83 (m, 4H)
MS(EST’, m/z): 211 [M+H]" <Step 2> Preparation of _4-amino-N-(1-(4-chloro-3-(pyrrolidin-1- ylmethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3.2-d]pyrimidine-7- carboxamide
The procedures of <Steps 3, 4 and 5> of Example 59 were repeated in sequence, except for using 4-chloro-3-(pyrrolidin-1-ylmethyl)aniline obtained in <Step 1> above instead of 4-chloro-3-((dimethylamino)methyl)aniline in <Step 3> of
Example 59 to obtain the title compound (147.4 mg, 29%). "H-NMR Spectrum (300 MHz, DMSO-dy): 8 11.56 (s, 1H), 9.33 (s, 1H), 8.94 (s, 1H), 8.58 (s, 1H), 8.49 (d, 1H), 7.99 (m, 5H), 7.62 (d, 1H), 7.35 (d, 1H), 7.17 (d, 1H), 3.55 (s, 2H), 2.50 (m, 4H), 2.42 (s, 3H), 1.74 (m, 4H)
MS(EST, m/z): 545 [M+H]"
Example 61: Preparation of 4-amino-N-(1-((4-chloro-3- ((diethylamino)methyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide <Step 1> Preparation of 4-chloro-3-((diethylamino)methyl)aniline
The procedures of <Steps 1 and 2> of Example 59 were repeated in sequence, except for using diethylamine instead of dimethylamine in <Step 1> of Example 59 to obtain the title compound (839 mg, 99%). 'H-NMR Spectrum (300 MHz, CDCl): § 7.09 (d, 1H), 6.91 (d, 1H), 6.51 : (dd, 1H), 3.63 (brs, 2H), 3.57 (s, 2H), 2.60 (q, 4H), 1.08 (t, 6H) ”
MS(ESI', m/z): 213 [M+H]" <Step __2> Preparation = of _ 4-amino-N-(1-((4-chloro-3- ((diethylamino)methyl)phenyl}amino)-6-methylisoquinolin-5-yl)thieno[3.2- dlpyrimidine-7-carboxamide
The procedures of <Steps 3, 4 and 5> of Example 59 were repeated in sequence, except for using 4-chloro-3-((diethylamino)methyl)aniline obtained in <Step 1> above instead of 4-chloro-3-((dimethylamino)methyl)aniline in <Step 3> of
Example 59 to obtain the title compound (18.3 mg, 5%). "H-NMR Spectrum (300 MHz, DMSO-d): 6 11.56 (s, 1H), 9.34 (s, 1H), 8.94 (s, 1H), 8.58 (s, 1H), 8.50 (d, 1H), 7.98 (m, 5H), 7.62 (d, 1H), 7.34 (d, 1H), 7.18 (d, 1H), 3.60 (s, 2H), 2.58 (q, 4H), 2.42 (s, 3H), 1.05 (t, 6H)
MS(ESIY, m/z): 547 [M+H]"
Example 62: Preparation of 4-amino-N-(1-((1,4-diethyl-1,2,3,4- tetrahydroquinoxalin-6-yl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 1,4-diethyl-1,2,3,4-tetrahydroquinoxalin-6-amine instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (6 mg, 1%). "H-NMR Spectrum (300 MHz, DMSO-d): 8 11.60 (s,1H), 8.97 (s,1H), 8.61 (m,2H), 8.41 (d,1H), 7.98 (s,2H), 7.61 (d,1H), 7.26 (s,1H), 7.10 (d, 1H), 6.89 (s,1H), 3.41 (m,8H), 2.41 (s,3H), 1.16 (s, 6H)
MS(EST', m/z): 539 [M+H]*
Example 63: Preparation of 4-amino-N-(1-((4-chloro-3-(piperidin-1- ylmethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide
<Step 1> Preparation of 4-chloro-3-(piperidin-1-ylmethyDaniline
The procedures of <Steps 1 and 2> of Example 59 were repeated in sequence, except for using piperidine instead of dimethylamine in <Step 1> of Example 59 to obtain the title compound (630 mg, 89%). "H-NMR Spectrum (300 MHz, DMSO-dg): 6 6.99 (d, 1H), 6.70 (s, 1H), 6.45 (d, 1H), 5.17 (s, 2H), 3.31 (s, 2H), 2.34 (m, 4H), 1.49 (m, 4H), 1.23 (m, 2H)
MS(ESI", m/z): 225 [M+H]" <Step 2> Preparation of 4-amino-N-(1-((4-chloro-3-(piperidin-1- ylmethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3.2-d]pyrimidine-7- carboxamide
The procedures of <Steps 3, 4 and 5> of Example 59 were repeated in sequence, except for using 4-chloro-3-(piperidin-1-ylmethyl)aniline obtained in <Step 1> above instead of 4-chloro-3-((dimethylamino)methyl)aniline in <Step 3> of
Example 59 to obtain the title compound (1 mg, 1%). "H-NMR Spectrum (300 MHz, DMSO-d): § 11.54 (s, 1H), 8.92 (s, 1H), 8.56 (s, 1H), 7.97 (m, SH), 7.60 (d, 1H), 7.35 (m, 3H), 7.17 (d, 1H), 3.77 (s, 2H), 2.40 (s, 3H), 1.54 (m, 6H), 1.42 (m, 4H)
MS(ESI", m/z): 558 [M+H]*
Example 64: Preparation of 4-amino-N-(1-((4-chloro-3- (morpholinomethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2, 3, 4 and 5> of Example 59 were repeated in sequence, except for using morpholine instead of dimethylamine in <Step 1> of
Example 59 to obtain the title compound (2 mg, 2.3%) "H-NMR Spectrum (300 MHz, DMSO-dy): § 11.56 (s, 1H), 9.35 (s, 1H),
8.94 (s, 1H), 8.58 (s, 1H), 8.49 (d, 1H), 7.99 (m, 5H), 7.62 (d, 1H), 7.37 (d, 1H), 7.18 (d, 1H), 3.63 (m, 4H), 3.55 (s, 2H), 2.48 (s, 3H), 2.42 (m, 4H) : MS(EST', m/z): 560 [M+H]*
Example 65: Preparation of 4-amino-N-(1-((4-chloro-3-((4-methylpiperazin-1- y)methyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide
The procedures of <Steps 1, 2, 3, 4 and 5> of Example 59 were repeated in sequence, except for using 1-methylpiperazine instead of dimethylamine in <Step 1> of Example 59 to obtain the title compound (14 mg, 6.5%) 'H-NMR Spectrum (300 MHz, DMSO-d): 8 11.56 (s, 1H), 9.34 (s, 1H), 8.94 (s, 1H), 8.58 (s, 1H), 8.49 (d, 1H), 7.98 (m, SH), 7.62 (d, 1H), 7.35 (d, 1H), 7.18 (d, 1H), 3.54 (s, 2H), 2.42 (s, 3H), 2.31 (m, 4H), 2.27 (m,4H), 2.16 (s,3H)
MS(EST’, m/z): 573 [M+H]"
Example 66: Preparation of 4-amino-N-(1-((4-chloro-3- ((diisopropylamino)methyl)phenyl)amino)-6-methylisoquinolin-5- yDthieno|3,2-d]pyrimidine-7-carboxamide <Step 1> Preparation of 4-chloro-3-((diisopropylamino)methyl)aniline
The procedures of <Steps 1 and 2> of Example 59 were repeated in sequence, except for using diisopropylamine instead of dimethylamine in <Step 1> of Example 59 to obtain the title compound (196.6 mg, 41%). "H-NMR Spectrum (300 MHz, CDCl): § 7.07 (m, 2H), 6.48 (dd, 1H), 3.62 (s, 4H), 3.08 (quin, 2H), 1.03 (d, 12H)
MS(EST', m/z): 241 [M+H]*
((diisopropylamino)methyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3.2- d]pyrimidine-7-carboxamide
The procedures of <Steps 3, 4 and 5> of Example 59 were repeated in sequence, except for using 4-chloro-3-((diisopropylamino)methyl)aniline obtained in <Step 1> above instead of 4-chloro-3-((dimethylamino)methyl)aniline in <Step 3> of
Example 59 to obtain the title compound (8.4 mg, 5%). "H-NMR Spectrum (300 MHz, DMSO-di): 6 9.30 (s, 1H), 8.94 (s, 1H), 8.58 (s, 1H), 8.48 (d, 1H), 8.20 (d, 1H), 7.96 (m, 3H), 7.74 (dd, 1H), 7.62 (d, 1H), 7.29 (d, 1H), 7.18 (d, 1H), 3.67 (s, 2H), 3.07 (quin, 2H), 2.42 (s, 3H), 1.23 (s, 3H), 1.04 (d, 12H)
MS(ESI', m/z): 575 [M+H]"
Example 67: Preparation of 4-amino-N-(6-methyl-1-((3- (methylsulfonamido)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine- 7-carboxamide <Step _ 1> Preparation of N-(3-((6-methyl-5-nitroisoquinolin-1- ylhamino)phenyl)methanesulfonamide
N-(3-aminophenyl)methanesulfonamide (382 mg, 2.05 mmol) and 1-chloro- 6-methyl-5-nitroisoquinoline (500 mg, 2.25 mmol) obtained in <Step 4> of
Preparation Example 2 were dissolved in isopropanol (10 mL), and the reaction solution was sealed, followed by stirring for 1.5 hours at 120°C. The reaction mixture was cooled to room temperature, and the resulting solid was filtered under ; reduced pressure, followed by washing with isopropanol and diethyl ether. The : filtered solid was dried under vacuum conditions to obtain the title compound (752.8 mg, 99%). "H-NMR Spectrum (300 MHz, DMSO-dp): & 9.80 (brs, 1H), 8.75 (d, 1H), 8.05 (d, 1H), 7.75 (m, 2H), 7.58 (d, 1H), 7.35 (t, 1H), 6.94 (d, 1H), 6.89 (d, 1H), 3.04 (s, 3H), 2.50 (s, 3H)
MS(ESI', m/z): 373 [M+H]" <Step _2> Preparation of N-(3-((6-methyl-5-nitroisoquinolin-1- yhamino)phenyl)methanesulfonamide
Iron (627.4 mg, 10.11 mmol) and concentrated hydrochloric acid (0.07 mL) were added to ethanol/water (15 mL/15 mL), and refluxed for 1 hour. The mixed reaction solution was added with N-(3-((6-methyl-5-nitroisoquinolin-1- yD)amino)phenyl)methanesulfonamide (752.8 mg, 2.02 mmol) obtained in <Step 1> above, and refluxed for 3 hours. The reaction mixture was filtered through a Celite pad under reduced pressure, and washed with ethanol and chloroform/2-propanol = 3/1 (v/v). The resulting filtrate was distilled under reduced pressure, and dissolved in chloroform/2-propanol = 3/1 (v/v). The organic layer was washed with an aqueous solution of sodium bicarbonate and brine. The obtained organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrated compound was purified using silica gel chromatography (ethyl acetate:hexane = 1:1 (v/v)) to obtain the title compound (543 mg, 79%). "H-NMR Spectrum (300 MHz, DMSO-d): 8 9.65 (brs, 1H), 8.92 (brs, 1H), 7.86 (d, 1H), 7.78 (s, 1H), 7.64 (t, 2H), 7.42 (d, 1H), 7.25 (m, 2H), 6.79 (d, 1H), 5.47 (brs, 2H), 3.02 (s, 3H), 1.99 (s, 3H)
MS(ESTY, m/z): 343 [M+H]* <Step 3> Preparation of 4-amino-N-(6-methyl-1-((3- carboxamide 4-aminothieno{3,2-d]pyrimidine-7-carboxylic acid (206 mg, 1.051 mmol) obtained in <Step 7> of Preparation Example 1 was dissolved in dimethylformamide, and added with HATU (799 mg, 2.102 mmol) and DIPEA (0.6 mL, 3.504 mmol), followed by stirring for 30 minutes. The mixed reaction solution was added with )
N-(3-((6-methyl-5-nitroisoquinolin-1-yl)amino)phenyl)methanesulfonamide ~~ (300 mg, 0.876 mmol) obtained in <Step 2> above, followed by stirring for 12 hours or more. The reaction mixture was diluted with ethyl acetate, and washed with a saturated aqueous solution of sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrated solid was added with ethyl acetate, followed by stirring for 1 hour or more. The resulting solid was filtered under reduced pressure, and washed with ethyl acetate and diethyl ether. The filtered solid was dried under vacuum conditions for 3 hours or more to obtain the title compound (103 mg, 23%). "H-NMR Spectrum (300 MHz, DMSO-ds): & 11.56 (brs, 1H), 9.70 (brs, 1H), 9.29 (brs, 1H), 8.94 (s, 1H), 8.58 (s, 1H), 8.48 (d, 1H), 7.99 (m, 3H), 7.80 (s, 1H), 7.64 (t, 2H), 7.28 (t, 1H), 7.18 (d, 1H), 6.84 (d, 1H), 3.03 (s, 3H), 2.42 (s, 3H)
MS(EST", m/z): 520 [M+H]"
Example 68: Preparation of tert-butyl 4-(5-((5-(4-aminothieno[3,2- d]pyrimidine-7-carboxamido)-6-methylisoquinolin-1-yl)amino)-2- chlorobenzyl)piperazine-1-carboxylate <Step 1> Preparation of tert-butyl 4-(2-chloro-5-nitrobenzyl)piperazine-1- carboxylate 2-chloro-5-nitrobenzaldehyde (1.03 g, 5.39 mmol) was dissolved in dichloromethane (20 mL), and added with tert-butyl-piperazine-1-carboxylate (1 g, 5.39 mmol). The reaction solution was cooled to 0°C, and slowly added with
NaBH(OAc); (1.6 g, 7.55 mmol), followed by stirring for 3 hours at room temperature. The reaction mixture was added with water, and subjected to extraction with dichloromethane. The separated organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The : concentrated compound was purified using silica gel chromatography (ethyl acetate:hexane = 1:7 (v/v)) to obtain the title compound (1.9 g, 99%). "H-NMR Spectrum (300 MHz, CDCl): § 8.42 (d, 1H), 8.10 (dd, 1H), 7.54 (d, 1H), 3.67 (s, 2H), 3.50 (t, 4H), 2.51 (t, 4H), 1.47 (s, SH)
MS(ESI', m/z): 356 [M+H]" <Step 2> Preparation of tert-butyl 4-(5-amino-2-chlorobenzyl)piperazine-1- carboxylate
Iron (1.7 g, 26.7 mmol) and concentrated hydrochloric acid (0.2 mL) were added to ethanol/water (45 mL/45 mL), and refluxed for 1 hour. The mixed reaction solution was added with tert-butyl 4-(2-chloro-5-nitrobenzyl)piperazine-1- carboxylate (1.9 g, 5.34 mmol) obtained in <Step 1> above, and further refluxed for 1 hour. The reaction mixture was filtered through a Celite pad under reduced pressure, and washed with ethanol and chloroform/2-propanol = 3/1 (v/v). The resulting filtrate was distilled under reduced pressure and dissolved in ethanol and chloroform/2-propanol = 3/1 (v/v). The organic layer was washed with an aqueous solution of sodium bicarbonate and brine. The obtained organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
The concentrated compound was purified using silica gel chromatography (chloroform:methanol = 30:1 (v/v)) to obtain the title compound (1.5 g, 86%). "H-NMR Spectrum (300 MHz, CDCL): 8 7.12 (d, 1H), 6.82 (d, 1H), 6.54 (dd, 1H), 3.65 (brs, 2H), 3.53 (s, 2H), 3.46 (t, 4H), 2.47 (t, 4H), 1.46 (s, 9H)
MS(EST', m/z): 326 [M+H]* <Step __3> Preparation of tert-butyl 4-(2-chloro-5-((6-methyl-5- nitroisoquinolin-1-yl)amino)benzyl)piperazine- 1-carboxylate tert-butyl 4-(5-amino-2-chlorobenzyl)piperazine-1-carboxylate (500 mg, 1.53 mmol) obtained in <Step 2> above and 1-chloro-6-methyl-5-nitroisoquinoline (375 mg, 1.683 mmol) obtained in <Step 4> of Preparation Example 2 were dissolved in 1,4-dioxane (15 mL), and added with Xantphos (91.3 mg, 0.153 mmol), Pd,(dba)s
(94 mg, 0.077 mmol) and Cs,CO; (997 mg, 3.06 mmol). The reaction solution was sealed, and stirred for 3 hours at 130°C. The reaction mixture was cooled to room temperature, and subjected to extraction with water and ethyl acetate. The separated organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrated compound was purified using silica gel chromatography (ethyl acetate:hexane = 1:2 (v/v)) to obtain the title compound (424 mg, 54%). "H-NMR Spectrum (300 MHz, CDCl): § 8.18 (d, 1H), 8.00 (d, 1H), 7.67 (m, 2H), 7.47 (d, 1H) 7.37 (d, 1H), 7.13 (brs, 1H), 7.01 (d, 1H), 3.65 (s, 2H), 3.46 (t,4H) 2.55 (m, 7H), 1.46 (s, 9H)
MS(ESI', m/z): 513 [M+H]" <Step 4> Preparation of tert-butyl 4-(5-((5-amino-6-methylisoquinolin-1- ylamino)-2-chlorobenzyl)piperazine- 1-carboxylate
Iron (257 mg, 4.145 mmol) and concentrated hydrochloric acid (0.03 mL) were added to ethanol/water (10 mL/10 mL), and refluxed for 1 hour. The mixed reaction solution was added with tert-butyl 4-(2-chloro-5-((6-methyl-5- nitroisoquinolin-1-yl)amino)benzyl) piperazine-1-carboxylate (424.5 mg, 0.829 mmol) obtained in <Step 3> above, and refluxed for 3 hours. The reaction mixture was filtered a Celite pad under reduced pressure, and washed with ethanol and chloroform/2-propanol = 3/1 (v/v). The filtrate obtained was distilled under reduced pressure, and dissolved in chloroform/2-propanol = 3/1 (v/v). The organic layer was washed with an aqueous solution of sodium bicarbonate and brine. The obtained organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrated compound was purified using silica gel chromatography (ethyl acetate:hexane = 1:3—1:2 (v/v)) to obtain the title compound (286 mg, 72%). "H-NMR Spectrum (300 MHz, CDCls): 8 8.06 (d, 1H), 7.68 (m, 2H), 7.34 (m, 3H), 7.07 (d, 2H), 4.15 (brs, 2H), 3.64 (s, 2H), 3.46 (t, 4H), 2.36 (s, 3H), 1.46
(s, 9H)
MS(ESI', m/z): 483 [M+H]" <Step 5> Preparation of tert-butyl 4-(5-((5-(4-aminothieno[3.2-d]pyrimidine- carboxylate 4-aminothieno[3,2-d]pyrimidin-7-carboxylic acid (140 mg, 0.713 mmol) obtained in <Step 7> of Preparation Example 1 was dissolved in dimethylformamide, and added with HATU (543 mg, 1.426 mmol) and DIPEA (0.4 mL, 2.376 mmol), followed by stirring for 30 minutes. The mixed reaction solution was added with tert-butyl 4-(5-((5-amino-6-methylisoquinolin- 1-yl)amino)-2- chlorobenzyl)piperazine-1-carboxylate (286.5 mg, 0.594 mmol) obtained in <Step 4> above, followed by stirring for 12 hours or more. The reaction mixture was diluted with ethyl acetate, and washed with a saturated aqueous solution of sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrated solid was added with ethyl acetate, and stirred for 1 hour or more. The resulting solid was filtered under reduced pressure, and washed with ethyl acetate and diethyl ether.
The filtered solid was dried under vacuum conditions for 3 hours or more to obtain the title compound (84.5 mg, 22%). "H-NMR Spectrum (300 MHz, DMSO-dg): 6 11.56 (brs, 1H), 9.34 (brs, 1H), 8.94 (s, 1H), 8.58 (s, 1H), 8.48 (d, 1H), 8.00 (m, SH), 7.63 (d, 1H), 7.37 (4, 1H), 7.19 (d, 1H), 3.58 (s, 2H), 3.33 (m, 4H), 2.50 (m, 4H), 2.42 (s, 3H), 1.39 (s, 9H)
MS(EST*, m/z): 660 [M+H]"
Example 69: Preparation of 4-amino-N-(1-((4-chloro-3-(piperazin-1- ylmethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide hydrochloride
Tert-butyl 4-(5-((5-(4-aminothieno[3,2-d]pyrimidine-7-carboxamido)-6- methylisoquinolin-1-yl)amino)-2-chlorobenzyl)piperazine-1-carboxylate (84.5 mg, 0.128 mmol) obtained in <Step 5> of Example 68 was dissolved in ethyl acetate (6 mL), and added with a hydrochloric acid solution (0.65 mL, 2.56 mmol, 4 N dioxane solution). The reaction solution was stirred for 12 hours or more at room temperature. The resulting solid was filtered under reduced pressure, washed with ethyl acetate and diethyl ether, and dried under reduced pressure to obtain the title compound (78.3 mg, 100%).
MS(EST', m/z): 560 [M+H]"
Example 70: Preparation of 4-amino-N-(1-((3-chloro-4- methoxyphenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d|pyrimidine-7- carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 3-chloro-4-methyoxyaniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (135 mg, 23%). : "H-NMR Spectrum (300 MHz, DMSO-ds): § 11.55 (s, 1H), 9.19 (s, 1H), : 8.93 (s, 1H), 8.57 (s, 1H), 8.44 (d, 1H), 8.07 (d, 1H), 7.97 (d, 3H), 7.78 (d, 1H), 7.61 (d, 1H), 7.15 (m, 2H), 3.83 (s, 3H), 2.41 (s, 3H)
MS(ESI', m/z): 491 [M+H]*
Example 71: Preparation of 4-amino-N-(1-((3- (dimethylcarbamoyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide ;
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 3-amino-N,N-dimethylbenzamide instead of 4- ]
chloroaniline in <Step 1> of Example 1 to obtain the title compound (20 mg, 5%). 'H-NMR Spectrum (300 MHz, DMSO-dg): 6 11.57 (br, 1H), 9.34 (br, 1H), 8.94 (s, 1H), 8.58 (s, 1H), 8.49-8.46 (d, 1H), 8.02-7.96 (m, SH), 7.63-7.61 (d, 1H), 7.40-7.35 (t, 1H), 7.18 (d, 1H), 7.00 (d, 1H), 2.99 (s, 6H), 2.42 (s, 3H)
MS(ESIY, m/z): 497 [M+H]"
Example 72: Preparation of 4-amino-N-(6-methyl-1-((3- (methylcarbamoyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 3-amino-N-methylbenzamide instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (36 mg, 11%). "H-NMR Spectrum (300 MHz, DMSO-dg): § 11.56 (br, 1H), 9.37 (br, 1H), 8.94 (s, 1H), 8.58 (s, 1H), 8.51 (d, 1H), 8.38 (d, 1H), 8.28 (s, 1H), 8.10 (d, 1H), 8.01 (m, 2H), 7.62 (d, 1H), 7.41 (m, 2H), 7.18 (d, 1H), 2.80 (d, 3H), 2.42 (s, 3H)
MS(ESI’, m/z): 483 [M+H]*
Example 73: Preparation of 4-amino-N-(1-((4-chloro-2-fluorophenyl)amino)- 6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-chloro-2-fluoroaniline instead of 4-chloroaniline in : <Step 1> of Example 1 to obtain the title compound (28.5 mg, 9.3%). : "H-NMR Spectrum (300 MHz, DMSO-dp): § 11.55 (s, 1H), 9.13 (s, 1H), 8.94 (s, 1H), 8.58 (s, 1H), 8.36 (d, 1H), 7.95 (s, 2H), 7.88 (d, 1H), 7.66 (m, 2H), 7.49 (dd, 1H), 7.31 (dd, 1H), 7.16 (d, 1H), 2.42 (s, 3H)
MS(EST, m/z): 479 [M+H]*
Example 74: Preparation of 4-amino-N-(1-((4-bromo-2-fluorophenyl)amino)- 6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-bromo-2-fluoroaniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (51.8 mg, 12.5%). "H-NMR Spectrum (300 MHz, DMSO-d): § 11.55 (s, 1H), 9.15 (s, 1H), 8.94 (s, 1H), 8.58 (s, 1H), 8.35 (d, 1H), 7.95 (s, 2H), 7.87 (d, 1H), 7.62 (m, 3H), : 7.41 (d, 1H), 7.14 (d, 1H), 2.42 (s, 3H)
MS(ESTY, m/z): 523 [M+H]"
Example 75: Preparation of 4-amino-N-(1-((4-methoxybenzyl)amino)-6- methylisoquinolin-S-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Step 1> of Example 15 and <Steps 2 and 3> of Example 1 were repeated in sequence, except for using 4-methoxybenzylamine instead of 4- (trifluoromethyl)pyridine-2-amine in <Step 1> of Example 15 to obtain the title compound (20 mg, 11%). "H-NMR Spectrum (300 MHz, DMSO-dj): 6 11.45 (s, 1H), 8.90 (s, 1H), 8.54 (s, 1H), 8.20 (d, 1H), 7.97 (m, 3H), 7.80 (d, 1H), 7.46 (d, 1H), 7.27 (d, 2H), ; 6.85 (m, 3H), 4.66 (d, 2H), 3.68 (s, 3H), 2.34 (s, 3H)
MS(ESI, m/z): 471 [M+H]"
Example 76: Preparation of 4-amino-N-(1-((4-chlorobenzyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Step 1> of Example 15 and <Steps 2 and 3> of Example 1 were repeated in sequence, except for using 4-chlorobenzylamine instead of 4- (trifluoromethyl)pyridine-2-amine in <Step 1> of Example 15 to obtain the title compound (20 mg, 11%). "H-NMR Spectrum (300 MHz, DMSO-ds): § 11.47 (s, 1H), 8.90 (s, 1H), : 8.54 (s, 1H), 8.21 (d, 1H), 8.08 (m, 1H), 7.93 (s, 2H), 7.78 (d, 1H), 7.48 (d, 1H), 7.33 (m, 4H), 6.87 (d, 1H), 4.71 (d, 2H), 2.35 (s, 3H)
MS(EST', m/z): 475 [M+H]"
Example 77: Preparation of 4-amino-N-(1-(2-(4-chlorophenyl)hydrazinyl)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using (4-chlorophenyl)hydrazine instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (53 mg, 25%). "H-NMR Spectrum (300 MHz, DMSO-dy): § 11.57 (br, 1H), 9.34 (br, 1H), 8.94 (s, 1H), 8.58 (s, 1H), 8.47 (d, 1H), 8.01 (m, SH), 7.64 (d, 1H), 7.38 (d, 2H), 7.19(d, 1H), 2.42 (s, 3H)
MS(ESI', m/z): 475 [M+H]"
Example 78: Preparation of 4-amino-N-(1-((3- ((dimethylamino)methyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide
The procedures of <Step 1> of Example 15 and <Steps 2 and 3> of Example 1 were repeated in sequence, except for using 3-((dimethylamino)methyl)aniline instead of 4-(trifluoromethyl)pyridine-2-amine in <Step 1> of Example 15 to obtain thetitle compound (34 mg, 12%). "H-NMR Spectrum (300 MHz, DMSO-d): 8 11.55 (s, 1H), 9.19 (s, 1H), ; 8.94 (s, 1H), 8.58 (s, 1H), 8.49 (d, 1H), 7.98 (m, 3H), 7.89 (d, 1H), 7.74 (s, 1H), 7.60 (d, 1H), 7.28 (t, 1H), 7.14 (d, 1H), 6.91 (d, 1H), 3.38 (s, 2H), 2.41 (s, 3H), 2.17 (s, 6H)
MS(EST', m/z): 484 [M+H]"
Example 79: Preparation of 4-amino-N-(6-methyl-1-((4-oxo-4H-chromen-6- yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide ;
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 6-amino-4H-chromen-4-one instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (10 mg, 2%). "H-NMR Spectrum (300 MHz, DMSO-ds): § 11.58 (brs, 1H), 9.56 (brs, 1H), 8.95 (s, 1H), 8.61 (m, 2H), 8.49 (d, 1H), 8.35 (dd, 1H), 8.30 (d, 1H), 8.05 (d, 1H), 7.96 (brs, 2H), 7.67 (m, 2H), 7.23 (d, 1H), 6.34 (d, 1H), 2.43 (s, 3H) ;
MS(EST", m/z): 494 [M+H]"
Example 80: Preparation of N-(1-((3-acetylphenyl)amino)-6- methylisoquinolin-5-yl)-4-aminothieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 3-aminoacetophenone instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (25 mg, 16%). "H-NMR Spectrum (300 MHz, DMSO-d): § 11.59 (s, 1H), 9.44 (s, 1H), 9.03 (s, 1H), 8.59 (s, 1H), 8.51 (d, 1H), 8.44 (s, 1H), 8.29 (d, 1H), 8.03 (d, 1H), 7.97 (s, 2H), 7.70 (m, 2H), 7.51 (d, 1H), 7.21 (d, 1H), 2.60 (s, 3H), 2.43 (s, 3H)
MS(ESI*, m/z): 469 [M+H]"
Example 81: Preparation of 4-amino-N-(1-((4-(2- methoxyethoxy)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-(2-methoxyethoxy)aniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (90 mg, 19.4%). "H-NMR Spectrum (300 MHz, DMSO-dy): § 11.55 (s, 1H), 8.93 (s, 1H), 8.56 (s, 1H), 8.49 (d, 1H), 7.96 (s, 2H), 7.70 (m, 2H), 7.61 (d, 2H), 7.13 (d, 1H), 7.04(d, 2H), 4.12 (m, 2H), 3.68 (m, 2H), 3.35 (s, 3H), 2.43 (s, 3H)
MS(ESI', m/z): 501 [M+H]"
Example 82: Preparation of 4-amino-N-(6-methyl-1((3- trifluoromethoxy)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in ; sequence, except for using 3-(trifluoromethoxy)aniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (71 mg, 15%). "H-NMR Spectrum (300 MHz, DMSO-d): § 11.57 (s, 1H), 9.55 (s, 1H), 8.96 (s, 1H), 8.59 (s, 1H), 8.49 (d, 1H), 8.09 (s, 1H), 8.03 (m, 2H), 7.93 (d, 1H), 7.66 (d, 1H), 7.45 (t, 1H), 7.23 (d, 1H), 6.97 (d, 1H), 2.43 (s, 3H)
MS(EST, m/z): 511 [M+H]*
Example 83: Preparation of N-(1-((4-acetylphenyl)amino)-6- methylisoquinolin-5-yl)-4-aminothieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-aminoacetophenone instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (46.7 mg, 14.5%). "H-NMR Spectrum (300 MHz, DMSO-dg): 6 11.58 (s, 1H), 9.61 (s, 1H), 8.94 (s, 1H), 8.57 (s, 1H), 8.48 (d, 1H), 8.08 (m, 3H), 7.96 (m, 4H), 7.64 (d, 1H), 7.27 (d, 1H), 2.52 (s, 3H), 2.42 (s, 3H) :
MS(ESI", m/z): 469 [M+H]"
Example 84: Preparation of 4-amino-N-(6-methyl-1-((4- (methylsulfonamido)phenyl)amino)isoquinolin-S-yl)thieno[3,2-d]pyrimidine- 7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using N-(4-aminophenyl)methanesulfonamide instead of 4- chloroaniline in <Step 1> of Example 1 to obtain the title compound (5 mg, 3%). "H-NMR Spectrum (300 MHz, DMSO-ds): § 11.56 (brs, 1H), 9.45 (brs, 1H), 9.23 (brs, 1H), 8.94 (s, 1H), 8.58 (s, 1H), 8.46 (d, 1H), 7.97 (brs, 2H), 7.97 (d, 1H), 7.84 (d, 2H), 7.61 (d, 1H), 7.20 (d, 1H), 2.94 (s, 3H), 2.41 (s, 3H)
MS(ESI', m/z): 519 [M+H]"
Example 85: Preparation of 4-amino-N-(6-methyl-1-((3- (methylsulfonyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 3-(methylsulfonyl)aniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (8 mg, 17%). "H-NMR Spectrum (300 MHz, DMSO-dq): & 11.59 (brs, 1H), 9.63 (brs, 1H), 8.95 (s, 1H), 8.59 (s, 1H), 8.52 (m, 2H), 8.36 (d, 1H), 8.06 (d, 1H), 7.97 (brs, 2H), 7.67 (m, 3H), 7.25 (d, 1H), 3.22 (s, 3H), 2.43 (s, 3H)
MS(ESI', m/z): 504 [M+H]"
Example 86: Preparation of 4-amino-N-(1-((4-chloro-3- (methoxymethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno|[3,2- d]pyrimidine-7-carboxamide 92 i
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-chloro-3-(methoxymethyl)aniline instead of 4- chloroaniline in <Step 1> of Example 1 to obtain the title compound.
MS(ESI', m/z): 505 [M+H]"
Example 87: Preparation of 4-amino-N-(1-((4-methoxy-3- (methylsulfonamido)phenyl)amino)-6-methylisoquinolin-5-yl)thieno|[3,2- d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using N-(5-amino-2-methoxyphenyl)methanesulfonamide instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (132 mg, 16%). 'H-NMR Spectrum (300 MHz, DMSO-d): 11.55 (brs, 1H), 9.18 (brs, 1H), 8.94 (s, 1H), 8.91 (brs, 1H), 8.58 (s, 1H), 8.46 (d, 2H), 7.98 (brs, 2H), 7.94 (d, 1H), 7.76 (s, 1H), 7.73 (d, 1H), 7.59 (d, 1H), 7.11 (d, 1H), 7.06 (d, 1H), 3.82 (s, 3H), 3.00 (s, 3H), 2.41 (s, 3H)
MS(ESI', m/z): 549 [M+H]"
Example 88: Preparation of 4-amino-N-(1-((4-chloro-3- (methylsulfonamido)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using N-(5-amino-2-chlorophenyl)methanesulfonamide instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (70 mg, 11%). "H-NMR Spectrum (300 MHz, DMSO-dg): § 11.58 (brs, 1H), 9.43 (brs, 2H), 8.95 (s, 1H), 8.58 (s, 1H), 8.48 (d, 2H), 8.02 (m, 3H), 7.92 (d, 1H), 7.64 (d,
1H), 7.45 (d, 1H), 7.21 (d, 1H), 3.08 (s, 3H), 2.42 (s, 3H)
MS(EST, m/z): 553 [M+H]*
Example 89: Preparation of 4-amino-N-(1-((6-chloropyridin-3-yl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Step 1> of Example 15 and <Steps 2 and 3> of Example 1 were repeated in sequence, except for using 5-amino-2-chloropyridine instead of aniline in <Step 1> of Example 15 to obtain the title compound (10 mg, 3.1%). "H-NMR Spectrum (300 MHz, DMSO-d): & 11.57 (s, 1H), 9.66 (s, 1H), 9.16 (s, 1H), 8.88 (d, 1H), 8.57 (s, 1H), 8.45 (m, 2H), 8.02 (d, 1H), 7.96 (s, 2H), 7.66 (d, 1H), 7.49 (d, 1H), 7.23 (d, 1H), 2.41 (s, 3H)
MS(ESI', m/z): 462 [M+H]"
Example 90: Preparation of 4-amino-N-(1-((2-chloropyridin-4-yl)amino)-6- methylisoquinolin-S-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Step 1> of Example 15 and <Steps 2 and 3> of Example 1 were repeated in sequence, except for using 4-amino-2-chloropyridine instead of aniline in <Step 1> of Example 15 to obtain the title compound (61.1 mg, 21%). ] "H-NMR Spectrum (300 MHz, DMSO-d): 6 11.62 (s, 1H), 9.86 (s, 1H), 8.95 (s, 1H), 8.59 (s, 1H), 8.45 (d, 1H), 8.21 (m, 3H), 7.97 (s, 2H), 7.88 (dd, 1H), 7.72 (d, 1H), 7.39 (d, 1H), 2.45 (s, 3H)
MS(EST', m/z): 462 [M+H]*
Example 91: Preparation of 4-amino-N-(6-methyl-1-((4- (methylsulfonamidomethyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using N-(4-aminobenzyl)methanesulfonamide instead of 4- chloroaniline in <Step 1> of Example 1 to obtain the title compound (123 mg, 34%). "H-NMR Spectrum (300 MHz, DMSO-ds): & 11.56 (brs, 1H), 8.94 (s, 1H), 8.58(s, 1H), 8.48 (d, 2H), 7.99 (m, 3H), 7.87 (d, 2H), 7.62 (d, 1H), 7.51 (br, 1H), 7.31 (d, 2H), 7.15 (d, 1H), 4.12 (m, 2H), 2.84 (s, 3H), 2.42 (s, 3H)
MS(ESI', m/z): 533 [M+H]"
Example 92: Preparation of 4-amino-N-(6-methyl-1-((3- (methylsulfonamidomethyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using N-(3-aminobenzyl)methanesulfonamide instead of 4- chloroaniline in <Step 1> of Example 1 to obtain the title compound (205 mg, 31%). "H-NMR Spectrum (300 MHz, DMSO-d): § 11.56 (brs, 1H), 9.27 (brs, 1H), 8.94 (s, 1H), 8.58 (s, 1H), 8.50 (d, 1H), 7.99 (m, 3H), 7.85 (m, 2H), 7.62 (m, 2H), 7.33 (t, 1H), 7.16 (d, 1H), 6.99 (d, 1H), 4.17 (d, 2H), 2.90 (s, 3H), 2.42 (s, 3H)
MS(ESI', m/z): 534 [M+H]"
Example 93: Preparation of 4-amino-N-(1-((4-chloro-3-fluorophenyl)amino)- 6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide :
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-chloro-3-fluoroaniline instead of 4-chloroaniline in : <Step 1> of Example 1 to obtain the title compound (200 mg, 29%). "H-NMR Spectrum (300 MHz, DMSO-d): 8 11.58 (s, 1H), 9.51 (s, 1H), : 8.94 (s, 1H), 8.58 (s, 1H), 8.46 (d, 1H), 8.22 (dd, 1H), 8.06(d, 1H), 7.96 (br, 2H),
7.74 (dd, 1H), 7.65 (d, 1H), 7.49 (t, 1H), 7.24 (4, 1H), 2.42 (s, 3H)
MS(ESI’, m/z): 479 [M+H]"
Example 94: Preparation of 4-amino-N-(1-((3-bromo-4-chlorophenyl)amino)- 6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 3-bromo-4-chloroaniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (269 mg,35%). "H-NMR Spectrum (300 MHz, DMSO-dy): & 11.59 (brs, 1H), 9.47 (brs, 1H), 8.95 (s, 1H), 8.58 (s, 1H), 8.49 (m, 2H), 8.07 (d, 1H), 8.01 (m, 3H), 7.66 (d, 1H), 7.57 (d, 1H), 7.24 (d, 1H), 2.43 (s, 3H)
MS(ESI", m/z): 538 [M+H]"
Example 95: Preparation of 4-amino-N-(1-((4- (dimethylcarbamoyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-amino-N,N-dimthylbenzamide instead of 4- chloroaniline in <Step 1> of Example 1 to obtain the title compound (6.7 mg, 2.1%). 'H-NMR Spectrum (300 MHz, DMSO-dg): § 11.58 (s, 1H), 9.40 (s, 1H), 8.95 (s, 1H), 8.59 (s, 1H), 8.48 (d, 1H), 8.02 (d, 1H), 7.97 (d, 4H), 7.63 (d, 1H), 7.40 (d, 2H), 7.21 (d, 1H), 2.992 (s, 6H), 2.43 (s, 3H)
MS(ESI', m/z): 498 [M+H]*
Example 96: Preparation of 4-amino-N-(1-((3-acetylaminophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in ; sequence, except for using N-(3-aminophenyl)-acetamide instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (42 mg, 41%). "H-NMR Spectrum (300 MHz, DMSO-dg): 8 11.59 (brs, 1H), 9.51 (brs, 1H), 8.94 (s, 1H), 5.60 (s, 1H), 8.44 (s, 1H), 8.11 (m, 4H), 7.67 (s, 1H), 7.27 (s, 1H), 7.14 (s, 1H), 2.44 (s, 3H)
MS(EST*, m/z): 484 [M+H]*
Example 97: Preparation of 4-amino-N-(6-methyl-1-((1-methyl-1H-indazol-6- yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide <Step 1> Preparation of 1-methyl-6-nitro-1H-indazole
NaH (1.47 g, 0.037 mol) was added to THF (25 mL) at 0°C. Separately, 6- nitro-1H-indazole (5.0 g, 0.031 mol) was dissolved in THF (25 mL) and the solution was slowly added to the solution prepared. Iodomethane (2.48 mL, 0.040 mol) was slowly added to the mixed solution at the same temperature, followed by stirring for 2 hours. The reaction solution was concentrated under reduced pressure, and added with water and ethyl acetate. The organic layer was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The concentrated compound (1-methyl added (Rt = 0.8):2-methyl added (Rf = 0.3) = 1:1) was purified using silica gel chromatography (ethyl acetate:hexane = 1:1 (v/v)) to obtain the title compound (R¢= 0.8,2.22 g, 41%). "H-NMR Spectrum (300 MHz, DMSO-dg): & 8.73 (m, 1H), 8.29 (d, 1H), 8.01 (dd, 1H), 7.94 (dd, 1H), 4.19 (s, 3H)
MS(ESI', m/z): 177 [M+H]* <Step 2> Preparation of 1-methyl-1H-indazol-ylamine 1-methyl-6-nitro-1H-indazole obtained in <Step 1> above and Pd/C were added to THF (50 mL), and stirred for 5 hours under hydrogen conditionss. The reaction solution was filtered through a Celite pad so as to remove Pd/C, followed by washing with methanol. The organic solvent was concentrated under reduced pressure and purified using silica gel chromatography (dichloromethane:methanol = 99:1 (v/v)) to obtain the title compound (1.72 g, 93%). <Step 3> Preparation of 4-amino-N-(6-methyl-1-((1-methyl-1H-indazol-6- yDamino)isoquinolin-5-yl)thieno[3.2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 was repeated in sequence, except for using 1-methyl-1H-indazol-6-ylamine obtained in <Step 2> above instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (89 mg, 22%). "H-NMR Spectrum (300 MHz, DMSO-ds): 8 11.56 (s, 1H), 9.38 (s, 1H), 8.94 (s, 1H), 8.57 (s, 1H), 8.52 (d, 1H), 8.35 (s, 1H), 8.04 (d, 1H), 7.95 (br, 2H), 7.91 (s, 1H), 7.64 (m, 2H), 7.53 (m, 1H), 7.19 (d, 1H), 3.98 (s, 3H), 2.42 (s, 3H)
MS(ESI’, m/z): 481 [M+H]"
Example 98: Preparation of 4-amino-N-(6-methyl-1-((4- (methylsulfinyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d] pyrimidine-7- carboxamide
The procedures of <Step 1> of Example 15 and <Steps 2 and 3> of Example 1 were repeated in sequence, except for using 4-methanesulfinylaniline instead of 4- (trifluoromethyl)pyridine-2-amine in <Step 1> of Example 15 to obtain the title compound (19.5 mg, 6.2%). "H-NMR Spectrum (300 MHz, DMSO-d): 6 11.58 (s, 1H), 9.51 (s, 1H), 8.95 (s, 1H), 8.58 (s, 1H), 8.50 (d, 1H), 8.12 (m, 2H), 8.05 (d, 1H), 7.97 (s, 2H), 7.65 (d, 3H), 7.24 (d, 1H), 2.73 (s, 3H), 2.43 (s, 3H) :
MS(ESI", m/z): 489 [M+H]*
Example 99: Preparation of 4-amino-N-(6-methyl-1-((2-methyl-1,3- ; dioxoisoindolin-5-yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-amino-N-methylphthalimide instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (3 mg, 1.2%). "H-NMR Spectrum (300 MHz, DMSO-d): 8 11.61 (s, 1H), 9.87 (s, 1H), 8.95 (s, 1H), 8.59 (s, 1H), 8.53 (m, 3H), 8.28 (d, 1H), 8.15 (d, 1H), 7.91 (s, 2H), 7.82 (d, 1H), 7.70 (d, 1H), 3.02 (s, 3H), 2.44 (s, 3H)
MS(ESI', m/z): 510 [M+H]"
Example 100: Preparation of 4-amino-N-(1-((6-methoxypyridin-3-yl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 5-amino-2-methoxypyridine instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (75 mg, 9.2%). "H-NMR Spectrum (300 MHz, DMSO-dy): § 11.55 (s, 1H), 9.22 (s, 1H), 8.94 (s, 1H), 8.58 (s, 1H), 8.54 (d, 1H), 8.43 (d, 1H), 8.14 (d, 1H), 7.96 (s, 2H), 7.92 (d, 1H), 7.61 (d, 1H), 7.12 (d, 1H), 6.84 (d, 1H), 3.84 (s, 3H), 2.41 (s, 3H)
MS(ESI', m/z): 458 [M+H]"
Example 101: Preparation of 4-amino-N-(6-methyl-1-((3-(2,2,2- trifluoroacetyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide
2,2.2-trifluoroacetophenone (0.5 mL, 3.68 mmol) was dissolved in sulfuric acid (3 mL), and added with NaNO; (0.31 g, 3.68 mmol). The reaction solution was stirred for about 1 hour at 0°C. The reaction mixture was calibrated to yield pH a range of 8 to 9 by adding an aqueous solution of 5 N NaOH. The reaction mixture was diluted with chloroform/2-propanol = 4/1 (v/v), and washed with distilled water. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrated compound was purified using silica gel chromatography to obtain the title compound (720 mg, 89%). "H-NMR Spectrum (300 MHz, DMSO-ds): 8 8.29 (s, 1H), 8.24 (d, 1H), 7.96 (d, 1H), 7.69 (t, 1H)
MS(EST, m/z): 220 [M-+H]" <Step 2> Preparation of 1-(3-aminophenyl)-2.2.2-trifluoroethanone 2,2,2-trifluoro-1-(3-nitrophenyl)ethanone (0.7 g, 3.26 mmol) obtained in <Step 1> above was dissolved in methanol, followed by stirring. The reaction solution was added with Pd/C (0.09 g, 0.82 mmol), and further stirred under hydrogen conditions for about 12 hours at room temperature. The reaction mixture was filtered through a Celite pad under reduced pressure, and washed with methanol.
The filtered solid was dried with warm wind in an oven (40°C) for 3 hour or more to obtain the title compound (400 mg, 68%). "H-NMR Spectrum (300 MHz, DMSO-ds): 8 7.02 (t, 1H), 6.97 (s, 1H), 6.56 (m, 2H), 5.15 (s, 2H)
MS(ESI’, m/z): 190 [M+H]" <Step 3> Preparation of _ 4-amino-N-(6-methyl-1-((3-(2,2.2- trifluoroacetyl)phenyl)amino)isoquinolin-5-yl)thieno[3.2-d]pyrimidine-7- carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 1-(3-aminophenyl)-2,2,2-trifluoroethanone obtained in
<Step 2> above instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (19.4 mg, 5%). "H-NMR Spectrum (300 MHz, DMSO-d): § 11.54 (s, 1H), 9.30 (s, 1H), 8.92 (s, 1H), 8.58 (s, 1H), 8.49 (d, 1H), 7.99 (m, 4H), 7.60 (d, 1H), 7.35 (t, 1H), 17.15(d, 1H), 7.09 (d, 1H), 6.83 (d, 1H), 2.40 (s, 3H)
MS(EST', m/z): 523 [M+H]"
Example 102: Preparation of 4-amino-N-(6-methyl-1-((4- propionylphenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-aminopropiophenone instead of 4-chloroaniline in : <Step 1> of Example 1 to obtain the title compound (72 mg, 23%). "H-NMR Spectrum (300 MHz, DMSO-ds): § 11.59 (s, 1H), 9.60 (s, 1H), 8.94 (s, 1H), 8.58 (s, 1H), 8.50 (d, 1H), 8.09 (m, 3H), 7.96 (m, 4H), 7.66 (d, 1H), 7.28 (d, 1H), 3.01 (q, 2H), 2.43 (s, 3H), 1.11 (t, 3H)
MS(ESI', m/z): 483 [M+H]*
Example 103: Preparation of 4-amino-N-(1-((4-hexanoylphenyl)amino)-6- methylisoquinolin-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-aminohexanophenone instead of 4-chloroaniline in ; <Step 1> of Example 1 to obtain the title compound (10 mg, 6.6%). "H-NMR Spectrum (300 MHz, DMSO-ds): & 11.59 (s, 1H), 9.62 (s, 1H), 8.95 (s, 1H), 8.58 (s, 1H), 8.50 (d, 1H), 8.09 (m, 4H), 7.98 (m, 3H), 7.66 (d, 1H), 7.28 (d, 1H), 2.95 (t, 2H), 2.43 (s, 3H), 1.33 (m, 2H), 1.09 (m, 4H), 0.89 (t, 3H)
MS(EST', m/z): 525 [M+H]"
Example 104: Preparation of N-(1-((1-acetyl-1H-indazol-6-yl)amino)-6- methylisoquinolin-5-yl)-4-aminothieno|3,2-d]pyrimidine-7-carboxamide <Step 1> Preparation of 1-(6-nitro-1H-indazol- 1-yl)ethanone 6-nitroindazole (1 g, 6.13 mmol) was dissolved in dimethylformamide (15 mL), and added with triethylamine (1.7 mL, 12.2 mmol), Ac;0O (0.69 mL, 7.4 mmol) and 18-Crown-6 (0.38 g, 1.23 mmol). The reaction solution was stirred for about 4 hours at room temperature. The reaction mixture was added with distilled water, and further stirred for about 1 hour. The resulting solid was filtered under reduced pressure, and washed with distilled water. The filtered solid was dried with warm wind in an oven (40°C) for 3 hours or more to obtain the title compound (0.9 g, 75%). 'H-NMR Spectrum (300 MHz, DMSO-dq): § 9.01 (s, 1H), 8.69 (s, 1H), 8.26 (d, 1H), 8.18 (d, 1H), 2.76 (s, 3H)
MS(ESI’, m/z): 206 [M+H]" <Step 2> Preparation of 1-(6-amino-1H-indazol-1-yl)ethanone 1-(6-nitro-1H-indazol-1-yl)ethanone obtained in <Step 1> above was dissolved in ethanone (2.2 g, 10.7 mmol), and stirred. The reaction solution was added with Pd/C (0.28 g, 2.68 mmol), followed by stirring under hydrogen conditions for about 12 hours or more at room temperature. The reaction mixture was filtered through a Celite pad under reduced pressure, and washed with methanol.
The filtered solid was dried with warm wind in an oven (40°C) for 3 hours or more to obtain the title compound (1.7 g, 90%).
MS(ESI", m/z): 176 [M+H]"
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 1-(6-amino-1H-indazol-1-yl)ethanone obtained in <Step 2> above instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (21 mg, 13.7%). "H-NMR Spectrum (300 MHz, DMSO-ds): § 11.59 (s, 1H), 9.64 (s, 1H), 8.98 (d, 2H), 8.59 (s, 1H), 8.54 (d, 1H), 8.34 (s, 1H), 8.06 (m, 4H), 7.80 (d, 1H), 7.65 (d, 1H), 7.25 (d, 1H), 2.71 (s, 3H), 2.43 (s, 3H)
MS(ESI', m/z): 509 [M+H]"
Example 105: Preparation of 4-amino-N-(1-((3-chloro-4-fluorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 3-chloro-4-fluoroaniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (332 mg, 35%). "H-NMR Spectrum (300 MHz, DMSO-ds): § 11.56 (s, 1H), 9.37 (s, 1H), 8.85 (s, 1H), 8.58 (s, 1H), 8.45 (d, 1H), 8.27 (dd, 1H), 8.02 (d, 1H), 7.95 (s, 2H), 7.88 (m, 1H), 7.40 (t, 1H), 7.20 (d, 1H), 2.42 (s, 3H)
MS(EST', m/z): 479 [M+H]"
Example 106: Preparation of 4-amino-N-(6-methyl-1-((5-0x0-5,6,7,8- tetrahydronaphthalen-2-yl)amino)isoquinolin-5-yl)thieno{3,2-d]pyrimidine-7- carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 6-amino-3,4-dihydro-2H-naphthalen-1-one instead of 4- chloroaniline in <Step 1> of Example 1 to obtain the title compound (46 mg, 6%). "H-NMR Spectrum (300 MHz, DMSO-dp): 8 11.58 (s, 1H), 9.55 (s, 1H), : 8.93 (s, 1H), 8.70 (s, 1H), 8.47 (d, 1H), 8.08 (d, 1H), 7.94 (m, 3H), 7.84 (m, 2H), 7.64 (d, 1H), 7.26 (d, 1H), 2.90 (t, 3H), 2.49 (t, 3H), 2.42 (s, 3H), 2.02 (m, 3H)
MS(ESI’, m/z): 495 [M+H]"
Example 107: Preparation of 4-amino-N-(6-methyl-1-((2-methyl-2H-indazol-6- yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 2 and 3> of Example 97 were repeated in sequence, except for using 6-nitro-2H-indazole to obtain methyl-6-nitro-2H-indazole (R= 0.3) instead of 6-nitro-1H-indazole in <Step 1> of Example 97 to obtain the title compound (8 mg, 2.5%). "H-NMR Spectrum (300 MHz, DMSO-ds): § 11.55 (s, 1H), 8.93 (s, 1H), 8.57 (s, 1H), 8.50 (d, 1H), 8.27 (s, 1H), 8.20 (s, 1H), 7.98 (m, 1H), 7.95 (s, 1H), 7.60 (m, 2H), 7.41 (d, 1H), 7.14 (d, 1H), 4.10 (s, 3H), 2.41 (s, 3H)
MS(ESI', m/z): 481 [M+H]"
Example 108: Preparation of methyl 4-((5-(4-aminothieno[3,2-d]pyrimidine-7- carboxamido)-6-methylisoquinolin-1-yl)amino)benzoate
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using methyl-4-aminobenzoate instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (95 mg,136%). "H-NMR Spectrum (300 MHz, DMSO-dj): § 11.59 (s, 1H), 9.61 (s, 1H), 9.02 (s, 1H), 8.58 (s, 1H), 8.50 (d, 1H), 8.08 (m, 3H), 7.97 (m, 4H), 7.66 (d, 1H), 7.28 (d, 1H), 3.82 (s, 3H), 2.42 (s, 3H)
MS(EST*, m/z): 485 [M-+H]"
Example 109: Preparation of 4-amino-N-(6-methyl-1-((1-methyl-1H- indazol-S-yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide <Step 1> Preparation of 1-methyl-5-nitro-1H-indazole :
NaH (1.47 g, 36.8 mmol) was added to THF (40 mL) at 0°C. Separately, 5- nitroindazole (5.0 g, 30.6 mmol) was dissolved in THF (30 mL), and the mixed solution was slowly added to the prepared solution. Iodomethane (2.1 mL, 33.7 mmol) was added to the reaction solution at the same temperature, followed by stirring for 3 hours at room temperature. The reaction solution was concentrated under reduced pressure, and added with water and ethyl acetate. The reaction mixture was added with distilled water for quenching, diluted with ethyl acetate, and ; washed with distilled water. The organic layer was dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The concentrated compound (1- methyl added (Rf = 0.3), 2-methyl added (Rf = 0.1)) was purified using silica gel chromatography (ethyl acetate:hexane = 1:1 (v/v)) to obtain the title compound (R¢= 0.3,2.29 g, 42%). "H-NMR Spectrum (300 MHz, DMSO-dy): § 8.74 (d, 1H), 8.31 (dd, 1H), 8.20 (s, 1H), 7.47 (d, 1H), 4.15 (s, 3H)
MS(ESI?, m/z): 178 [M+H]" <Step 2> Preparation of 1-methyl-1H-indazol-5-amine
Iron (3.62 g, 64.7 mmol) and concentrated hydrochloric acid (0.1 mL) were added to ethanol/water (20 mL/20 mL), and refluxed for 1 hour. The mixed reaction solution was added with 1-methyl-5-nitro-1H-indazole (2.29 g, 12.9 mmol) obtained in <Step 1> above, and further refluxed for 3 hours or more. The reaction mixture was filtered through a Celite pad under reduced pressure, and washed with chloroform/2-propanol = 4/1(v/v). The filtrate obtained was distilled under reduced pressure, and dissolved in chloroform/2-propanol = 4/1 (v/v). The organic layer was washed with an aqueous solution of sodium bicarbonate and brine. The obtained organic layer was dried over anhydrous sodium sulfate, filtered, and ; concentrated under reduced pressure to obtain the title compound (1.35 g, 71%). "H-NMR Spectrum (300 MHz, DMSO-dg): 8 7.65 (d, 1H), 7.31 (d, 1H), 6.80 (d, 1H), 6.71 (d, 1H), 4.78 (s, 2H), 3.89 (s, 3H)
MS(ESI', m/z): 148 [M+H]" <Step 3> Preparation of 4-amino-N-(6-methyl-1-((1-methyl-1H-indazol-5- yl)amino)isoquinolin-5-yl)thieno[3.2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 1-methyl-1H-indazol-5-amine obtained in <Step 2> above instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (15 mg, 6.3%). "H-NMR Spectrum (300 MHz, DMSO-ds): 8 11.54 (s, 1H), 9.23 (s, 1H), 8.84 (s, 1H), 8.57 (s, 1H), 8.49 (d, 1H), 8.31 (s, 1H), 7.98 (m, 4H), 7.74 (d, 1H), 7.60 (d, 1H), 7.10 (d, 1H), 4.00 (s, 3H), 2.40 (s, 3H)
MS(EST’, m/z): 481 [M+H]"
Example 110: Preparation of 4-amino-N-(6-methyl-1-((2-methyl-2H-indazol-5- yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide <Step 1> Preparation of 2-methyl-5-nitro-2H-indazole
The procedures of <Step 1> of Example 109 were repeated to obtain the title compound (R¢=0.1, 1.51 g, 28%). "H-NMR Spectrum (300 MHz, DMSO-dg): 6 8.73 (d, 1H), 8.20 (s, 1H), 8.09 (dd, 1H), 7.74 (d, 1H), 4.29 (s, 3H)
MS(EST', m/z): 178 [M+H]" <Step 2> Preparation of 2-methyl-2H-indazol-5-amine
The procedures of <Step 2> of Example 109 were repeated to obtain the title compound (0.6 g, 48%). "H-NMR Spectrum (300 MHz, DMSO-dg): 8 7.82 (s, 1H), 7.51 (d, 1H), 6.72 (dd, 1H), 6.53 (d, 1H), 4.74 (s, 2H), 4.01 (s, 3H)
MS(EST', m/z): 148 [M+H]*
<Step 3> Preparation of 4-amino-N-(6-methyl-1-((2-methyi-2H-indazol-5- ylamino)isoquinolin-5-yl)thieno[3.2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 2-methyl-2H-indazol-5-amine obtained in <Step 2> above instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (24.2 mg, 10%). "H-NMR Spectrum (300 MHz, DMSO-dy): § 11.54 (s, 1H), 9.47 (s, 1H), 8.93 (s, 1H), 8.49 (s, 1H), 8.46 (d, 1H), 8.31 (s, 1H), 7.98 (m, 3H), 7.74 (d, 1H), 7.60 (m, 2H), 7.10 (d, 1H), 4.02 (s, 3H), 2.40 (s, 3H)
MS(ESI’, m/z): 481 [M+H]"
Example 111: Preparation of 4-amino-N-(6-methyl-1-((6-methylpyridin-3- yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Step 1> of Example 15 and <Steps 2 and 3> of Example 1 were repeated in sequence, except for using 5-amino-2-methylpyridine instead of aniline in <Step 1> of Example 15 to obtain the title compound (5 mg, 3%). "H-NMR Spectrum (300 MHz, DMSO-dg): 6 11.61 (s, 1H), 9.34 (s, 1H), 8.98 (s, 1H), 8.90 (s, 1H), 8.62 (s, 1H), 8.51 (d, 1H), 8.27 (m, 1H), 8.02 (m, 3H), 7.68 (d, 1H), 7.27 (m, 2H), 2.54 (s, 3H), 2.48 (s, 3H) ;
MS(EST', m/z): 442 [M+H]*
Example 112: Preparation of 4-amino-N-(6-methyl-1-((1-methyl-1H-indol-6- yDamino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide <Step 1> Preparation of 1-methyl-1H-indol-6-ylamine
The procedures of <Step 1> of Example 97 were repeated, except for using 1H-indol-6-ylamine instead of 6-nitro-1H-indazole in <Step 1> of Example 97 to obtain the title compound (151 mg, 33%). <Step 2> Preparation of 4-amino-N-(6-methyl-1-((1-methyl-1H-indol-6- ylamino)isoquinolin-5-yhthieno(3.2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 1-methyl-1H-indol-6-ylamine obtained in <Step 1> above instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (65 mg, 31%). "H-NMR Spectrum (300 MHz, DMSO-d): § 11.53 (s, 1H), 9.21 (br, 1H), 8.93 (s, 1H), 8.57 (s, 1H), 8.49 (d, 1H), 8.02 (s, 1H), 7.95-7.92 (m, 3H), 7.58 (d, 1H), 7.44 (m, 2H), 7.23 (d, 1H), 7.07 (d, 1H), 6.35 (d, 1H), 3.75 (s, 3H), 2.40 (s, 3H)
MS(ESI’, m/z): 480 [M+H]"
Example 113: Preparation of tert-butyl 6-((5-(4-aminothieno3,2- d]pyrimidine-7-carboxamido)-6-methylisoquinolin-1-yl)amino)-1H-indazol-1- carboxylate <Step 1> Preparation of (1H-indazol-6-yl)-(6-methyl-5-nitro-isoquinolin-1- yl)-amine
The procedures of <Step 1> of Example 1 were repeated, except for using ; 1H-indazol-6-amine instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (639 mg, 68%). "H-NMR Spectrum (300 MHz, DMSO-dg): 6 9.01 (d, 1H), 8.12 (s, 1H), 8.01 (s, 1H), 7.88 (d, 2H), 7.79 (d, 1H), 7.33 (d, 1H), 6.93 (d, 1H), 2.52 (s, 3H)
MS(ESI', m/z): 319 [M+H]" <Step 2> Preparation of 6-(6-methyl-5-nitro-isoquinolin-1-ylamno)- indazol-1-carboxylic acid tert-butyl ester
(1H-indazol-6-yl)-(6-methyl-5-nitro-isoquinolin-1-yl)-amine (300 mg, 0.942 mmol) obtained in <Step 1> above, triethylamine (0.131 mL, 0.942 mmol) and DMAP (58 mg, 0.471 mmol) were dissolved in CH,Cl, (10 mL), and slowly added with di-tert-butyl dicarbonate (0.216 mL, 0.942 mmol) at 0°C. The reaction solution was stirred for 3 hour at room temperature, diluted with ethyl acetate, and washed with a saturated aqueous solution of sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound (395 mg, 99%).
MS(EST’, m/z): 419 [M+H]" <Step 3> Preparation of tert-butyl 6-((5-(4-aminothieno[3.2-d]pyrimidine- 1-carboxamido)-6-methylisoquinolin-1-yl)amino)-1H-indazol-1-carboxylate
The procedures of <Steps 2 and 3> of Example 1 were repeated in sequence, except for using 6-(6-methyl-5-nitro-isoquinolin-1-ylamino)-indazol-1- carboxylic acid tert-butyl ester obtained in <Step 2> above instead of N-(4- chlorophenyl)-6-methyl-5-nitroisoquinolin-1-amine in <Step 2> of Example 1 to obtain the title compound (130 mg, 30%).
MS(ESI, m/z): 566 [M+H]*
Example 114: Preparation of N-(1-((1H-indazol-6-yl)amino)-6- methylisoquinolin-5-yl)-4-aminothieno(3,2-d]pyrimidine-7-carboxamide hydrochloride tert-butyl 6-((5-(4-aminothieno[3,2-d]pyrimidine-7-carboxamido)-6- methylisoquinolin-1-yl)amino)-1H-indazol-1-carboxylate (50 mg, 0.088 mmol) obtained in Example 113 was dissolved in ethyl acetate (5 mL), and added with 4 M
HCI (dioxane solution, 0.5 mL). The reaction solution was stirred for 5 hours, and then the filtrate was filtered to obtain the title compound (40 mg, 90%).
MS(ESI", m/z): 467 [M+H]"
Example 115: Preparation of 4-amino-N-(1-((5-chloro-2-fluorophenyl)amino)- 6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using S5-chloro-2-fluoroaniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (380 mg, 6%). "H-NMR Spectrum (300 MHz, DMSO-dg): § 11.55 (s, 1H), 9.14 (s, 1H), 8.93 (s, 1H), 8.56 (s, 1H), 8.32 (m, 1H), 7.92 (m, 3H), 7.77 (dd, 1H), 7.61 (d, 1H), 7.30 (t, 1H), 7.20 (m, 2H), 2.41 (m, 3H)
MS(ESI’, m/z): 479 [M+H]"
Example 116: Preparation of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)- 6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 3-chloro-2-fluoroaniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (10 mg, 6.3%). "H-NMR Spectrum (300 MHz, DMSO-ds): § 11.56 (s, 1H), 9.24 (s, 1H), 8.93 (s, 1H), 8.57 (s, 1H), 8.36 (d, 1H), 7.95 (s, 2H), 7.90 (d, 1H), 7.63 (d, 1H), 7.57 (t, 1H), 7.37 (t, 1H), 7.24 (m, 2H), 2.42 (s, 3H)
MS(ESIY, m/z): 479 [M+H]*
Example 117: Preparation of 4-amino-N-(1-((3-fluoro-4-(4-methylpiperazin-1- yhphenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 3-fluoro-4-(4-methylpiperazin-1-yl)aniline instead of 4- :
chloroaniline in <Step 1> of Example 1 to obtain the title compound (20 mg, 16%). "H-NMR Spectrum (300 MHz, DMSO-dp): 8 11.53 (s, 1H), 9.19 (s, 1H), 8.92 (s, 1H), 8.57 (s, 1H), 8.43 (d, 1H), 7.98-7.85 (m, 4H), 7.59 (d, 1H), 7.54 (dd, 1H), 7.12 (d, 1H), 7.00 (t, 1H), 3.31 (m, 4H), 2.96 (m, 4H), 2.40 (s, 3H), 2.21 (s, 3H)
MS(EST, m/z): 543 [M+H]"
Example 118: Preparation of 4-amino-N-(1-((3-chloroe-1-methyl-1H-indazol- 6-yl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 3-chloro-1-methyl-1H-indazol-6-amine instead of 4- chloroaniline in <Step 1> of Example 1 to obtain the title compound (143 mg, 16%). 'H-NMR Spectrum (300 MHz, DMSO-dg): § 11.57 (s, 1H), 9.48 (s, 1H), 8.93 (s, 1H), 8.57 (s, 1H), 8.52 (d, 1H), 8.44 (s, 1H), 8.08 (d, 1H), 7.94 (s, 2H), 7.63 (m, 2H), 7.56 (d, 1H), 7.22 (d, 1H), 3.95 (s, 3H), 2.42 (s, 3H)
MS(EST’, m/z): 515 [M+H]"
Example 119: Preparation of 4-amino-N-(6-methyl-1-((4-(prop-2-yn-1- yloxy)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 4-(2-propyn-1-yloxy)aniline instead of 4-chloroaniline in : <Step 1> of Example 1 to obtain the title compound (22 mg, 9.3%). "H-NMR Spectrum (300 MHz, DMSO-d): § 11.53 (s, 1H), 9.10 (s, 1H), 8.93 (s, 1H), 8.57 (s, 1H), 8.44 (d, 1H), 7.94 (m, 3H), 7.76 (d, 1H), 7.58 (d, 1H), 7.09 (d, 1H), 6.98 (d, 1H), 4.77 (d, 2H), 3.55 (t, 1H), 2.40 (s, 3H)
MS(ESI', m/z): 481 [M+H]*
Example 120: Preparation of 4-amino-N-(1-((2-methoxy-4- morpholinophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine- 7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 2-methoxy-4-morpholinoaniline instead of 4- chloroaniline in <Step 1> of Example 1 to obtain the title compound (29 mg, 6.5%). "H-NMR Spectrum (300 MHz, DMSO-ds): § 11.50 (s, 1H), 8.93 (s, 1H), 8.57 (s, 1H), 8.42 (s, 1H), 8.30 (d, 1H), 7.94 (s, 2H), 7.67 (m, 2H), 6.99 (d, 1H), 6.67 (d, 1H), 6.48 (d, 1H), 3.78 (m, 7H), 3.12 (m, 4H), 2.40 (s, 3H)
MS(EST", m/z): 542 [M+H]"
Example 121: Preparation of 4-amino-N-(1-(benzo[d]thiazol-6-ylamino)-6- methylisoquinolin-5-yl)thieno|3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 6-aminobenzothiazole instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (37 mg, 15.7%). 'H-NMR Spectrum (300 MHz, DMSO-d): § 11.57 (s, 1H), 9.47 (s, 1H), 9.21 (s, 1H), 8.94 (s, 1H), 8.85 (s, 1H), 8.58 (s, 1H), 8.50 (d, 1H), 8.05 (m, 2H), 8.01 (s, 1H), 7.94 (m, 2H), 7.65 (d, 1H), 7.21 (d, 1H), 2.43 (s, 3H)
MS(ESI’, m/z): 484 [M+H]" :
Example 122: Preparation of N-(1-((1H-indazol-5-yl)amino)-6- methylisoquinolin-5-yl)-4-aminothieno[3,2-d]pyrimidine-7-carboxamide hydrochloride
The procedures of <Steps 1, 2 and 3> of Example 113 and Example 114 were repeated in sequence, except for using 1H-indazol-5-amine instead of 1H-indazol-6-
amine in <Step 1> of Example 113 to obtain the title compound (5 mg, 5%).
MS(ESI', m/z): 466 [M+H]"
Example 123: Preparation of 4-amino-N-(1-((3-chloro-2,4- difluorophenyl)amino)-6-methylisoquinolin-S-yl)thieno[3,2-d]pyrimidine-7- carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using 3-chloro-2,4-difluoroaniline instead of 4-chloroaniline in <Step 1> of Example 1 to obtain the title compound (95 mg, 6%). "H-NMR Spectrum (300 MHz, DMSO-d): § 11.51 (s, 1H), 8.93 (s, 1H), 8.57 (s, 1H), 8.34 (d, 1H), 7.94 (s, 2H), 7.87 (d, 1H), 7.63 (m, 2H), 7.37 (m, 1H), 7.14 (d, 1H), 2.43 (s, 3H)
MS(ESI', m/z): 515 [M+H]"
Example 124: Preparation of 4-amino-N-(1-((3- (dimethylamino)propyl)amino)-6-methylisoquinolin-5-yl)thieno|3,2- d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using NI1,N1-dimethylpropan-1,3-diamine instead of 4- chloroaniline in <Step 1> of Example 1 to obtain the title compound (25 mg, 8%). "H-NMR Spectrum (300 MHz, DMSO-d): & 11.46 (s, 1H), 8.90 (s, 1H), 8.55 (s, 1H), 8.11 (d, 1H), 7.92 (s, 2H), 7.84 (d, 1H), 7.60 (m, 1H), 7.47 (d, 1H), 6.87 (d, 1H), 3.62 (m, 2H), 2.87 (m, 2H), 2.67 (s, 3H), 2.58 (s, 6H), 1.89 (m, 2H)
MS(EST", m/z): 436 [M+H]"
Example 125: Preparation of 4-amino-N-(6-methyl-1-(piperidin-1- yl)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide
The procedures of <Steps 1, 2 and 3> of Example 1 were repeated in sequence, except for using piperidine instead of 4-chloroaniline in <Step 1> of
Example 1 to obtain the title compound (8 mg, 2%). 'H-NMR Spectrum (300 MHz, DMSO-d): § 11.42 (s, 1H), 9.10 (s, 1H), 8.62 (s, 1H), 8.05 (m, 3H), 7.93 (s, 1H), 7.54 (m, 1H), 7.30 (d, 1H), 3.21 (m, 4H), 2.48 (s, 3H), 1.77 (m, 4H), 1.64 (m, 2H)
MS(EST", m/z): 419 [M+H]"
The compounds obtained in Examples 1 to 125 are represented by the following structural formula, as shown in Table 1 below.
Table 1
EL 4-amino-N-(1-((4-chlorophenyl)amino)-6- NNO© H 1 methylisoquinolin-5-yljthieno(3,2-d]pyrimidine-7- wT NX ,
Lo carboxamide
LL
Lie 4-amino-N-(6-methyl-1-((3- J . 2 (trifluoromethyl)phenyl)amino)isoquinolin-5- y AN er yDthieno[3,2-d]pyrimidine-7-carboxamide <3 ha
N-(1-((4-chlorophenyl)amino)-6- WN © H a methylisoquinolin-5-yi)-4- A = O. es (cyclopropylamino)thieno[3,2-d]pyrimidine-7- LES cl
Ba carboxamide
Pe +-(cyclopropy amino)- -(6-methyl-1-((3- NSA H £ 4 (trifluoromethyl)phenyl)amino)isoquinolin-5- BT HOI O°
Le yDthieno[3,2-d]pyrimidine-7-carboxamide :
En © | 4-amino-N-(6-methyl-1-((3-(4-methyl-1H- NYRR on, imidazol-1-yl)-5- wT AQ oe (trifluoromethyl)phenyl)amino)isoquinolin-5- My yl)thieno[3,2-d]pyrimidine-7-carboxamide + N - : ~N O H 4(cyclopropylamino)-N-(6-methyl-1-((3-(4- OA cr, ec methyl-1H-imidazol-1-yl)-5- Ped vA Qo a (trifluoromethyl)phenyl)amino)isoquinolin-5- 2
Ee yDthieno[3,2-d]pyrimidine-7-carboxamide
Le : Co N32 i 4-amino-N-(1-((4-((4-ethylpiperazin-1-yl)methyl)- y SAA
Eo 3-(trifluoromethyl)phenyl)amino)-6- ? ® )
Ee methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- (J a carboxamide L . . : a H
Lo 4-(cyclopropylamino)-N-(1-((4-((4-ethylpiperazin- A =r r CFs iy 1-yl)methyl)-3 ~(trifluoromethyl)phenyl)amino)-6- Nos HK methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- 0) a carboxamide v
Li
N-(1-((4-((d-ethylpiperazin-1-ylmethyl)-3- ON
Ba (trifluoromethy!l)phenyl)amino)-6- - SA Ae 9 methylisoquinolin-5-yl)-4- HS n
Po (methylamino)thieno(3,2-d]pyrimidine-7- (J ae carboxamide C i 4-amino-N-(1-((4-(4-ethylpiperazin-1- NN © H 0 yl)phenyl)amino)-6-methylisoquinolin-5- w= HK on yDthieno[3,2-d]pyrimidine-7-carboxamide (No
LL 4-amino-N-(1-((4-((4-ethylpiperazin-1- " STN C NCL ir yl)methyl)phenyl)amino)-6-methylisoquinolin-5- © 8 M
FE yl)thieno[3,2-d]pyrimidine-7-carboxamide (J o. )
Lo
BE nino N.(metiyl I phenylaminoisoquinal SA | 4-amino-N-(6-methyl-1-(phenylamino)isoquinolin- LOY NYY
Cin 5-yl)thieno[3,2-d]pyrimidine-7-carboxamide AS HORN Q
_4-amino-N-(1-((4-chloro-3- © \ a (trifluoromethyl)phenyl)amino)-6- ry er
Co methylisoquinolin-5-yl)thienof3,2-d]pyrimidine-7- 2 x <I
Co carboxamide 4-amino-N-(1-((2-methoxy-5- VN © be
CL . . \ 3 . 14 (trifluoromethyl)phenyl)amino)-6- leg 4 Ne methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- ee carboxamide i 4-amino-N-(6-methyl-1-(4- ne ‘ 1 (trifluoromethyl)phenyl)amino)isoquinolin-3- Neg NX CL, a . NET .
PF yDthieno[3,2-d]pyrimidine-7-carboxamide 3
Le
SEE
4-amino-N-(1-((4-methoxyphenyl)amino)-6- WN © H 16 methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- wT NCE 2, i carboxamide i a ~~ 0 eo . Ce ey = H 4-amino-N-(6-methyl-1-(p-tolylamino)isoquinolin- CA 7 hips : iN N i 5-ylthieno[3,2-d]pyrimidine-7-carboxamide LA SAP! a
Be
Bo
LL 4-amino-N-(1-((4-isopropylphenyl)amino)-6- oe k 18 | methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- Nien NX Qa,
EL carboxamide 0 . . . ~N O
Ce 4-amino-N-(1-((5-(t-butyl)isoxazol-3-yl)amino)-6- Dem Nn ' 19 | methylisoquinolin-5-yljthieno[3,2-d]pyrimidine-7- HN HON ix eo carboxamide
Lo is 4-amino-N-(1-((4-fluorophenyl)amino)-6- NO i | methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- wT NUT TL oo carboxamide F 116 j
Ly 4-amino-N-(6-methyl-1-(thiazol-2- WENO f 21 ylamino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine- TN OX TT)
Eel 7-carboxamide
LL 4-amino-N-(1-((4-cyanophenyl)amino)-6- yo H 2 methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- HN sd HON CL, ha carboxamide bona oo i
FE 4-amino-N-(6-methyl-1-(quinolin-5- No ‘Oh 23 | ylamino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine- TN x N aE A « - 7-carboxamide os 0 oo
Eases an 4-amino-N-(1-((4-ethoxyphenyl)amino)-6- NO u 24 | methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- neg XY TL -
Lo carboxamide ° a fe sn tee no .
La 4-amino-N-(6-methyl-1-((4- NO H oe \ N & 3 Re : . . , . - 25 | phenoxyphenyl)amino)isoquinolin-5-yl)thieno[3,2- wad NK TL, iq
Le d]pyrimidine-7-carboxamide 4-amino-N-(I-((4-hydroxyphenyl)amino)-6- NR b 26 methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- wT NE 7,
Le carboxamide
A4-amino-N-(1-((4-isopropoxyphenyl)amino)-6- 8 ‘ 2 methylisoquinolin-5-yl)thieno|3,2-d]pyrimidine-7- leg Q CLL
PL carboxamide : 4-amino-N-(1-((4-(dimethylamino)-6- 4 H 28 methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- HN 3] Nl 7,
Lo carboxamide \
Le aaa
Lo 4-amino-N-(1-((2,3-dihydrobenzo[b][1,4]dioxin-6- NY 0 Hoo 29 yl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- lee Nx Tc) a d]pyrimidine-7-carboxamide
Fo 4-amino-N-(1-((3,4-dimethoxyphenyl)amino)-6- oy or * 30 | methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- Sd Hh
Lo carboxamide oo . 4-amino-N-(1-((3-fluoro-4-methoxyphenyl)amino)- CAA ay . . . . sve ! : 31 | 6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine- PUA BEN 2,
Lo 7-carboxamide F
Ls
Lo 4-amino-N-(6-methyl-1-((3,4,5- or Hod 1:32 trimethoxyphenyl)amino)isoquinolin-5- Ned HIN cL ay yDthieno[3,2-d]pyrimidine-7-carboxamide Lo! ag oo 3 33 4-amino-N-(6-methylisoquinolin-5-yl)thieno[3,2- " se Nh edi . “qe . 2 d]pyrimidine-7-carboxamide . | 4-amino-N-(1-(benzo[d][1,3]dioxol-5-ylamino)-6- re EE a 34. methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- | JL A= To
Gh carboxamide ST NL le i. 4-amino-N-(6-methyl-1-((5,6,7,8- WN © H tetrahydronaphthalen-2-yl)amino)isoquinolin-5- " STN r “CO oe . Ne . 2 8 x :
Lal yDthieno[3,2-d]pyrimidine-7-carboxamide
Co - -N-(4-((4- ino)-7- a 4 amino N (4 (4 chlorophenyl)amino) 7 WSN © TK 36 | methylquinazolin-8-yl)thieno[3,2-d]pyrimidine-7- “ Or TX “CL
Fo ; ? =
Pa carboxamide ¥ ct ;
i 4-(cyclopropylamino)-N-(1-((4- NHS OF oa . RT i 37 | methoxyphenyl)amino)-6-methylisoquinolin-3- wT LG TL yl)thieno[3,2-d]pyrimidine-7-carboxamide > i 4-amino-N-(1-((3-chlorophenyl)amino)-6- WN © H aq | . . sg . _ ssi A Ww N 1 3% methylisoquinolin > -Ylyhienol3.2 d]pyrimidine-7 SEA Y O° oo 4-amino-N-(1-((3-bromophenyl)amino)-6- NNR H 39 | methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- wT NCE Cl,
LL carboxamide i 4-amino-N-(1-((2,4-dichlorophenyl)amino)-6- NN Hg 40 | methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- wT NL OL
Lo carboxamide - = 4-amino-N-(1-((3,4-dichlorophenyl)amino)-6- ~N © " 41 | methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- Ny Aer
Li carboxamide wT Sh ci . 4-amino-N-(1-((3,5-dichlorophenyl)amino)-6- NN 2, NaCl 42 | methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- wT NL © lo carboxamide ie 4-amino-N-(6-methyl-1-((3,4,5- HOY 43 | trichlorophenyl)amino)isoquinolin-5-yl)thieno(3,2- SARA “ a d]pyrimidine-7-carboxamide S © 4-amino-N-(1-((4-chloro-3- ~N © " 44 methoxyphenyl)amino)-6-methylisoquinolin-5- at
FE yl)thieno[3,2-d]pyrimidine-7-carboxamide Ns HORN cl
| 4-amino-N-(1-benzylamino-6-methylisoquinolin-5- CS
Lo yDthieno[3,2-d]pyrimidine-7-carboxamide HN 52 HON
Eo . . . ee 0 . | 4-amino-N-(6-methyl-1-phenoxyisoquinolin-5- NN 4 40 yl)thieno[3,2-d]pyrimidine-7-carboxamide an? 8 oN © = 4-amino-N-(6-methyl-1-((4- NO a morpholinophenyl)amino)isoquinolin-5- wT Ore a yl)thieno[3,2-d]pyrimidine-7-carboxamide "3 fs . ~N 0 - N-(1-((4-(1H-pyrrol-1-yl)phenyl)amino)-6- Ae 48 | methylisoquinolin-5-yl)-4-aminothieno(3,2- HAN 52 HON NS a d]pyrimidine-7-carboxamide iy 4-amino-N-(6-methyl-1-(pyrimidin-4- © ae ee eq . ee qe NC Hox 49 | ylamino)isoquinolin-5-yl)thieno(3,2-d]pyrimidine- wT Y JC re 7-carboxamide hag 4-amino-N-(1-((4- J oy (difluoromethoxy)phenyl)amino)-6- Cr methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- | HA $7 HSM Qe carboxamide l i 4-amino-N-(6-methyl-1-((4- NN © f al (trifluoromethoxy)phenyl)amino)isoquinolin-5- wa CX; CL er
PE yDthieno[3,2-d]pyrimidine-7-carboxamide oy 4-amino-N-(1-((4-chlorophenyl)amino)isoquinolin- NNR 4
BL 5-yl)thieno[3,2-d]pyrimidine-7-carboxamide wT AC RGH
4-amino-N-(5-((4-chlorophenyl)amino)naphthalen- Cry > | 1-ylthieno[3,2-d]pyrimidine-7-carboxamide ma IH CL, 4-amino-N-(1-((4-ethynylpheny)amino)-6- nial = 54 | methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- | NH Naw eo carboxamide hy § = i; 4-amino-N-(1-(isopropylamino)-6- NO H > 55 methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- i. ae 0 carboxamide ® i 4-amino-N-(1-(indolin-6-ylamino)-6- VN In 56 | methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- wT IG To
Lo carboxamide be 4-amino-N-(1-((4-(fluoromethoxy)phenyl)amino)- NNR H 57 | 6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine- LT TN Cl,
Wy 7-carboxamide : : N-(1-(4-chlorophenylamino)-6-methylisoquinolin- NCS BA 38 | 5.ylythieno[3,2-d]pyrimidine-7-carboxamide rruig,
Tie 4-amino-N-(1-((4-chloro-3- = co ((dimethylamino)methyl)phenyl)amino)-6- NNR RAH y 39 methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- ree N oN CL,
Lo carboxamide 4-amino-N-(1-((4-chloro-3-(pyrrolidin-1- ~~ LQ 60 | ylmethyl)phenyl)amino)-6-methylisoquinolin-5- " Se yDthieno[3,2-d]pyrimidine-7-carboxamide ’ > !
LL 4-amino-N-(1-((4-chloro-3- o (J a ((diethylamino)methyl)phenyl)amino)-6- Parnes oC 91 | ethylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- | HN sd H KN oe carboxamide 4-amino-N-(1-((1 4-diethyl-1,2,3,4- oo _ © > tetrahydroquinoxalin-6-yl)amino)-6- OP or 3 a methylisoquinolin-5-yl)thieno{3,2-d]pyrimidine-7- HN 54 HORN N carboxamide J 4-amino-N~(1-((4-chloro-3-(piperidin-1- oo } ® 63 | ylmethyl)phenyl)amino)-6-methylisoquinolin-5- 4 a yl)thieno[3,2-d]pyrimidine-7-carboxamide HN = HON io 4-amino-N-(1-((4-chloro-3- A)
Cr (morpholinomethyl)phenyl)amino)-6- WN © Hu ON oh methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- "lee NC CL eh carboxamide 4-amino-N-(1-((4-chloro-3-((4-methylpiperazin-1- _ © (J 65 | yl)methyl)phenyl)amino)-6-methylisoquinolin-5- OY yl)thieno[3,2-d]pyrimidine-7-carboxamide HN sd HON cl
Bo 4-amino-N-(1-((4-chloro-3- 1 6 ((diisopropylamino)methyl)phenyl)amino)-6- NN 2 Hoy methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- ia NLT CL carboxamide 67 (methylsulfonamido)phenyl)amino)isoquinolin-5- wad OX “OK lo yDthieno[3,2-d]pyrimidine-7-carboxamide ° tert-butyl 4-(5-((5-(4-aminothieno[3,2- 68 d]pyrimidine-7-carboxamido)-6-methylisoquinolin- () ay - ino)- ; : ~N 0 H N wa 1-yDamino)-2-chlorobenzyl)piperazine-1- CA : : carboxylate WHC,
Wa 4-amino-N-(1-((4-chloro-3-(piperazin-1- Ct)69 | ylmethyl)phenyl)amino)-6-methylisoquinolin-5- NNR SO y - yl)thieno[3,2-d]pyrimidine-7-carboxamide wT MN CL, - 4-amino-N-(1-((-chloro-4- See 70 | methoxyphenyl)amino)-6-methylisoquinolin-3- HN 52 HON 0
Lo yD)thieno[3,2-d]pyrimidine-7-carboxamide 4-amino-N-(1((3- 91 (dimethylcarbamoyl)phenyl)amino)-6- og RS methylisoquinolin-5-yl)thieno(3,2-d]pyrimidine-7- " Coy NOW orn
La carboxamide ’ = 4-amino-N-(6-methyl-1-((3- ONY © 72 | (methylcarbamoyl)phenyl)amino)isoquinolin-5- Cr Sey i : yD)thieno[3,2-d]pyrimidine-7-carboxamide HN S SN 0 4-amino-N-(1-((4-chloro-2-fluorophenyl)amino)-6- — YE 73 | methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- Crore i carboxamide uN ost HON o er 4-amino-N-(1-((4-bromo-2-fluorophenyl)amino)-6- = ° IP 74 | methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- " Noy - 0
Lo carboxamide ? Br 4-amino-N-(1-((4-methoxybenzyl)amino)-6- a LO 75 | methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- CPG carboxamide wa so HON i 4-amino-N-(1-((4-chlorobenzyl)amino)-6- Nw © 4 ci 76 | methylisoquinolin-5-yl)thieno([3,2-d]}pyrimidine-7- CP a carboxamide asd HORN
4-amino-N-(1-(2-(4-chlorophenyDhydrazinyl)-6- \ Ay ~ Ne 17 methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- HN NZ carboxamide SN
Lo 4-amino-N-(1-((3- Lo a oh ((dimethylamino)methyl)phenyl)amino)-6- Cree methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- Ns” HORN
LL = carboxamide
Me 4-amino-N-(6-methyl-1-((4-oxo-4H-chromen-6- NO wo 0 7g yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine- Chr . N-(1-((3-acetylphenyl)amino)-6- — hoo 80 methylisoquinolin-5-yl)-4-aminothieno[3,2- CEA eS vi d]pyrimidine-7-carboxamide wns” Hos i 4-amino-N-(1-((4-(2- o1 methoxyethoxy)phenyl)amino)-6- 3 H methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- | Noy Hg CL, ~_O. + carboxamide ’ oe 4-amino-N-(6-methyl-1-((3- ~N 0 " 82 | (trifluoromethoxy)phenyl)amino)isoquinolin-5- yen yDthieno[3,2-d]pyrimidine-7-carboxamide HA 5 HRN
Lo N-(1-((4-acetylphenyl)amino)-6- © 83°] methylisoquinolin-5-yl)-4-aminothieno[3,2- Ch
LL d]pyrimidine-7-carboxamide HN 8 x Cy 0 4-amino-N-(6-methyl-1-((4- \ " 84 | (methylsulfonamido)phenyl)amino)isoquinolin-5- (YT NYS TL Qo i cid , HN gd HN S. a yDthieno[3,2-d]pyrimidine-7-carboxamide NS
4-amino-N-(6-methyl-1-((3- ~N Ho QP 85 | (methylsulfonyl)phenyl)amino)isoquinolin-5- Hh Or ;
Lo yD)thieno[3,2-d]pyrimidine-7-carboxamide HA sd HRN
Lo 4-amino-N-(1-((4-chloro-3- . in (methoxymethyl)phenyl)amino)-6- Ci o- °" | methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- ws? HK CL, carboxamide : 4-amino-N-(1-((4-methoxy-3- o " 0e- 9 (methylsulfonamido)phenyl)amino)-6- Cer he "| methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- ms” HORN °
Ea carboxamide > 4-amino-N-(1-((4-chloro-3- o 8 (methylsulfonamido)phenyl)amino)-6- ~N 9 H 0:8 77 | methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- \ Coy _ CX cit carboxamide ’ “ . on 4-amino-N-(1-((6-chloropyridin-3-yl)amino)-6- 89 methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- ChAT n carboxamide aN st HORN , iy 4-amino-N-(1-((2-chloropyridin-4-yl)amino)-6- 0 H 90 | methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- Cie carboxamide mse MSN 4-amino-N-(6-methyl-1-((4- Jo q 91 | (methylsulfonamidomethyl)phenyl)amino)isoquino Sr NU Ts © | lin-5-yDthieno[3,2-d]pyrimidine-7-carboxamide ° ” 7
LL 4-amino-N-(6-methyl-1-((3- JE } Xs 92 | (methylsulfonamidomethyl)phenyl)amino)isoquino A A lin-5-ylthieno[3,2-d]pyrimidine-7-carboxamid | "* AN ’
LL 4-amino-N-(1-((4-chloro-3-fluorophenyl)amino)-6- N © u 93 | methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- a carboxamide HN S ~ t
Lo 4-amino-N-(1-((3-bromo-4-chlorophenyl)amino)- Nn © H 94 | 6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine- Cte
Fo 7-carboxamide HANS x o
Lo 4-amino-N-(1-((4- N 9 " 05 (dimethylcarbamoyl)phenyl)amino)-6- Ny ¢ W "OL methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- He xX : 0 ot carboxamide in N-(1-((3-acetamidophenyl)amino)-6- NS Wow 96 | methylisoquinolin-5-yl)-4-aminothienol[3,2- CP Ney po d]pyrimidine-7-carboxamide HN 8 4-amino-N-(6-methyl-1-((1-methyl-1H-indazol-6- 0 ) * 97 | yh)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine- et
Lo 7-carboxamide ws) HON Ro
Bo 4-amino-N-(6-methyl-1-((4- ! i 98 (methylsulfinyl)phenyl)amino)isoquinolin-5- HN CTV BD TL _ a ybthieno[3,2-d]pyrimidine-7-carboxamide > 7 § 0
Pe 4-amino-N-(6-methyl-1-((2-methyl-1,3- 0 “ o 99 dioxoisoindolin-5-yl)amino)isoquinolin-5- Ch - oo yDthieno[3,2-d]pyrimidine-7-carboxamide wns” TN
Lo 4-amino-N-(1-((6-methoxypyridin-3-yl)amino)-6- yO 4 100 methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- Cre
Ee carboxamide wns” RN See
Lo
Lo 4-amino-N-(6-methyl-1-((3-(2,2,2- A Ww 0 101 trifluoroacetyl)phenyl)amino)isoquinolin-5- Ci ee yDthieno[3,2-d]pyrimidine-7-carboxamide HN 8 = 4-amino-N-(6-methyl-1-((4- AOL 102. propionylphenyl)amino)isoquinolin-5- hse NE TC
Lo yl)thieno[3,2-d]pyrimidine-7-carboxamide o 4-amino-N-(1-((4-hexanoylphenyl)amino)-6- ° ) 103 methylisoquinolin-yl)thieno[3,2-d]pyrimidine-7- Chey oo carboxamide HN 8 N Cyne
N-(1-((1-acetyl-1H-indazol-6-yl)amino)-6- 0 1104 | methylisoquinolin-5-yl)-4-aminothieno(3,2- Cert en d]pyrimidine-7-carboxamide ws” NN ’ i 4-amino-N-(1-((3-chloro-4-fluorophenyl)amino)-6- 0
Lo NN ) ee N H 105 | methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- CMe a carboxamide aN os” Hs F be 4-amino-N-(6-methyl-1-((5-0x0-5,6,7,8- © \ 106° tetrahydronaphthalen-2-yl)amino)isoquinolin-5- Chr be yl)thieno[3,2-d]pyrimidine-7-carboxamide HN S$ > oY
Lo 4-amino-N-(6-methyl-1-((2-methyl-2H-indazol-6- NO ’ 107 yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine- Cr Ae ne 7-carboxamide nso HORN RA ao methyl 4-((5-(4-aminothieno[3,2-d]pyrimidine-7- Ch 108 carboxamido)-6-methylisoquinolin-1- Hy sd HON Co. i : ylamino)benzoate © oo 4-amino-N-(6-methyl-1-((1-methyl-1H-indazol-5- - " 109 | yD)amino)isoquinolin-5-ylthieno[3,2-d]pyrimidine- CP en . 7-carboxamide HN 8 X N he 4-amino-N-(6-methyl-1-((2-methyl-2H-indazol-5- NY 0 4 110 | yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine- "lee NC Cn
L 7-carboxamide 4-amino-N-(6-methyl-1-((6-methylpyridin-3- ng y hl yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine- CSL oe 7-carboxamide HN 3 4-amino-N-(6-methyl-1-((1-methyl-1H-indol-6- N © y 112 | yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine- Cr ey a 7-carboxamide Ns” PN 4
E Ce tert-butyl 6-((5-(4-aminothieno[3,2-d]pyrimidine- ~y 0 , Bos 113 | 7-carboxamido)-6-methylisoquinolin-1-yl)amino)- oy 5 Or . 1H-indazol-1-carboxylate CS MN ci N-(1-((1H-indazol-6-yl)amino)-6- o~N0 iu 114 methylisoquinolin-5-yl1)-4-aminothieno[3,2- , ort NY TI» dlpyrimidine-7-carboxamide hydrochloride Ts AN ’
Hl 4-amino-N-(1-((5-chloro-2-fluorophenyl)amino)-6- N © H 115 | methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- CPA
Ca carboxamide un se PKR
Le 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6- oy y CE 116 | methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- LJ TO cl i oo carboxamide wT S ©
SEE ha 4-amino-N-(1-((3-fluoro-4-(4-methylpiperazin-1- N 8 TA 117 . coaninali NC NY 117 | yl)phenyl)amino)-6-methylisoquinolin-5- a Hon 2, ~ yl)thieno[3,2-d]pyrimidine-7-carboxamide FON
El 4-amino-N-(1-((3-chloro-1-methyl-1H-indazol-6- = HN 118 yl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- " oy LN oy be d]pyrimidine-7-carboxamide
Gey 4-amino-N-(6-methyl-1-((4-(prop-2-yn-1- N 9 i 1119 | yloxy)phenyl)amino)isoquinolin-5-yl)thieno[3,2- nts Fr CL ma d]pyrimidine-7-carboxamide
PL 4-amino-N-(1-((2-methoxy-4- AY 120 | morpholinophenyl)amino)-6-methylisoquinolin-5- St NE 0, ~
Fo yDthieno[3,2-d]pyrimidine-7-carboxamide (oO 4-amino-N-(1-(benzo[d]thiazol-6-ylamino)-6- _— , 121 methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- CA er a carboxamide mals? HORN ¥
BE N-(1-((1H-indazol-5-yl)amino)-6- 9 ’ 122| methylisoquinolin-5-yl)-4-aminothieno3,2- | or A or c d]pyrimidine-7-carboxamide os AN N he 4-amino-N-(1-((3-chloro-2,4- ] WE 123 | difluorophenyl)amino)-6-methylisoquinolin-5- Ce os yl)thieno[3,2-d]pyrimidine-7-carboxamide HN S$ x F 4-amino-N-(1-((3-(dimethylamino)propyl)amino)- ° H 4 6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine- Ch win 7-carboxamide Nose Hs
Pe 4-amino-N-(6-methyl-1-(piperidin-1- Nn © 9 125 | yl)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- Cry
Lo carboxamide HN 8 S
The compounds prepared in Examples were tested for biological assays as follows.
Experimental Example 1: Evaluation of RAF kinase activity
The compounds prepared in Examples were tested for inhibitory activity against three subtypes of RAF, i.e., RAF1 Y340D Y341D (C-RAF), B-RAF normal type and B-RAF YE using Kinase Profiling Service (Invitrogen, U.S.) according to the manufacturer’s instructions. The levels of enzymatic inhibition of the compounds were calculated as percent inhibition at various concentrations. Based on percent inhibition, dose-response curves were plotted using GraphPad Prism software. The ICs values of representative compounds against C-RAF are listed in Table 2, and Vemurafenib (PLX-4032, Roche) was used as a control. :
Table 2 (ICs, nM) (ICs, nM) (ICs, nM) 3% | oe 0 0009 00} 05 2s | 0 0 7 1 6
Experimental Example 2: Evaluation of FMS, DDR1 and DDR2 kinases activity
As such, the compounds prepared in Examples were tested for inhibitory activity against FMS, DDR1 and DDR2 kinases using Kinase Screening and
Profiling Service (Invitrogen, U.S.). The ICs, values of representative compounds oo are listed in Table 3, and Vemurafenib (PLX-4032) was used as a control.
Table 3 (ICsp, NM) (1Cs0, nM) (ICsp, AM)
Experimental Example 3: Evaluation of inhibition on cell growth of N-RAS mutant cell HepG: (hepatoma carcinoma cell)
The inventive compounds having an inhibitory activity for protein kinase, thieno[3,2-d]-pyrimidine derivatives or pharmaceutically acceptable salts thereof, were tested for inhibitory activities on proliferation of aberrant cells as follows.
N-RAS mutant cells HepG; cells (HCC) cell lines (ATCC # HB-8065™), were obtained from ATCC (American Type Culture Collection: Rockville, MD).
HepG; cell lines were incubated in a MEM medium supplemented with 10% FBS and 1% penicillin/streptomycin (Gibco BRL) under 37°C, 5% CO; and 95% air.
The cell lines were transferred into 96-well plates at a density of 5,000 cells/well, and cultured for 18 hours or more. The cell lines were treated with 10 pl~0.1 nM of test compounds, and cultured for 72 hours.
To evaluate cell viabilities, HepG, cell lines were fixed with 10% TCA (trichloroacetic acid), stained with SRB (sulfohodamine B), and an absorbance was measured at 540 nm. Then, Gls, ie., the concentration of drug to cause 50% :
reduction in proliferation of cancer cells, were calculated therefrom. The growth rates of cancer cells were calculated by Equation 1 or 2.
Equation 1 [(Ti-Tz)/(C-Tz)] x 100 (for Ti>=Tz)
Equation 2 [(Ti-Tz/Tz) x 100 (for Ti<Tz)
In Equations 1 and 2, ‘TZ’ refers to a density of untreated cells, which is an absorbance in 0% cell growth groups. ‘C’ refers to a density of cells cultured by adding only medium, and ‘Ti’ refers to a density of cells treated with test compounds.
Glso value is the concentration of test compound when the value of
Equation 1 is 50, which indicates the concentration of test compound needed to reduce the growth of cancer cells to 50%. On each measurement, test compounds were compared with a control. Vemurafenib (PLX-4032) was used as a control, and the ICs values of each compound were measured and shown in Table 4.
Table 4
CC Eame [ HeGCamh ov yy ss a se Ta sy 8 00 Tm rs Tee
Experimental Example 4: Evaluation of inhibition on cell growth of N-RAS mutant cell SK-Mel-2 (melanoma)
The inventive compounds having an inhibitory activity for protein kinase, thieno[3,2-d]-pyrimidine derivatives or pharmaceutically acceptable salts thereof, were tested for their inhibitory activities on proliferation of aberrant cells as follows.
N-RAS mutant cells, SK-Mel-2 cell lines (ATCC #HTB-68™), were obtained from ATCC (American Type Culture Collection: Rockville, MD). SK-
Mel-2 cell lines were incubated in a MEM medium supplemented with 10% FBS and 1% penicillin/streptomycin (Gibco BRL) under 37°C, 5% CO; and 95% air.
The cell lines were transferred into 96-well plates at a density of 5,000 cells/well, and cultured for 18 hours or more. The cells were treated with 10 pl~0.1 nM of test compounds, and cultured for 72 hours.
To evaluate cell viabilities, SK-Mel-2 cell lines were fixed with 10% TCA (trichloroacetic acid), stained with SRB (sulfohodamine B), and an absorbance was measured at 540 nm. Then, Gls, i.e., the concentration of drug to cause 50% reduction in proliferation of cancer cells, were calculated therefrom. The growth rates of cancer cells were calculated by Equation 1 or 2.
Equation 1 [(Ti-Tz)/(C-Tz)] x 100 (for Ti>=Tz)
Equation 2 [(Ti-Tz/Tz) x 100 (for Ti<Tz)
In Equations 1 and 2, ‘Tz’ refers to a density of untreated cells, which is an absorbance in 0% cell growth groups. ‘C’ refers to a density of cells cultured by adding only medium, and ‘Ti’ refers to a density of cells treated with test compounds.
Glsp value is the concentration of a test compound when the value of
Equation 1 is 50, which indicates the concentration of test compound needed to reduce the growth of cancer cells to 50%. On each measurement, test compounds were compared with a control. Vemurafenib (PLX-4032) was used as a control, and the ICs, values of each compound were measured and shown in Table 5.
Table5 hr se s&s re 00] we 1% 0000000
As evidenced above, the inventive compounds, thieno[3,2-d]-pyrimidine derivative having inhibitory activity for protein kinases, can effectively inhibit various protein kinases including RAF, FMS, DDR1 and DDR2, and thus can be : used, singly or in combination, for prevention and treatment of diseases associated with aberrant cell growth which are caused by mutation or overexpression of RAS protein or overactivation of its protein kinase.
Claims (1)
- Tm Png, WHAT IS CLAIMED IS: “ls 2 > I1. A thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically 7 acceptable salt thereof: " s~N 0 = AE I (A (Fn s XY @ wherein, : A is hydrogen, Cs alkyl, Css cycloalkyl, 3- to 6-membered heterocycloalkyl, Ce.1paryl or 5- to 10-membered heteroaryl, wherein said aryl or heteroaryl is optionally reduced or substituted with hydrogen; W is O, S, S(O), S(O), NH, -NHNH- or 3- to 6-membered heterocycloalkyl; X and Y are each independently CH or N; Z is hydrogen, C,. alkyl or NR’R*, wherein said R® and R* are each independently hydrogen, C,.¢ alkyl or -(CH,)q-B-, B representing NR’R®, Ci alkoxy, Cj.¢ cycloalkyl or 3- to 6-membered heterocycloalkyl; R! is hydrogen, halogen, C,.; alkyl or C,.; alkoxy, wherein said alkyl or alkoxy is unsubstituted or substituted with one or more halogen atoms; R? is hydrogen, halogen, -CF3, -NO,, -OH, -CN, C|.¢alkoxy, C,.¢alkyl, Co : alkenyl, Cp4 alkynyl, -NR'R®, -NHSO,R’, -SO,R?, -C(O)R!!, -NHC(O)R?, - NHC(O)OR", -S(O)R!, Cs. cycloalkyl, 5- to 10-membered heterocycloalkyl, Ce-10 aryl, Ce.10 aryloxy, 5- to 10-membered heteroaryl or 3- to 6-membered heteroaryloxy, wherein said R? is connected to A by -(CH,)p- or substituted with Ciaalkyl, Cyaalkynyl, Ci4alkylcarbonyl or one or more halogen atoms;R’, RS, R, RS, R’, RI RY : R! and R! are each independently hydrogen, -NH,, Ci alkyl, Ci. alkoxy, Cs. cycloalkyl or 3-to 6-membered heterocycloalkyl, said alkyl, alkoxy, cycloalkyl or heterocycloalkyl being unsubstituted or substituted with one or more halogen atoms; q is an integer ranging from 0 to 3; p is an integer ranging from 0 to 3; m is an integer ranging from 0 to 5; n is an integer ranging from 0 to 2; and when A is hydrogen, m is 0.2. The thieno[3,2-d]pyrimidine derivative or its pharmaceutically acceptable salt of claim 1, wherein A is Cg.1o aryl or 5- to 10-membered heteroaryl.3. The thieno[3,2-d]pyrimidine derivative or its pharmaceutically acceptable salt of claim 1, wherein W is NH.4. The thieno[3,2-d]pyrimidine derivative or its pharmaceutically acceptable salt of claim 1, wherein Z is NR’R*.5. The thieno[3,2-d]pyrimidine derivative or its pharmaceutically acceptable salt of claim 1, wherein X is CH and Y is N.6. The thieno[3,2-d]pyrimidine derivative or its pharmaceutically acceptable salt of claim 1, which is selected from the group consisting of: 1) 4-amino-N-(1-((4-chlorophenyl)amino)-6-methylisoquinolin-5- yDthieno[3,2-d]pyrimidine-7-carboxamide; 2) 4-amino-N-(6-methyl-1-((3- (trifluoromethyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide;3) N-(1-((4-chlorophenyl)amino)-6-methylisoquinolin-5-y1)-4- (cyclopropylamino)thieno[3,2-d]pyrimidine-7-carboxamide;4) 4-(cyclopropylamino)-N-(6-methyl-1-((3- (trifluoromethyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;5) 4-amino-N-(6-methyl-1-((3-(4-methyl-1H-imidazol-1-y1)-5- (trifluoromethyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide; 6) 4-(cyclopropylamino)-N-(6-methyl-1-((3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 7 4-amino-N-(1-((4-((4-ethylpiperazin-1-yl)methyl)-3- (trifluoromethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno(3,2- d]pyrimidine-7-carboxamide;8) 4-(cyclopropylamino)-N-(1-((4-((4-ethylpiperazin-1-yl)methyl)- 3-(trifluoromethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide;9 N-(1-((4-((4-ethylpiperazin-1-yl)methyl)-3- (trifluoromethyl)phenyl)amino)-6-methylisoquinolin-5-yl)-4- (methylamino)thieno[3,2-d]pyrimidine-7-carboxamide; 10) 4-amino-N-(1-((4-(4-ethylpiperazin-1-yl)phenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 11) 4-amino-N-(1-((4-((4-ethylpiperazin-1- yDmethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 12) 4-amino-N-(6-methyl-1-((3- (trifluoromethyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide;13) 4-amino-N-(1-((4-chloro-3-(trifluoromethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 14) 4-amino-N-(1-((2-methoxy-5-(trifluoromethyl)phenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 15) 4-amino-N-(6-methyl-1-((4- (trifluoromethyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide; 16) 4-amino-N-(1-((4-methoxyphenyl)amino)-6-methylisoquinolin- 5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 17) 4-amino-N-(6-methyl-1-(p-tolylamino)isoquinolin-5- yhthieno[3,2-d]pyrimidine-7-carboxamide; 18) 4-amino-N-(1-((4-isopropylphenyl)amino)-6-methylisoquinolin- 5-yDthieno[3,2-d]pyrimidine-7-carboxamide; 19) 4-amino-N-(1-((5-(t-butyl)isoxazol-3-yl)amino)-6- methylisoquinolin-5-yl)thieno|[3,2-d]pyrimidine-7-carboxamide; 20) 4-amino-N-(1-((4-fluorophenyl)amino)-6-methylisoquinolin-5- yDthieno[3,2-d]pyrimidine-7-carboxamide; 21) 4-amino-N-(6-methyl-1-(thiazol-2-ylamino)isoquinolin-5- yDthieno[3,2-d]pyrimidine-7-carboxamide; 22) 4-amino-N-(1-((4-cyanophenyl)amino)-6-methylisoquinolin-5- ylthieno[3,2-d]pyrimidine-7-carboxamide; 23) 4-amino-N-(6-methyl-1-(quinolin-5-ylamino)isoquinolin-5- yDythieno[3,2-d]pyrimidine-7-carboxamide; 24) 4-amino-N-(1-((4-ethoxyphenyl)amino)-6-methylisoquinolin-5- yDthieno[3,2-d]pyrimidine-7-carboxamide; 25) 4-amino-N-(6-methyl-1-((4-phenoxyphenyl)amino)isoquinolin- 5-yDthieno[3,2-d]pyrimidine-7-carboxamide; 26) 4-amino-N-(1-((4-hydroxyphenyl)amino)-6-methylisoquinolin- 5-yDthieno[3,2-d]pyrimidine-7-carboxamide; 27) 4-amino-N-(1-((4-isopropoxyphenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 28) 4-amino-N-(1-((4-(dimethylamino)-6-methylisoquinolin-5- yl)thieno[3,2-d]pyrimidine-7-carboxamide; 29) 4-amino-N-(1-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 30) 4-amino-N-(1-((3,4-dimethoxyphenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 31) 4-amino-N-(1-((3-fluoro-4-methoxyphenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;32) 4-amino-N-(6-methyl-1-((3,4,5- trimethoxyphenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide;33) 4-amino-N-(6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine- 7-carboxamide;34) 4-amino-N-(1-(benzo[d][1,3]dioxol-5-ylamino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;35) 4-amino-N-(6-methyl-1-((5,6,7,8-tetrahydronaphthalen-2- yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 36) 4-amino-N-(4-((4-chlorophenyl)amino)-7-methylquinazolin-8-ylthieno[3,2-d]pyrimidine-7-carboxamide;37) 4-(cyclopropylamino)-N-(1-((4-methoxyphenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;38) 4-amino-N-(1-((3-chlorophenyl)amino)-6-methylisoquinolin-5- yDthieno[3,2-d]pyrimidine-7-carboxamide; 39) 4-amino-N-(1-((3-bromophenyl)amino)-6-methylisoquinolin-5- yl)thieno[3,2-d]pyrimidine-7-carboxamide;40) 4-amino-N-(1-((2,4-dichlorophenyl)amino)-6- ] methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 41) 4-amino-N-(1-((3,4-dichlorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 42) 4-amino-N-(1-((3,5-dichlorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 43) 4-amino-N-(6-methyl-1-((3,4,5- trichlorophenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 44) 4-amino-N-(1-((4-chloro-3-methoxyphenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 45) 4-amino-N-(1-benzylamino-6-methylisoquinolin-5- yl)thieno[3,2-d]pyrimidine-7-carboxamide; 46) 4-amino-N-(6-methyl-1-phenoxyisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide; 47) 4-amino-N-(6-methyl-1-((4- morpholinophenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide; 48) N-(1-((4-(1H-pyrrol-1-yl)phenyl)amino)-6-methylisoquinolin-5- yl)-4-aminothieno[3,2-d]pyrimidine-7-carboxamide; 49) 4-amino-N-(6-methyl-1-(pyrimidin-4-ylamino)isoquinolin-5- yDthieno[3,2-d]pyrimidine-7-carboxamide; 50) 4-amino-N-(1-((4-(difluoromethoxy)phenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 51) 4-amino-N-(6-methyl-1-((4- (trifluoromethoxy)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide; 52) 4-amino-N-(1-((4-chlorophenyl)amino)isoquinolin-5- yljthieno[3,2-d]pyrimidine-7-carboxamide; 53) 4-amino-N-(5-((4-chlorophenyl)amino)naphthalen-1- yDthieno[3,2-d]pyrimidine-7-carboxamide; 54) 4-amino-N-(1-((4-ethynylphenyl)amino)-6-methylisoquinolin-5- yDthieno[3,2-d]pyrimidine-7-carboxamide;55) 4-amino-N-(1-(isopropylamino)-6-methylisoquinolin-5- yl)thieno[3,2-d]pyrimidine-7-carboxamide;56) 4-amino-N-(1-(indolin-6-ylamino)-6-methylisoquinolin-5- yl)thieno[3,2-d]pyrimidine-7-carboxamide;57) 4-amino-N-(1-((4-(fluoromethoxy)phenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;58) N-(1-(4-chlorophenylamino)-6-methylisoquinolin-5- yDthieno[3,2-d]pyrimidine-7-carboxamide; 59) 4-amino-N-(1-((4-chloro-3-((dimethylamino)methyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide;60) 4-amino-N-(1-((4-chloro-3-(pyrrolidin-1- ylmethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide;61) 4-amino-N-(1-((4-chloro-3- ((diethylamino)methyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide; ]62) 4-amino-N-(1-((1,4-diethyl-1,2,3,4-tetrahydroquinoxalin-6- yl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 63) 4-amino-N-(1-((4-chloro-3-(piperidin-1- ylmethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide;64) 4-amino-N-(1-((4-chloro-3-(morpholinomethyl)phenyl)amino)- 6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;65) 4-amino-N-(1-((4-chloro-3-((4-methylpiperazin-1- yl)methyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- ; carboxamide;66) 4-amino-N-(1-((4-chloro-3- ((diisopropylamino)methyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 67) 4-amino-N-(6-methyl-1-((3- (methylsulfonamido)phenyl)amino)isoquinolin-5-yl)thienof3,2-d]pyrimidine-7- carboxamide; 68) tert-butyl 4-(5-((5-(4-aminothieno[3,2-d]pyrimidine-7- carboxamido)-6-methylisoquinolin-1-yl)amino)-2-chlorobenzyl)piperazine-1- carboxylate; 69) 4-amino-N-(1-((4-chloro-3-(piperazin-1- ylmethyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide; 70) 4-amino-N-(1-((3-chloro-4-methoxyphenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 71) 4-amino-N-(1-((3-(dimethylcarbamoyl)phenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 72) 4-amino-N-(6-methyl-1-((3- (methylcarbamoyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide; 73) 4-amino-N-(1-((4-chloro-2-fluorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d}pyrimidine-7-carboxamide; 74) 4-amino-N-(1-((4-bromo-2-fluorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 75) 4-amino-N-(1-((4-methoxybenzyl)amino)-6-methylisoquinolin- 5-yDthieno[3,2-d]pyrimidine-7-carboxamide; 76) 4-amino-N-(1-((4-chlorobenzyl)amino)-6-methylisoquinolin-5- ylthieno[3,2-d]pyrimidine-7-carboxamide; 77) 4-amino-N-(1-(2-(4-chlorophenyl)hydrazinyl)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 78) 4-amino-N-(1-((3-((dimethylamino)methyl)phenyl)amino)-6- : methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; ;79) 4-amino-N-(6-methyl-1-((4-oxo0-4H-chromen-6- yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 80) N-(1-((3-acetylphenyl)amino)-6-methylisoquinolin-5-yl)-4- aminothieno|3,2-d]pyrimidine-7-carboxamide; 81) 4-amino-N-(1-((4-(2-methoxyethoxy)phenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 82) 4-amino-N-(6-methyl-1-((3- (trifluoromethoxy)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide; 83) N-(1-((4-acetylphenyl)amino)-6-methylisoquinolin-5-yl)-4-aminothieno[3,2-d]pyrimidine-7-carboxamide; 84) 4-amino-N-(6-methyl-1-((4-(methylsulfonamido)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;85) 4-amino-N-(6-methyl-1-((3- (methylsulfonyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide;86) 4-amino-N-(1-((4-chloro-3-(methoxymethyl)phenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;87) 4-amino-N-(1-((4-methoxy-3- (methylsulfonamido)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide;88) 4-amino-N-(1-((4-chloro-3-(methylsulfonamido)phenyl)amino)- 6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;89) 4-amino-N-(1-((6-chloropyridin-3-yl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide;90) 4-amino-N-(1-((2-chloropyridin-4-yl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; : 91) 4-amino-N-(6-methyl(4-(methylsulfonamidomethyl)phenyl)amino)isoquinolin-5-yl)thieno|[3,2- d]pyrimidine-7-carboxamide; 92) 4-amino-N-(6-methyl-1-((3- (methylsulfonamidomethyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide; 93) 4-amino-N-(1-((4-chloro-3-fluorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 94) 4-amino-N-(1-((3-bromo-4-chlorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 95) 4-amino-N-(1-((4-(dimethylcarbamoyl)phenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 96) N-(1-((3-acetamidophenyl)amino)-6-methylisoquinolin-5-yl)-4- aminothieno[3,2-d]pyrimidine-7-carboxamide; 97) 4-amino-N-(6-methyl-1-((1-methyl-1H-indazol-6- yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 98) 4-amino-N-(6-methyl-1-((4- (methylsulfinyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide; 99) 4-amino-N-(6-methyl-1-((2-methyl-1,3-dioxoisoindolin-5- yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 100) 4-amino-N-(1-((6-methoxypyridin-3-yl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 101) 4-amino-N-(6-methyl-1-((3-(2,2,2- trifluoroacetyl)phenyl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7- carboxamide; ; 102) 4-amino-N-(6-methyl-1-((4-propionylphenyl)amino)isoquinolin- 5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 103) 4-amino-N-(1-((4-hexanoylphenyl)amino)-6-methylisoquinolin- yl)thieno[3,2-d]pyrimidine-7-carboxamide;104) N-(1-((1-acetyl-1H-indazol-6-yl)amino)-6-methylisoquinolin-3- yl)-4-aminothieno[3,2-d]pyrimidine-7-carboxamide; 105) 4-amino-N-(1-((3-chloro-4-fluorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3 ,2-d]pyrimidine-7-carboxamide; 106) 4-amino-N-(6-methyl-1-((5-0x0-5,6,7,8-tetrahydronaphthalen-2- yl)amino)isoquinolin-5-yl)thieno[3 ,2-d]pyrimidine-7-carboxamide; 107) 4-amino-N-(6-methyl-1-((2-methyl-2H-indazol-6- yl)amino)isoquinolin-5-yl)thieno[3 ,2-d]pyrimidine-7-carboxamide; 108) methyl 4~((5-(4-aminothieno(3,2-d]pyrimidine-7-carboxamido)- 6-methylisoquinolin-1-yl)amino)benzoate; 109) 4-amino-N-(6-methyl-1-((1-methyl-1H-indazol-5- yl)amino)isoquinolin-5-y!)thieno[3,2-d]pyrimidine-7-carboxamide; 110) 4-amino-N-(6-methyl-1-((2-methyl-2H-indazol-5- yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 111) 4-amino-N-(6-methyl-1-((6-methylpyridin-3- yl)amino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 112) 4-amino-N-(6-methyl-1-((1-methyl-1H-indol-6- ylamino)isoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 113) tert-butyl 6-((5-(4-aminothieno[3,2-d]pyrimidine-7-carboxamido)-6- methylisoquinolin-1-yl)amino)-1H-indazol-1-carboxylate; 114) N-(1-((1H-indazol-6-yl)amino)-6-methylisoquinolin-5-yl)-4- aminothieno|[3,2-d]pyrimidine-7-carboxamide hydrochloride; 115) 4-amino-N-(1-((5-chloro-2-fluorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 116) 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 117) 4-amino-N-(1-((3-fluoro-4-(4-methylpiperazin-1- yl)phenyl)amino)-6-methylisoquinolin-5-ylthieno[3,2-d]pyrimidine-7- carboxamide;118) 4-amino-N-(1-((3-chloro-1-methyl-1H-indazol-6-yl)amino)-6- methylisoquinolin-5-yl)thieno{3,2-d]pyrimidine-7-carboxamide; 119) 4-amino-N-(6-methyl-1-((4-(prop-2-yn-1- yloxy)phenyl)amino)isoquinolin-5-yl)thieno{3,2-d]pyrimidine-7-carboxamide; 120) 4-amino-N-(1-((2-methoxy-4-morpholinophenyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 121) 4-amino-N-(1-(benzo[d]thiazol-6-ylamino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 122) N-(1-((1H-indazol-5-yl)amino)-6-methylisoquinolin-5-yl)-4- aminothieno[3,2-d]pyrimidine-7-carboxamide; 123) 4-amino-N-(1-((3-chloro-2,4-difluorophenyl)amino)-6- methylisoquinolin-5-yl)thienof3,2-d]pyrimidine-7-carboxamide; 124) 4-amino-N-(1-((3-(dimethylamino)propyl)amino)-6- methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; and 125) 4-amino-N-(6-methyl-1-(piperidin-1-yl)isoquinolin-5- yl)thieno[3,2-d]pyrimidine-7-carboxamide.7. A pharmaceutical composition comprising the compound of any one of claims 1 to 6 as an active ingredient.8. Use of the pharmaceutical composition of claim 7, in the manufacture of a medicament for the prevention or treatment of a disease caused by abnormal activation of a protein kinase selected from the group consisting of: RAF kinase, FMS kinase, DDR1 kinase and DDR2 kinase.9. The use of claim 8, wherein said disease is selected from the group consisting of: gastric cancer, lung cancer, liver cancer, colorectal cancer, small intestine cancer, pancreatic cancer, brain cancer, bone cancer, melanoma, breast cancer, sclerosing adenosis, uterine cancer, cervical cancer, head and neck cancer, :esophagus cancer, thyroid cancer, parathyroid cancer, renal cancer, sarcoma, prostate cancer, urethral cancer, bladder cancer, blood cancer, lymphoma, fibroadenoma, inflammation, diabetes, obesity, psoriasis, rheumatoid arthritis, hemangioma, acute or chronic kidney disease, coronary restenosis, autoimmune diseases, asthma, neurodegenerative diseases, acute infection or ocular diseases caused by angiogenesis.10. The pharmaceutical composition of claim 7, wherein the pharmaceutical composition further comprises a drug selected from the group consisting of cell signal transduction inhibitors, mitosis inhibitors, alkylating agents, : antimetabolites, antibiotics, growth factor inhibitors, cell cycle inhibitors, topoisomerase inhibitors, biological reaction modifiers, antihormonal agents, antiandrogen, cell differentiation/proliferation/survival inhibitors, apoptosis inhibitors, inflammation inhibitors and P-glycoprotein inhibitors.11. A pharmaceutical formulation comprising the pharmaceutical composition of ; claim 7.12. The pharmaceutical formulation of claim 11, wherein said formulation is an oral formulation.13. The pharmaceutical formulation of claim 11 or claim 12, wherein said formulation is in the form of a tablet, a pill, powder, a capsule, syrup, an emulsion or a microemulsion.14. The pharmaceutical formulation of claim 11, which is used in combination : or developed into a combined formulation with a drug selected from the group consisting of cell signal transduction inhibitors, mitosis inhibitors, alkylating agents, antimetabolites, antibiotics, growth factor inhibitors, cell 147 i cycle inhibitors, topoisomerase inhibitors, biological reaction modifiers, antihormonal agents, antiandrogen, cell differentiation/proliferation/survival inhibitors, apoptosis inhibitors, inflammation inhibitors and P-glycoprotein inhibitors. .15. Use of the compound of any one of claims 1-6 in the manufacture of a medicament for the prevention or treatment of a disease caused by abnormal activation of a protein kinase selected from the group consisting of: RAF kinase, FMS kinase, DDR1 kinase and DDR2 kinase.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110146818 | 2011-12-30 | ||
PCT/KR2012/011571 WO2013100632A1 (en) | 2011-12-30 | 2012-12-27 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES |
Publications (2)
Publication Number | Publication Date |
---|---|
PH12014501504A1 PH12014501504A1 (en) | 2014-10-08 |
PH12014501504B1 true PH12014501504B1 (en) | 2014-10-08 |
Family
ID=48697978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH12014501504A PH12014501504B1 (en) | 2011-12-30 | 2014-06-27 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES |
Country Status (33)
Country | Link |
---|---|
US (2) | US9156852B2 (en) |
EP (2) | EP3617213A1 (en) |
JP (1) | JP5797345B2 (en) |
KR (1) | KR101490761B1 (en) |
CN (1) | CN104039798B (en) |
AR (1) | AR089489A1 (en) |
AU (1) | AU2012363558C1 (en) |
BR (2) | BR122019019582B1 (en) |
CA (1) | CA2859668C (en) |
CL (1) | CL2014001729A1 (en) |
CO (1) | CO7010840A2 (en) |
DK (1) | DK2797927T3 (en) |
ES (1) | ES2751608T3 (en) |
HK (1) | HK1200833A1 (en) |
HR (1) | HRP20191840T8 (en) |
HU (1) | HUE045957T2 (en) |
IL (2) | IL233441B (en) |
IN (1) | IN2014DN06101A (en) |
LT (1) | LT2797927T (en) |
MX (2) | MX363659B (en) |
MY (1) | MY170988A (en) |
PE (1) | PE20141404A1 (en) |
PH (1) | PH12014501504B1 (en) |
PL (1) | PL2797927T3 (en) |
PT (1) | PT2797927T (en) |
RS (1) | RS59420B1 (en) |
RU (2) | RU2625799C2 (en) |
SG (2) | SG11201402765TA (en) |
SI (1) | SI2797927T1 (en) |
TW (1) | TWI462927B (en) |
UA (1) | UA109614C2 (en) |
WO (1) | WO2013100632A1 (en) |
ZA (1) | ZA201405583B (en) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2918588T3 (en) | 2010-05-20 | 2017-10-31 | Array Biopharma Inc | Macrocyclic compounds as TRK kinase inhibitors |
TWI713455B (en) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | Mnk inhibitors and methods related thereto |
US10040745B2 (en) | 2014-10-14 | 2018-08-07 | Syngenta Participations Ag | Process for the preparation of 1-(3,5-dichlorophenyl)-2,2,2-trifluoroethanone and derivatives thereof |
EA035049B1 (en) | 2015-07-16 | 2020-04-22 | Аррэй Байофарма Инк. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS |
CA3002558A1 (en) | 2015-10-29 | 2017-05-04 | Effector Therapeutics, Inc. | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2 |
BR112018008714A2 (en) | 2015-10-29 | 2018-10-30 | Effector Therapeutics Inc | isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2 |
US10000487B2 (en) | 2015-11-20 | 2018-06-19 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers |
CN106928252B (en) * | 2015-12-31 | 2019-09-27 | 成都先导药物开发股份有限公司 | A kind of compound and the preparation method and application thereof inhibiting ROCK |
EP3414247B1 (en) | 2016-02-08 | 2021-04-21 | F. Hoffmann-La Roche AG | Spiroindolinones as ddr1 inhibitors |
KR20180134347A (en) | 2016-04-15 | 2018-12-18 | 제넨테크, 인크. | Diagnosis and Treatment of Cancer |
CN106153920B (en) * | 2016-07-25 | 2018-04-27 | 四川大学华西医院 | A kind of screening lung cancer kit |
TWI704148B (en) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
JOP20190077A1 (en) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
WO2018122746A1 (en) * | 2016-12-28 | 2018-07-05 | Minoryx Therapeutics S.L. | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase |
EP3571203B1 (en) | 2017-01-18 | 2023-06-07 | Array BioPharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
CN110719781A (en) | 2017-02-14 | 2020-01-21 | 效应治疗股份有限公司 | Substituted piperidine MnK inhibitors and methods related thereto |
JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
AU2018308038B2 (en) | 2017-07-28 | 2022-02-03 | Yuhan Corporation | Improved process for preparing aminopyrimidine derivatives |
EP3679159A1 (en) | 2017-09-08 | 2020-07-15 | H. Hoffnabb-La Roche Ag | Diagnostic and therapeutic methods for cancer |
TWI791053B (en) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof |
TWI812649B (en) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
BR112020010903A2 (en) * | 2017-11-30 | 2020-11-17 | Hanmi Pharm. Co., Ltd. | compound, salt of a compound of formula (I), pharmaceutical composition, use of a pharmaceutical composition, use of a compound, method of preparing a crystalline form of the salt |
TWI803541B (en) * | 2017-11-30 | 2023-06-01 | 韓商韓美藥品股份有限公司 | Thieno[3,2-d]pyrimidine compound having inhibitory activity for protein kinase |
TWI802635B (en) | 2018-01-18 | 2023-05-21 | 美商亞雷生物製藥股份有限公司 | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
JP6997876B2 (en) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Substituted pyrazolyl [4,3-C] pyridine compound as a RET kinase inhibitor |
EP3752200A1 (en) | 2018-02-13 | 2020-12-23 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
EP3762379A1 (en) | 2018-03-07 | 2021-01-13 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
CA3111984A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
EP3870178A4 (en) | 2018-10-24 | 2022-08-03 | Effector Therapeutics Inc. | Crystalline forms of mnk inhibitors |
TW202038957A (en) | 2018-12-21 | 2020-11-01 | 日商第一三共股份有限公司 | Combination of antibody-drug conjugate and kinase inhibitor |
CN110183464B (en) * | 2019-05-31 | 2021-08-31 | 淮阴工学院 | Anti-cancer compound estinib and synthesis method and application thereof |
CA3178927A1 (en) | 2020-05-26 | 2021-12-02 | Hanmi Pharm. Co., Ltd. | Belvarafenib for use in cancer treatment |
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
KR20230096965A (en) | 2020-10-27 | 2023-06-30 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | Arylamide compound, pharmaceutical composition containing the same, and preparation method and use thereof |
JP2024509269A (en) | 2021-03-09 | 2024-02-29 | ジェネンテック, インコーポレイテッド | Bervarafenib for use in the treatment of brain cancer |
JP2024514112A (en) | 2021-04-06 | 2024-03-28 | ジェネンテック, インコーポレイテッド | Combination therapy with bervarafenib and cobimetinib or combination therapy with bervarafenib, cobimetinib and atezolizumab |
CN117202897A (en) | 2021-04-09 | 2023-12-08 | 基因泰克公司 | Combination therapy using RAF inhibitors and PD-1 axis inhibitors |
WO2023278981A1 (en) | 2021-06-30 | 2023-01-05 | Genentech, Inc. | Synthesis of a bis-mesylate salt of 4-amino-n-(1 -((3-chloro-2- fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2- d]pyrimidine-7-carboxamide and intermediates thereto |
CN114213430B (en) * | 2021-12-28 | 2022-12-02 | 深圳湾实验室 | Preparation method of 4-aminothiophene [3,2-d ] pyrimidine-7-carboxylic acid and protein kinase inhibitor intermediate |
CN114524826A (en) * | 2022-02-18 | 2022-05-24 | 郑州猫眼农业科技有限公司 | Preparation process of 7-bromo-4-chlorothiophene [3,2-d ] pyrimidine |
TW202342766A (en) | 2022-03-02 | 2023-11-01 | 瑞士商諾華公司 | Precision therapy for the treatment of cancer |
WO2024033381A1 (en) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0402518D0 (en) * | 2004-02-05 | 2004-03-10 | Astrazeneca Ab | Therapeutic agents |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
RU2528046C2 (en) * | 2004-06-24 | 2014-09-10 | Вертекс Фармасьютикалз Инкорпорейтед | Modulators of atp-binding cartridge transporters |
MY146795A (en) | 2005-06-09 | 2012-09-28 | Novartis Ag | Process for the synthesis of organic compounds |
US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
AU2007227602A1 (en) * | 2006-03-16 | 2007-09-27 | Novartis Ag | Heterocyclic organic compounds for the treatment of in particular melanoma |
US8633201B2 (en) | 2006-04-07 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions |
WO2008044688A1 (en) * | 2006-10-11 | 2008-04-17 | Daiichi Sankyo Company, Limited | Urea derivative |
KR101257158B1 (en) | 2008-05-23 | 2013-04-23 | 노파르티스 아게 | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
BRPI0921862A2 (en) * | 2008-12-05 | 2015-12-29 | Arqule Inc | raf inhibitors and their uses |
WO2010101302A1 (en) | 2009-03-05 | 2010-09-10 | Takeda Pharmaceutical Company Limited | Thienopyrimidine as cdc7 kinase inhibitors |
DE102009035754A1 (en) | 2009-07-24 | 2011-01-27 | Hartmetall-Werkzeugfabrik Paul Horn Gmbh | Cutting insert for a cutting tool for machining, in particular for high-feed milling |
US20120157439A1 (en) | 2009-08-28 | 2012-06-21 | Genentech, Inc. | Raf inhibitor compounds and methods of use thereof |
KR101147550B1 (en) | 2009-10-22 | 2012-05-17 | 한국과학기술연구원 | 2,7-Substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors |
KR101094446B1 (en) | 2009-11-19 | 2011-12-15 | 한국과학기술연구원 | 2,4,7-Substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors |
KR101483215B1 (en) * | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinases |
CA2786438C (en) | 2010-01-29 | 2015-10-13 | Hanmi Science Co., Ltd. | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases |
CN105367577B (en) * | 2010-07-13 | 2019-04-23 | 弗·哈夫曼-拉罗切有限公司 | Pyrazolo [1,5A] pyrimidine and thieno [3,2B] pyrimidine derivatives as IRAK4 regulator |
-
2012
- 2012-12-27 JP JP2014550010A patent/JP5797345B2/en active Active
- 2012-12-27 HU HUE12861811A patent/HUE045957T2/en unknown
- 2012-12-27 LT LT12861811T patent/LT2797927T/en unknown
- 2012-12-27 UA UAA201408629A patent/UA109614C2/en unknown
- 2012-12-27 EP EP19198802.1A patent/EP3617213A1/en active Pending
- 2012-12-27 PE PE2014001048A patent/PE20141404A1/en active IP Right Grant
- 2012-12-27 SG SG11201402765TA patent/SG11201402765TA/en unknown
- 2012-12-27 BR BR122019019582-0A patent/BR122019019582B1/en active IP Right Grant
- 2012-12-27 US US14/363,857 patent/US9156852B2/en not_active Ceased
- 2012-12-27 MY MYPI2014701742A patent/MY170988A/en unknown
- 2012-12-27 IN IN6101DEN2014 patent/IN2014DN06101A/en unknown
- 2012-12-27 AU AU2012363558A patent/AU2012363558C1/en active Active
- 2012-12-27 PL PL12861811T patent/PL2797927T3/en unknown
- 2012-12-27 US US15/783,240 patent/USRE47451E1/en active Active
- 2012-12-27 AR ARP120105010A patent/AR089489A1/en active IP Right Grant
- 2012-12-27 ES ES12861811T patent/ES2751608T3/en active Active
- 2012-12-27 WO PCT/KR2012/011571 patent/WO2013100632A1/en active Application Filing
- 2012-12-27 MX MX2014007230A patent/MX363659B/en unknown
- 2012-12-27 CA CA2859668A patent/CA2859668C/en active Active
- 2012-12-27 KR KR20120154061A patent/KR101490761B1/en active IP Right Grant
- 2012-12-27 SI SI201231684T patent/SI2797927T1/en unknown
- 2012-12-27 CN CN201280064739.8A patent/CN104039798B/en active Active
- 2012-12-27 RU RU2014131390A patent/RU2625799C2/en active
- 2012-12-27 RS RSP20191305 patent/RS59420B1/en unknown
- 2012-12-27 BR BR112014015720-0A patent/BR112014015720B1/en active IP Right Grant
- 2012-12-27 DK DK12861811T patent/DK2797927T3/en active
- 2012-12-27 RU RU2017124993A patent/RU2705577C2/en active
- 2012-12-27 SG SG10201701999QA patent/SG10201701999QA/en unknown
- 2012-12-27 PT PT128618113T patent/PT2797927T/en unknown
- 2012-12-27 EP EP12861811.3A patent/EP2797927B1/en active Active
- 2012-12-28 TW TW101151181A patent/TWI462927B/en active
-
2014
- 2014-06-16 MX MX2019003468A patent/MX2019003468A/en unknown
- 2014-06-26 CL CL2014001729A patent/CL2014001729A1/en unknown
- 2014-06-27 PH PH12014501504A patent/PH12014501504B1/en unknown
- 2014-06-29 IL IL233441A patent/IL233441B/en active IP Right Grant
- 2014-07-25 CO CO14162082A patent/CO7010840A2/en active IP Right Grant
- 2014-07-29 ZA ZA2014/05583A patent/ZA201405583B/en unknown
-
2015
- 2015-02-11 HK HK15101503.1A patent/HK1200833A1/en unknown
-
2019
- 2019-04-28 IL IL266285A patent/IL266285B/en unknown
- 2019-10-11 HR HRP20191840TT patent/HRP20191840T8/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2797927B1 (en) | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | |
JP2023027203A (en) | Pyrimidine compound and pharmaceutical use thereof | |
US9388165B2 (en) | Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase | |
CN113454081A (en) | Imidazopyridinyl compounds and their use for the treatment of proliferative diseases | |
US20230060973A1 (en) | Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase | |
NZ628013B2 (en) | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | |
CN114728963B (en) | Novel triazolopyridine derivatives and pharmaceutical compositions comprising the same |